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Abstract
There are eight described human herpesviruses. All share the ability to achieve latency
in their host following primary infection and may subsequently reactivate later in life.
In immunocompetent individuals herpesvirus infections, especially those caused by
reactivating virus, are usually mild however in patients with impaired cellular immune
function they may cause significant morbidity and mortality.
In this thesis molecular and serological techniques were used to define the prevalence
of the human herpesviruses in a variety of immunocompromised groups as these
individuals are at greatest risk of severe herpesviral disease.
Human herpesvirus 8 (HHV8) is the most recently discovered of the human
herpesviruses. A nested polymerase chain reaction (PCR) for detecting HHV8
genome was designed and used to examine the association between infection with
HHV8 and FIIV-associated Kaposi's sarcoma (KS). The prevalence of HHV8
genome carriage in the general UK population was defined, as were potential routes of
HHV8 transmission. Novel treatments for HIV-KS were investigated.
The value of herpesviral genome detection in predicting associated disease was
evaluated, together with the genome load response of cytomegalovirus (CMV), a
significant herpesviral pathogen, to a novel chemotherapeutic protocol for
immunosuppressed patients receiving allogenic bone marrow transplantation.
The prevalence and epidemiology of HHV8 were found to be compatible with that
predicted for a causal agent of KS, but not the haematological malignancy multiple
myeloma. Apart from 1-IHV8, Epstein-Barr virus and CMV were found to be the most
significant herpesvirus pathogens in the immunocompromised host.. The use of
molecular detection techniques, such as PCR, were shown to be of great value in the
diagnostic and epidemiological determination of herpesviral infection in
immunocompromised patients.
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Section 1: Introduction
During the last two decades there has been a significant increase in the number
of individuals receiving medical care who are defined as immunocompromised.
The two most significant factors in this increase have been the use of
immunosuppressive therapies in patients undergoing solid and bone marrow
transplantation and the advent of the AIDS pandemic. Although fundamentally
different in nature these two factors have resulted in a large number of
individuals in whom the ability to combat effectively certain infectious agents
has been reduced. Of particular concern in these patients are organisms which
are commonly found in the majority of the general population including the
commensal micro-flora and a number of viral types. These organisms are
normally prevented from causing symptomatic disease by the actions of the
host immune system, but in individuals lacking such immune control they can
result in significant morbidity and mortality. The herpesviridae in particular
have been associated with severe disease in the immunocompromised host.
Usually causing mild, self-limiting disease in the human host they are
associated with a number of severe and often life-threatening conditions in
individuals with reduced immunological response.
This thesis is an investigation of the 8 human herpesviruses (table 1.1), in
terms of their detection in the clinical setting and association with disease. The
following sections describe the life cycle of these viruses and diseases with
which each virus has been associated, especially in the immunocompromised
patient. Where appropriate particular topics are highlighted as an introduction
to work presented later in the text.
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1. a. The herpesviridae
1. a. 1. Herpesviral genome structure and life cycle
Viruses of the herpesvirus family share a number of common features in both
their physical characteristics and biological properties. All have genomes of
double-stranded deoxyribose nucleic acid (DNA) (Roizman, 1993). These
genomes are linear while contained within the virus particle and circularise to
form episomes after infection of a susceptible cell and ently into the nucleus.
Herpesvirus genomes, at between 130 and 230 Kb in size, are large in
comparison with other DNA viruses (Roi7Jmrn, 1993). The genomes have a
conserved arrangement with sections of unique nucleotide sequence separated
by multiply repeated shorter sequences. This type of genome arrangement is
complex with up to six forms of gene organisation currently described within
the virus family (Roizman, 1993). The presence and number of multiply-
rep eated genome sequences may vary and in consequence the size of
individual genomes may alter by as much as 10 kilobases (Kb) in any one
herpesvirus species (Roizrnan, 1993).
The mature virus particle is also complex in form; the genome is supported
and attached to a protein core called the torus (Nazerian et al., 1974). This
torus-DNA complex is held within an icosahedral capsid consisting of 162
individual capsomer polypeptides, which is approximately lOOnm in diameter
(Wildy et a!., 1962). Surrounding the highly ordered capsid is an amorphous
tegument region which is bounded by the outer layer of the particle; the
envelope (Roizman et a!., 1974 and Epstein et al., 1962). The envelope is a
double membrane structure sequestered from the host plasma membrane
during exit of the virion from the cell (Morgan et aL, 1959). Projecting
through the viral membrane are a number of virus-encoded glycoproteins. It is
these glycoproteins which facilitate the attachment of the virus to the cell and
are major targets for host immunological response (Nemerow et a!., 1989 and
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Marshall et aL, 1992). The overall size of the herpesvirus particle may vary
from between 120-200 nm (figure la).
Cellular infection begins with attachment of the virion to the cell surface. A
number of cell-surface proteins have been described as potential sites of virus
interaction, including heparin and the fibroblast growth factor receptor for
/ herpes simplexvirus 1 (HSV-1), and the CD 21 molecule of B-lymphocytes
for Epstein Barr virus (EBV) (Shieh et aL, 1992 and Li et aL, 1992). Pre-
incubation of cells with monoclonal antibodies against these proteins has been
shown to inhibit viral infection (Fingeroth et aL, 1984). One, or more, of a
range of herpesvirus glycoproteins may be involved in cell-surface / virus
attachment, including, for HSV- 1 gD, gH and gL, and for EBV glycoprotein
(gp) 350 / 220. Following attachment of the virus to the cell surface an
extremely rapid flision process occurs between the viral envelope and the cell
plasma membrane. Phagocytosis seems to be of little importance in herpesviral
cell entry (Huang et aL, 1964). Naked virion capsids are then transported to
the cell nuclear pores, via the cellular cytoskeleton, where the viral DNA is
released into the nucleus (Dales et a!., 1973).
After shutting off host macromolecular synthesis herpesviral transcription
occurs in the host cell nucleus, with the subsequent translation by cellular
proteins taking place in the cytoplasm. Herpesviral protein synthesis occurs
via a controlled cascade system with each temporal set of proteins synthesised
regulating the production of subsequent viral gene products (Stamminger et
aL, 1990). The immediate-early genes (a-genes) are the first to be expressed.
Most a-gene-products have been found to have regulatory functions and begin
to be synthesised approximately 2 - 4 hours post-infection. A failure in
production of these proteins results in failure to produce the early gene (f3-
gene) products responsible for the organisation of viral DNA replication. Viral
DNA replication, by the "roIling-circle" method, is mediated by a group of 7
virus-encoded polypeptides including a DNA polymerase, a single-strand DNA
binding protein and a protein complex which has primase and helicase
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Figure 1. a. Schematic representation of a mature herpesvirus virion
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Figure 1. b. Negatively-stained herpesvirus particle (varicella-zoster virus)
examined b y electron-microscopy. Photograph supplied h Mr. Steven Rice,
Department of Virology, UCLMS. Bar = lOOnm.
functions (Challberg et aL, 1986 and Crute et aL, 1989). The appearance of
the viral f3-gene products signals the onset of viral genome replication. The
final group of herpesvirus gene products are encoded by the late genes
(y genes), of which the most important and prevalent is the major capsid
protein (ICP5 in HSV- 1, p150 in EBV and UL86 in CMV all of which have
significant intervirus homology: Dolyniuk et a!., 1976 and Chee et a!., 1989).
It is believed that the capsid protein, although a y-gene product, is produced
throughout the cascade sequence but its concentration increases dramatically
during and after DNA replication (Roizman, 1993). Following production in
the cell cytoplasm capsid proteins are amalgamated into empty capsids and
transported to the nucleus where the newly-synthesised, concantermeric, viral
DNA is processed and inserted (Ladin et a!., 1982).
After construction of the viral capsid and introduction of the viral genome the
progeny particles are transported to the cell surface where they are enveloped
in the cell membrane. Prior to this envelopment the synthesised viral
glycoproteins are processed cytoplasmicaly (Campadelli-Fiunie et a!., 1985).
After passage through the plasma membrane and acquisition of these
membrane-based glycoproteins the progeny virions are released into the
extracellular environment by reverse endocytosis displaying a typical
morphology common to all members of the herpesvirus family (figure ib).
As well as having a regular physical structure herpesviruses share two
properties which may be considered characteristics of members of the family.
Firstly they are widespread in the animal kingdom, with over 100 animal
species having at least one associated herpesvirus (Roizman, 1993). Amongst
humans eight distinct species of herpesvirus have already been discovered
most of which are present in much of the world's populations, with little
regard of race, geographical origin or socioeconomic status. Secondly, all
members of the family are able to establish latency in infected cells. This is the
ability of these viruses, following infection of a cell, to not only subvert the
host cellular machinery and produce new virions; the lytic cycle of virus
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replication, but also to persist indefinitely in the infected cell (see section 1. a.
2.) (Baringer et a!., 1976 and Henderson et al., 1977). The majority of
individuals who have been infected by a herpesvirus will continue to cariy the
virus in its latent state for life, occasionally experiencing brief periods of viral
emergence or low level chronic replication. It is the high incidence of
herpesviruses in the population together with their ability to reactivate from
latency, replicate to high titre and cause disease in the absence of effective
immunological control which makes this group of viruses of such clinical
significance in the immunocompromised host.
1. a. 2. Herpesviral latency
Crucial to the understanding of the clinical consequences of herpesvirus
infection in man is the process of virus latency. It would appear that all human
herpesviruses can achieve latency in certain cell-types allowing evasion of host
immune surveillance and subsequent reactivation and replication at a later
time. In this section the current theories of viral latency as they apply to the
neurotropic herpesviruses HSV-1 and HSV-2 as well as the lymphotrophic
herpesviruses EBV and human herpesvirus 8 (HHV8) are examined.
Latency may be divided into a number of stages, each of which appear highly
controlled but are not currently well understood. The first process in the
establishment of latency is the primary infection of susceptible cells. It is
important at this stage that the virus does not enter into its cascade of gene-
product translation as this will result in cytocidal death of the cell (B rmanns
et al., 1993). For HSV-1 the site of latency is the body of sensory neuronal
cells (Rock et al., 1983). Once the virus has reached this cell site the a-gene
trans-induction factor (ct-T1[F), a structural part of the virion, would usually
interact with the de-encapsulated viral DNA to initiate the transcription
cascade (Post et aL, 1981). However, by binding with the cellular transcription
factor Oct-2 it is thought that such interaction is inhibited and the cascade
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arrested before production of the ICPO gene product. ICPO is a nuclear
phosphoprotein which acts as the initiator of the HSV lytic cycle protein
cascade (Jordan and Schaffer, 1997). In this latent condition the viral DNA is
maintained as a circular molecule in the nucleus in an episomal state. During
latency none of the usual a, (3 or y genes are translated, instead two types of
latency-associated transcripts (LAT) are produced (Stevens et aL, 1987 and
Rock et a!., 1987). The two most abundant forms of LAT are 1.5 and 2.0 Kb
in size with the smaller transcript derived from the larger by post-
transcriptional splicing. The functions of these transcripts are still to be fully
determined but as they are sequence-complementary to the ICPO gene, and
overlap that site, they may act to maintain latency by anti-sense action
preventing ICPO transcription (Rock et aL, 1987). As no HSV viral proteins
have yet been detected during the state of latency it would appear that by
whatever action these LAT's exert their activity it is they alone which ensure
the continuance of the viral latent state.
Mechanisms by which the latent HSV genome can reactivate are also currently
poorly understood. It is known that a variety of stimuli are capable of initiating
reactivation including; local tissue damage, unassociated host illness, a
reduction in the host immune level and irradiation with ultra-violet light
(Spruance et a!., 1985 and Muller et a!., 1972). The actual molecular
mechanisms required for production of ICPO and entry into the cascade of
viral polypeptide production are unclear, although it has been suggested that
the latent genome load in a cell nucleus may influence the ease by which the
latent state is broken (Roizman, 1993).
The y-herpesviruses EBV and HF{V8 appear to exhibit a number of differences
from HSV in the establishment and maintenance of latency and, rather than
their site of latency being the bodies of sensory neuronal cells, both these
viruses are able to become latent in peripheral blood B lymphocytes (Tosato et
a!., 1985). The establishment of EBV latency results in the ihimortalisation of
those latently infected cells (Sudgen et a!., 1977) and, unlike HSV, a larger
28
portfolio of viral transcripts are produced by EBV during latency. In common
with HSV two small non-p olyadenylated RNA molecules are transcribed and
may be present at extremely high copy number, up to i07 copies per infected
nucleus (Howe et al., 1986). There have been two proposed functions of these
transcripts, although in vitro data is far from conclusive. They may have effect
by directly inhibiting the activation of a cellular interferon-induced protein
kinase. This would cause a block in cellular translation by preventing
phosphorylation of the protein synthesis factor eIF-2 alpha, thus stopping
EBV protein production. Alternatively they may exert influence by acting as
RNA-splicing catalysts for the post-transcriptional processing of the Epstein
Barr viral nuclear antigen (EBNA) complex. The EBNA complex was first
detected by immunofluorescence and has been found in the nucleus of EBV
latently-infected cells (Klein et a!., 1974). The complex is now known to
consist of at least six proteins but their individual functions are not all clearly
understood. EBNA 1 appears to have a primary function of maintaining the
episomal state of the EBV genome during latency (in contrast to the inert
genome of HSV during latency) and exerts its activity by binding to the latent
replication origin of the viral genome (Rawlins et aL, 1985). From studies of a
variety of EBV-associated conditions EBNA 1 would appear to be the only
viral protein which is uniformly expressed in all EBV-infected cells. EBNA 2
is a transcription factor but interacts with the cellular protein RBK-JK rather
than directly with viral or cellular DNA. Its role, if any, in latency is undefined
but it appears to be important in the up-regulation of certain cellular proteins,
including the B-cell activation protein, CD23, which in soluble form has been
found to act as a growth factor for B cells and to up-regulate the production
of the EBV receptor protein CD21 (Wang et a!., 1987). It is the antigeuicity
of the EBNA 2 gene product which defines the two sub-types of EBV; EBV 1
which is more common in Western populations and EBV 2 which is prevalent
in central Africa. The family of EBNA 3 genes are also type-specific and as
well as causing up-regulation of CD21, the EBV receptor, modulate the
transcription of the EBV latent membrane protein (LMP).
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Also expressed during EBV latency are the EBNA leader protein and the two
LMP's. Functions of the EBNA leader protein are unknown although co-
localisation with the cellular retinoblastoma protein and p53 has been noted
(Mannick et aL, 1995). LMP 1 is found in the cell membrane and has been
shown to have a direct cellular transforming ability in epithelial cell lines as
well as inducing cellular anti-apoptotic genes, including bcl-2, thereby
supporting cell immortalisation (Nicholson et al., 1997). LMP 1 effects on
cellular expression are mediated Through the cellular NFx:B transcription
factors and through direct interaction with the cellular tumour necrosis factor
receptor-associated factors (TRAF) which are responsible for cell cycle and
apoptosis regulation. Studies using EBV mutants which produce truncated
LMP 1 gene products, unable to bind TRAF, have shown that this interaction
is an absolute requirement for EBV-transformation of primary B-lymphocytes
(Izumi et a!., 1997). The second membrane protein, LMP 2, co-localises with
LMP 1 in patches on the cell membrane (Lougnecker et a!., 1990) and is
associated with the lyn-tyrosine kinase. The association would appear to block
activation of infected B-cells by interfering with the signaling pathway from
activated immunoglobulin receptors and is thought to be crucial to
maintenance ofEBV in its latent state (reviewed in Roizman, 1993).
As can be seen information on the molecular processes by which EBV
maintains latency in iminortalised B-lymphocytes remains fragmented. Even
less is known about the entry of HIHV8 into latency. Currently two KNA
transcripts have been detected in HHV8 latently-infected B cells. One of these
0.7 Kb in size (T0.7) has been found difficult to express as a protein, the other
1.1 Kb (Tl.1) in size has no perceived translational form (Staskus et al.,
1997). Neither of these transcripts have any known function but may both be
commonly detected in latently infected cells, although Tl.l also appears to be
an important factor in HHV8 lytic replication. Currently only one latency-
associated nuclear protein has been described in HHV8-infected cells, the
1{HV8 latent nuclear protein (LNP) (Rainbow et al., 1997)' This protein, of
230 Kd, is encoded by a region of the HHV8 genome which shows poor
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homology with other 'y-herpesviruses and any functional similarities between
LNP and the EBV EBNA proteins is undetermined at this time (Neipel et al.,
1997).
Transcriptional activation from the latent state by the y-herpesviruses is also
poorly described, however studies have highlighted the importance of the Z-
encoded Epstein-Barr replication activator, or ZEBRA protein in EBV (Miller
1990). This is a viral switch protein encoded in the BZLF1 gene of EBV
which acts as a transcriptional activator to allow production of the EBV a-
gene products, including possibly ICP0nd the viral DNA polymerase (Miller
1990). Activation of these genes re-initiates the cascade system of lytic
virus replication with the viral polymerase producing new linear genomes
which may then be packaged into naked virion capsids. The detection of
ZEBRA is a definitive marker of permissive, lytic infection in the cell.
Unfortunately the HHV8 genome does not appear to have a genome sequence
with homology to the BZLF1 gene, although it does possess a homologue to
the EBV BRLF1 transactivator which has also been postulated to have role in
viral reactivation (Russo et al.1996, Zalanai etal., 1996).
-r
the analogue of HSV-1 ICPO
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1. a. 3. Herpes simplex viruses
There are two closely related, but distinct, types of herpes simplex virus; type
1 (HSV-1) and type 2 (HSV-2). Both have been classified as a-herpesvimses,
this designation relates to their variable host range, short replicative cycle
both in vivo and in vitro, and capacity to establish latency in sensory ganglia
(reviewed in Steiner, 1996). As well as these factors these two closely-related
herpesviruses share many biological properties, including their preference for
initial infection via mucosal epitheliwn, either orally (J)redominantly HSV- 1) or
ano-genitally (predominantly HSV-2) (Juretic et a!., 1966). The HSV-1 and
HSV-2 encoded proteins have been extensively studied (Knipe, 1989 and
Roizman and Sears, 1990) with two (gB and gH) having homologues in all
other members of the human herpesvirus subfamily.
During primary HSV infection shallow fragile vesicles, which rapidly ulcerate,
can be seen in the involved mucous membranes. These are associated with
localised pain, itching, swelling and discharge. Systemic symptoms of fever
and malaise are also common. After entry into the host and systemic spread
the virions are transferred by retrograde axonal transport to the dorsal root
ganglia where life-long latency is established (see section 1. a. 2.). From this
site of latency there may be periodic bouts of reactivation which usually only
cause the local symptoms of primary infection but do allow for horizontal virus
transfer to susceptible contacts (esario et a!., 1969). Such reactivation is
common following unrelated illness, fatigue and iinmunosuppression. For both
the types transmission may. be via infected saliva, , cervical secretions
or infected genital epithelium. By the end of pubescence over 50% of most
world populations have been infected with either or both types of HSV
(Wentworth eta!., 1971).
HSV infections are usually minor clinical events requiring no specific
treatment and resolving through the actions of the host immune system,
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particularly the CD8+ve T cell-mediated immunity, within a few weeks
(reviewed in Roizman, 1993). However in more susceptible individuals, such
as the immunocompromised host, HSV infection, both primary, and as a result
of viral reactivation, may result in widespread, systemic, disease. In neonates
transmission from the mother may occur either in utero or more commonly at
birth during passage through the HSV-infected vagina. Symptoms can range
from localised eye and skin lesions to involvement of the brain in the form of
an encephalopathy and a life-threatening systemic infection affecting multiple
organ systems including the central nervous system (CNS), lungs, liver,
adrenals, skin, eye and mouth. In the systemic form of neonatal HSV infection
up to an 80% case-fatality rate has been recorded, with survivors frequently
suffering from long-term neurological sequelae (Whitley et aL, 1985). Such a
spectrum of disease is also seen in the adult inimunocompromised host where,
however, the source of virus is most likely to be from the reactivation of latent
HSV following a previous infection, rather than from a primary infection. Such
reactivation leads to viral transfer by axonal transport to the sites of primary
infection where viral replication may cause extensive genital and oro-facial
lesions which are both painful and disfiguring (Whitley et a!., 1984 and Mann
et aL, 1984). A range of internal organ sites may also become affected by
HSV infection, most severely the brain and CNS where infection, in these
individuals, may lead to a number of central and peripheral neurological
symptoms associated with damage to the temporal lobes and mening es. The
incidence of HSV-related neurological disease in the immunocompromised
host is not thought to be significantly higher than in the general population,
however in patients with severe inimunodeficiency its course may be
protracted and the sequelae more pronounced (Schiffet al., 1998).
Treatment of individuals with severe HSV infection is with the anti-
herpesvirus chemotheraputic acyclovir (ACV), a nucleoside analogue inhibitor
of HSV genome replication. To be active against HSV ACV first requires
triphosphorylation. The conversion to the monophosphate foim is mediated by
the action of a viral thymidine kinase (TK) enzyme. Cellular kinases then
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complete the phosphorylation producing the active ACV-triphosphate. The
triphosphorylated. form of acyclovir acts as a DNA chain terminator by
incorporation into the newly-formed lengths of HSV genome synthesised by
the HSV-encoded polymerase enzyme (Elion et al., 1977). Its effectiveness is
due to the 100-fold higher affinity of the drug for the HSV-encoded
polymerase in comparison to the host cell polymerase, as well as an absolute
requirement of the viraly-encoded thymidine kinase for drug
monophosphorylation. Both these factors allow high plasma levels of ACV to
be tolerated in the patient without the development of undue toxicity. Indeed
in certain inimunocompromised patients, such as those experiencing severe T-
cell mediated immune dysfunction because of HIV-infection or due to
radiological preparation for organ transplantation, acyclovir can be given for
prolonged periods as a prophylactic therapy to prevent HSV and
cytomegalovirus (see section 1. a. 6.) reactivation and disease (Wolf et a!.,
1993). Although not usually necessary for the self .limiting disease seen in the
immunocompetent host ACV has been a highly effective drug in the treatment
of HSV infections in the immunocompromised. The use of conventional and
multiplex PCR for the diagnosis of HSV infection in the CNS and ocular sites
of HI\T-infected patients is discussed in sections 3. e. and 3. f.. Such molecular
detection methodologies have significantly decreased the time required to
confirm a diagnosis of cutaneous and / or systemic HSV infection and initiate
appropriate ACV therapy.
1. a. 4. Varicella-Zoster virus
In common with the two herpes simplex viruses varicella-zoster virus (VZV) is
an a-herpesvirus which shows significant homology in gene layout with HSV-
1 and HSV-2 (Davidson and Scott, 1986). VZV is globally widespread, with
the majority of infection occurring before puberty (Preblud et a!., 1984). Two
distinct patterns of disease are associated with VZV, depeiding on whether
the infection is of a primary or reactivative nature. Primary infection most
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often occurs by inhalation of expelled droplets containing virus particles and
infection of the mucosa of the upper respiratory tract and oropharynx. From
this site there is rapid dissemination of the virus through the body via the
blood and lymphatic systems. When the virus reaches the epithelial cells of the
skin focal lesions develop, containing high titres of virus (1O mF' ), which
form the characteristic "chicken-pox" rash. Usually this disease is mild and the
host immune-system terminates the viremic phase in approximately 3 days,
after which no new lesions are seen (Asano et a!., 1985). Disease associated
with primary infection may be significantly more severe when acquired in
utero during the first trimester of pregnancy and in adults past the age of
pubescence (Feldman et a!., 1975 and Stagno and Wlritley, 1985).
Occasionally in these individuals lesions can be found in the mucosa of the
respiratory, gastrointestinal and genitourinary tracts and the parenchymal
membrane of almost all organs. In these patients varicella-associated
pneumonia is the most serious consequence of infection. Infection and direct
damage to the central nervous system (CNS) has been described and is
responsible for about 20% of chicken pox-associated hospitalisations in
children aged 5 - 14 (Fleisher eta!., 1981).
As is characteristic with all the herpesvirus infections VZV will enter a latent
phase following primary infection. The sight of latency are the dorsal sensory
ganglia where the virus remains quiescent. Various factors have been
associated with viral reactivation. As for HSV most of these have the effect of
temporarily lowering host immune function, particularly the cell-mediated
immunity, and it is believed that it is this drop in immunological control which
contributes to the re-commencement of VZV replication in the sensory
ganglion. Virus particles then pass down the sensory nerves sometimes
producing neuronal necrosis and inflammation until reaching the skin, where a
number of clustered vesicles form in a dermatomal pattern closely associated
with the underlying nerve cells down which the virus has traveled (Straus et
aL, 1984). These vesicles are the visual manifestation of VZV reactivation;
known as herpes zoster. Such zoster lesions will generally heal quickly in a
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similar manner to those produced during chicken pox although there may be
an associated post herpetic neuralgia especially in patients over the age of 60.
This neuralgia may be prolonged even if ACV therapy has been initiated
during the herpes zoster episode. A less common site of zoster is the eye and
associated skin. Occurring in approximately 15% of patients this is the result
of virus transfer down the ophthalmic division of the trigeminal nerve
(Ragozzino et al., 1982). Morbidity arising from this complication demands
ACV therapy.
The severity of VZV infection may be significantly increased in the
immunocompromised host, especially in those experiencing a primary
infection, where persistent viremia may result in severe cutaneous zoster as
well as involvement of the lungs, liver and CNS. These symptoms can be
particularly serious and potentially fatal in paediatric patients with an
underlying inimunodeficiency who have lost immune protection from maternal
antibodies. However, in general, VZV disease due to reactivation in adults
with severe immunodeflciency can be effectively treated with high dose
intravenous ACV and is not associated with significant levels of patient
mortality (Geib et aL, 1990). The multiplex PCR
methodology described in section 3. f includes reagents for the detection of
VZV DNA. Commonly CNS and ocular fluids from immunocompromised
patients would be analysed by this method to determine the presence of VZV
genome allowing rapid intervention with ACV.
1. a. 5. Epstein-Barr Virus
Epstein-Barr virus (EBV), a y-herpesvirus, has markedly different biological
properties to those of the a-herpesvimses described above and is more closely
related at the genomic level to a number of old world monkey herpesviruses
such as herpesvirus saimiri (HVS) (Baer et al., 1984). All of these
y-herpesviruses have a restricted host cell range and replicate predominantly in
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immunoglobulin-producing B lymphocytes, the site where latency is also
established. Following latency a group of viraly-encoded proteins; the EBV
nuclear antigens (EBNA's) are produced both to maintain the state of latency
and, in the case of EBNA-2 induce B-cell immortalisation, a well-described
characteristic of EBV infection (see section 1. a. 2.). As well as B-cells EBV
has also been found to infect some types of epithelioid and fibroblastic cells,
where lytic infection occurs with the production of projeny virions and cell
death (Sixbey et aL, 1984). Attachment of EBV to susceptible cells is
mediated by the virus-encoded gp 350 / 220 complex with the C3d
complement receptor, CR2, of cells (Fingeroth et aL, 1984). It is the epithelial
cells of the oropharynx which are commonly the site of primary infection and
may support a continuing low level of persistent replication and phaiyngeal
shedding for extended periods of time allowing efficient transfer to other
susceptible individuals (Gerber et al., 1972 and Ailday and Crawford, 1988).
Most transmission of EBV is via infected saliva and usually occurs during
social contact early in life, with little associated disease, resulting in a
seroprevalence of 80-90% in most populations by early adulthood (Crawford,
1994). However, if a susceptible individual is infected with EBV late in
childhood or during adolescence a range of clinical symptoms may then occur
including sore throat, fever, headache and malaise and are given the general
name infectious mononucleosis (IM), or glandular fever (Henle and Henle,
1986 and Neiderman et a!., 1970). Such symptoms may be due to the
cytotoxic T-cell response the body mounts to EBV-infected B lymphocytes.
Complications of IM such as jaundice, myalgia and neurological symptoms are
rare and although there have been reports of fatal lymphoproliferative disease
in pregnant women with IM there are few reports of foetal damage during
maternal primary infection (Straus eta!., 1985 and Hotchin et a!., 1989). Most
fatalities associated with IM have occurred in individuals with X-linked
lymphoproliferative syndrome (Crawford, 1994) as such patients are unable to
mount a cell-mediated immune response to EBV infection.
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The range of EBV-associated disease in immunocompetent populations has
been found to differ dramatically depending upon geographical location. In
western Europe, Australasia and the America s IM is by far the most usual
clinical consequence of EBV infection, however in equatorial Africa Burkitt's
Lymphoma (BL) is a common EBV-associated childhood malignancy which
accounts for nearly 80% of all childhood cancers in the area (Burkitt et a!.,
1958). The general incidence of BL is 1 case per 3000 children during the first
15 years of life, with one prospective study in Uganda of 42,000 children
showing that 12 developed BL (The et a!., 1978). Because of the restricted
geographical nature of BL associated co-factors have been suggested
including malnutrition and the high local incidence of malaria. It has been
postulated that EBV-infection stimulates B-cell division and hence the number
of infected B-cells, an undefined co-factor (probably co-incidental malaria)
then impairs T-cell capacity to control proliferation of the immortalised B-cells
(in an analogous manner to the X-Iinlced lymphoproliferative syndrome) in
which activation of the c-myc oncogene is common. This sequence of cell
cycle control failure then leads to the establishment of lymphatomous tissue
(reviewed in Roizman, 1993). BL was also one of the first tumors shown to
have a characteristic chromosomal translocation involving chromosome 8 near
the location of the c-myc oncogene and a site on either chromosome 14 or 22.
This rearrangement alters the regulation of expression of c-myc by placing it
under the control of a strong immunoglobulin gene promoter present in
chromosome 22 (Lenoir et aL, 1982). All African BL tumours contain EBV
DNA in each malignant cell and in every tumor the latent EBV episomal
genome has been found to be clonal indicating tumour generation from a
single EBV-infected cell (Nonoyama et a!., 1973). The latency-associated
protein EBNA 1 has also been consistently detected in BL tissue (Rymo et czL,
1979).
In southern China nasophaiyugeal carcinoma (NPC) is another EBV-
associated tumor which is over 50 times more common in that population than
in European and north American Caucasians (Ho et a!., 1978). In a similar
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manner to African BL EBV genomes have been found in all NPC-associated
cells and the tumours have been shown to be clonal in origin (Wolfe et aL,
1973). However in contrast to the lymphoid BL in NPC, an epithelial tumour,
not only is EBNA 1 expressed so too are LMP 1 and 2 as well as the EBER
RNA transcripts (Brooks et al., 1992). No c-myc rearrangement has been
noted in NPC. Other co-factors which are thought to be required for disease
development include a genetic susceptibility, possibly HLA-driven, and
environmental factors including local diet. Recently it has been shown that the
EBV positive NPC-transformed cells appear able to avoid cytotoxic T-cell
immunological responses (Tsukuda et a!., 1993). It is thought that an, as yet,
unidentified viral protein inhibits viral antigen presentation and thereby
circumvents immunological response allowing development of the tumour.
In the immunocompromised host, especially those who are HIV-infected, EBV
has been found to be present in a much greater percentage of peripheral blood
cells than in normal EBV-seropositive individuals (Birx et al., 1986). In
section 3. a. 4. detection of EBV DNA in the peripheral blood of }IIV-infected
individuals is analysed as a control in determining the proposed association of
the other y-human herpesvirus, I{HV8, with Kaposi's sarcoma. The increased
systemic titre of EBV DNA in immunocompromised patients is probably a
reflection of the reduction of immune surveillance in these patients and
consequent increase in EBV replication. The increase in EBV viral load is also
paralleled by the number of EBV-associated diseases found in the
immunocompromised host. These are generally known as progressive
lymphoproliferative disorders. Such diseases have a wide spectrum of severity,
from inconvenient to life-threatening. Oral hairy leukoplakia (OHL) was at
first thought to be a direct result of 11EV-infection as it was almost completely
restricted to HIV-seropositive individuals. Subsequently OIIL has been shown
by in situ hybridisation to be LB V-related and manifests as a bilateral white
lesion of the tongue of usually no more than cosmetic significance (Neidobitek
et a!., 1992). Of far more clinical importance is the high incidence of non-
Hodgkin lymphoma (NEIL) in immunosupressed individuals (Levine et al.,
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1990). AIDS-related NT{L probably occurs after the loss of function of
CD4+ve helper lymphocytes and is due to the immortalisation and
uncontrolled replication of EBV-infected B-cells. It is described as an "end-
stage" disease, i.e. occurring when immune status, as defined by CD4 T-
lymphocyte count, has fallen from the norm of 1200-1500 to below 200. NHIL
is actually a spectrum of disease which ranges from polyclonal
lymphoproliferation to mono clonal lymphoma, all of which may have systemic
involvement, most AIDS-related NTiIL's are high-grade with approximately
60% being B-cell immunoblastic in type. Although EBV can be detected in the
majority of N}IL types, other factors such as re-arrangement of the c-myc
gene have also been found to be associated, in a similar fashion to African BL
(Bhiata et a!., 1994). As well as in systemic NELL EBV has been found in
virtually all AIDS NELL presenting as primaiy central nervous system (CNS)
lymphoma (MacMahon et a!., 1991). Almost 40% of AJDS-NT{L have CNS
involvement. Although response to therapy for CNS lymphoma, involving
combination chemotherapy and radiotherapy is noted, in a large percentage of
patients median survival is less than six months due to the frequent
uncontrolled relapse of disease.
Patients experiencing acute immunosuppression following solid organ, or bone
marrow, transplantation are prone to a spectrum of post-transplant
lymphoproliferative diseases associated with EBV infection (especially primary
infection), (Crawford et al., 1980 and Languas et a!., 1991). These are
characterised by an unregulated expansion of EBV-immortalised B-cells and
most have been shown to be clonal in origin (reviewed in Nalesnik, 1996). As
with the fflV-infected individuals immunosuppressed transplant patients have
a poor prognosis with such disease, and although initially responsive to
chemotherapy commonly experience only a short duration of remission. In fact
in these non-HIV-infected patients the most effective "treatment" appears to
be a return of the patient to a normal immune status as rapidly as possible.
This allows restored functioning of the individuals cytotokic T-cell (CTL)
response which, in contrast to NPC, is effective against the EBV-infected
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lymphocytes due to their fill expression of all EBV-latent proteins (Murry et
a!., 1988). Immune function can be restored by the reduction of
immunosuppressive therapy used in such patients although this may not always
be possible as reduction often results in subsequent rejection of the
transplanted organ. Alternatively studies have recently begun on the
therapeutic effectiveness of EBV-specific CTL infusions in patients for whom
a return to normal immunological status is impossible (O'Reilly et a!., 1997
andHeslopand Rooney, 1997).
1. a. 6. Cytomegalovirus
Human cytomegalovims (CMV) is a 3-herpesvirus with a highly complex
genome showing a number of regions with extensive homology with human
DNA sequences (Ruger et a!., 1984). The only cells fully permissive for CMV
infection in vitro are human fibroblasts, with the CMV replication cycle slower
than that of the a-herpesviruses. CMV is, among the herpesvirus family, the
single greatest cause of morbidity and mortality in the immunocompromised
patient. As with all the herpesviruses described previously it is a widespread
virus in most populations with over 50% of individuals commonly infected by
adulthood (reviewed in Ho, 1990). CMV may be transmitted casually via
infected saliva or sexually via semen or cervical secretions (Wenzel et a!.,
1973 and Lang et a!., 1974). Sexual transmission of CMV is particularly
common in homosexual males (Spector, et a!., 1984). Maternal-infant
transmission has also been noted in utero and via infected breast milk
(Dworsky et al., 1983). Primary infection, usually early in life, is
predominantly sub-clinical although if transmission occurs in utero, especially
in the first trimester of pregnancy following maternal primary infection, the
foetus may experience cytomegalic inclusion disease, a syndrome that can
result in the subsequent still-birth of the child or damage to a number of foetal
organs such as the CNS, liver and kidneys (Sawyer et al., 197).
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After primary infection CMV can be isolated from monocytes and T-
lymphocytes, the virus has also been detected in endothelial and ductal
epithelial cells in the salivary glands where a chronic low-level production of
virus, in a similar manner to EBV, may be established and be a source of
transmissible virus to other susceptible individuals. Cytomegalovirus appears
to achieve latency in peripheral blood mononuclear cells, with approximately 1
in iø of such cells containing viral genome (Garrett et a!., 1982). Latency is
maintained by the CMV major innnediate-early gene (IEJ). Reactivation of
CMV from latency may occur frequently and as with primary infection is
usually sub-clinical, however these periods of reactivation may be prolonged
due to the ability of the virus to evade certain parts of the immune system. The
virus is able to transfer directly from cell to cell thus reducing its
immunological "profile" to the cell-based and humoral arms of the immune
system. CMV also encodes a polypeptide (the UL1 8 protein) which has
homology to the heavy chain of the MHC class I molecule. This homologue
can bind with circulating cell-free j32-microglobulin causing interference with
CD8+ve T-lymphocyte recognition (Browne et al., 1990). Such CD8 T-
lymphocyte recognition has been shown, in murine CMV models, to be
important in immune control of CMV infection. By these mechanisms
persistent low-titre, as well as latent, CMV infections may occur, with up to
10% of infected individuals found to be shedding virus, usually in saliva or
semen, at any one time (Roizman, 1993).
Whilst infection in the inimunocompetent individual is of little clinical
significance CMV replication in the immunocompromised host, usually due to
reactivation from latency, may cause severe disease with associated morbidity
and mortality. CMV-associated disease is of such concern in the
immunocompromised host that great care is taken not to introduce CJ\'IV-
infected organs or blood products into a CMV naive solid-organ transplant
recipient or to introduce CMV-naive bone marrow into a previously CMV-
infected bone marrow recipient (see section 3. d.). However even if
transmission of CMV at the time of transplant can be avoided the level of
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immune suppression associated with such transplantation is sufficient to allow
reactivation of CMV in a previously infected host. Up to 50% of CMV
seropositive transplant patients may experience CMV-associated disease due
to viral reactivation (Pollard et al., 1988).
In the transplant patient population CMV disease usually presents as a high
grade fever, unresponsive to antibiotics, one to four months post-transplant.
This fever is probably caused by the systemic spread and replication of the
virus throughout the body. The virus may then cause specific disease at a
number of organ sites including the kidneys, liver and, most severely in bone
marrow recipients, the lungs (Weiner et al., 1986). Such a pneumonitis, even
with appropriate CMV therapy, has an associated mortality rate of
approximately 50%. If untreated, or if treatment is delayed, over 90% of
affected patients will die of respiratory failure (van der Meer et a!., 1996). -
Primary CMV infection and CMV reactivation have also been associated with
organ graft rejection and graft versus host disease (GVHI)) in all forms of
transplant, especially in those patients receiving renal and heart transplants
(Grattan et aL, 1989). Because of the high levels of morbidity and mortality
experienced from CMV replication in immunosuppressed transplant patients it
is common to treat prophylactically all patients, with serological evidence of
previous CMV infection, with ACV throughout their period of
immunosuppression. (Wolf et a!., 1993).
The spectrum of CMV disease in patients who are immune-suppressed due to
infection with FIIV differs subtly from that seen in the transplant patients. This
is due to the more extensive type of immunosuppression that HIV-infected
patients experience, especially in their ability to mount a cell-mediated
immunological response. CMV disease is also more common in HIV-iiifected
patients who have contracted HIIV through homosexual contact, reflecting the
increased number of CMV strains these patients have been exposed to through
such sexual contact (Drew, 1984). Instead of CMV pneuinonitis, which is
thought to require host T-Iymphocyte activity, as seen in transplant recipients,
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the most common sites of CMV disease in HIV-infected patients are the CNS,
the eye and the gastrointestinal (GI) tract. Infection of the eye may occur in up
to 30% of patients who have contracted H[V by homosexual contact and
affects the cells of the retina (Jabs et a!., 1989). If left untreated such infection
will result in rapid destruction of the retinal surface through direct viral lysis
and irreversible blindness. Following an initial unilateral retinal CMV infection
subsequent involvement of the second eye occurs in approximately 40% of
patients (Jacobson et a!., 1988). Infection of the GI tract may result in a
chronic disease characterised by mucosal ulceration, profuse watery diarrhea
and abdominal tenderness (Meiselinan et a!., 1985). Although not directly life-
threatening such disease is thought to contribute to the syndrome of 'HTV-
wasting" in which patients may lose up to 35% of their body weight and have
an associated poor life expectancy. With greatest significance to patient health
is CMV infection of the CNS. CMV encephalopathy and polyradiculopathy
are both common end-stage diseases in AIDS and have a high associated
mortality. The proportion of mV-infected patients that die as a direct
consequence of CMV disease is difficult to establish accurately. By this late
stage of AIDS, patients are commonly suffering from multiple organ disease
caused by a wide range of opportunistic infections and malignancies. However
some post-mortem studies of gay men who have died of AIDS have shown
that nearly half have direct damage of the CNS associated with CMV infection
(Morgello et al., 1987).
As well'behaving as an opportunistic pathogen in patients with I{[V-infection
there is a significant body of evidence that shows CMV infection directly
contributing to the immune destruction these patients experience. Indeed
primary CMV infection in homosexual men may in itself lead to an inversion of
the CD4+ve / CD8+ve lymphocyte ratio which is a hallmark characteristic of
AIDS (Camey et a!., 1981). CMV, like HHV6 and EBV, may also destroy a
number of cells important in control of the immune system by infection of
lymphoblasts, granulocytes and mononuclear cells (Detels et iL, 1984). It also
interferes with certain leucocyte functions including the release and response
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to 11-1 and fl-2 by 1-cells, HLA-DR expression and antigen presentation by
monocytes (Kapasi et aL, 1988). In addition to these direct effects CMV has
been found to interact with HP/-i. In vitro studies have found that
lymphoblastoid cell cultures infected with both CMV and I{IV-1 show
complete cellular lysis, whereas HI-i, or CMV-only infected cells show only
30% lysis (Casareale et a!., 1989). Bi-directional enhancement of CM\T by
HIV-1 and HIV-1 by CMV has been observed in CD4+ve cell lines, the later
due to the transactivation of transcription by CMV gene products of the long
terminal repeat sequence of H1V-1. Such interaction in vivo has been
suggested to be important in the progression of HTV-infection leading to the
development of the AIDS complex (Duclos et al., 1989 and Wiley et a!.,
1988). Additionally HIV- 1 infection of monocytes has been shown to render
these cells permissive for CMV infection and subsequent viral lysis. Analysis
of seroepidemiological data suggests that I{IV-1 infected patients with active
CMV infection are indeed at a greater risk of developing AIDS than CMV-
uninfected patients and that CMV retinitis is associated with H[V-1 p24
antigenemia and severe immune deficiency, whereas HIV- 1 p24 antigeneniia is
by itself not associated with a CD4 count decrease (Fiala et a!., 1986).
CMV disease in the immunocompromised host can be seen to be of extreme
clinical importance. Since the number of patients undergoing organ
transplantation is increasing and patients with H[V-infection are living longer
CMV-associated morbidity is likely to become evermore burdensome. Unlike
HSV-1 and 2 and VZV, ACV has little effect against active CMV disease,
although it appears a reasonable prophylaxis treatment in preventing CMV
disease in organ transplant recipients (Meyers et aL, 1988). There are however
two highly effective drugs, ganciclovir (GCV) and phosphonoformic acid
(foscarnet, PFA) which are currently licensed for treatment of CMV disease
(reviewed by Serody, 1993). Both GCV, a nucleoside analogue, and PFA, a
pyrophosphate analogue can interact with the CMV-encoded DNA
polymerase enzyme in preference to the host-cell polymerase thereby inhibiting
synthesis of new viral genomes. GCV may also function in the triphosphate
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modification as a chain terminating molecule in a similar manner as ACV-
triphosphate. Unlike ACV, both GCV and PFA are highly toxic in vivo
causing severe neutropenia and thrombocytopenia, and nephrotoxicity
respectively (Buhies et a!., 1988 and Meyers et a!., 1988). This toxicity makes
prophylactic use inappropriate and even when restricted to use in severe and
life threatening CMV disease either drug may have to be withdrawn or
exchanged for the other. Recently there have also been an increasing number
of reports of CMV isolates which have phenotypic resistance to one or both
drugs, either by mutation in the their CMV polymerase gene product or in the
CMV UL97 gene product which is a thymidine kinase-like molecule
responsible for the initial phosphoiylation of GCV to GCV-triphosphate
(Drew eta!., 1991, Baldanti et a!., 1995 and Chou et a!., 1997).
The development of improved diagnostic techniques for the diagnosis of CMV
disease in the inimunocompromised host and the monitoring of response to
treatment in a variety of affected patient groups forms a major section of this
thesis. The monitoring of systemic CMV DNA levels in recipients of
allogeneic bone marrow transplants is described in section 3. d.. This study
was undertaken in an attempt to reduce the time required for chemotheraputic
intervention in patients at risk of CMV pneumonitis and investigate the
incidence of active CMV replication in a cohort of these severely
immunocompromised patients in the first six months after their transplant. The
association between ocular and neurological CMV infection and disease in
end-stage AIDS patients is also examined in section 3. e..
1. a. 7. Human herpesvfruses 6 and 7
Both these 3-herpesviruses have only recently been described and are now
known to be closely related at the genomic level (Salahuddin et a!., 1986 and
Frenkel et a!., 1990). They were each first isolated from thd peripheral blood
of 11EV-infected individuals and can be cultured to high titre in T-lymphocyte
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cultures, reflecting their in vivo sites of replication. Although common at
extremely high frequency world-wide, due to their apparent ease of casual
transmission via infected saliva, neither human herpesvirus 6 (HHV6) nor 7
(HHV7) are associated with significant disease in the immunocompetent host.
However soon after discovery it was shown by in vitro studies that HHV6 was
able to transactivate the HIV long terminal repeat (LTR) sequences involved
in initiation of HIV replication and that both HHV6 and HHV7 could co-infect
the same target cell as IH1IV; the CD4+ve T-lymphocyte (Gab et a!., 1990). It
was therefore suggested that HHV6 infection, or reactivation, may act as a co-
factor for the up-regulation of HIV in infected individuals and may be
associated with progression of HIV-infected patients to the AIDS syndrome.
Currently little epidemiological evidence exists to support this hypothesis and
although single case studies have found HHV6 to be present in a variety of
EIIV-associated systemic tumors and CNS disease there is only rare evidence
for significant disease causation by either these viruses even in highly
immunosuppressed individuals (Fox et a!., 1988). The presence of FIHV6 and
HHV7 DNA in ocular fluid and neurological tissue of individuals who died of
AIDS-related disorders is investigated in section 3. f. T'his analysis was
performed to determine whether either of these viruses may be associated with
disease pathology at these specific sites in patients with extremely severe
immunodeficiency.
1. a. 8. Human herpesvirus 8/ Kaposi 's sarcoma-associated herpesvirus
Human herpesvirus 8 (HHIV8) is the most recently described of the
herpesviridae and like EBV belongs to the B-cell associated y-herpesvirus
group. Unlike the previous seven human herpesviruses HHV8 was not
discovered by culture isolation from clinical material but by direct detection of
sections of its genome sequence using the method representational difference
analysis (RDA) in tissue samples from an HI[V-infected patient with the
tumour Kapsoi's sarcoma (KS) (Chang et a!., 1994). The possibility of an
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infectious cause for KS was first suggested over thirty years ago (Giraldo et
a!., 1972), but it was not until KDA was performed and HHV8 DNA
discovered in KS tissue that a probable link with any one pathogen was
proposed.
KS is characterised as an angioproliferative, multifocal neoplasm localised
mainly in the skin, but which may have systemic involvement especially of the
lungs, oral cavity and GI tract (Friedman-Kein, 1982). Macroscopically the
cutaneous lesions first appear as small, flat lesions which progress to raised
purple nodules. These are generally painless, non-puritic and follow the sub-
dural pattern of lymphatic drainage. As the lesions develop they may be
associated with local edema and can evolve to form large infiltrating lesions
with or without ulceration and secondary bacterial infection (reviewed by
Levine et al., 1992). Histologically all forms of KS (see below) are
indistinguishable. The tumour is highly vascular, consisting of open slits of
endothelial spindle cells, lymphatic channels, an inflammatory infiltrate and
extravasculated erythrocytes. The spindle cells secrete paracrine factors and
cytokines that appear to promote angiogenesis (Ensoli et a!., 1989). The
mononuclear cells secrete cytokines which in turn stimulate the growth of the
spindle cells (Barillari et aL, 1992), these appear to be obligatory for the
formation of the tumour. In vitro studies have shown that the spindle cells
express receptors for a number of cytokines, including 11-1, 11-2, 11-6 and 11-8
as well as TNF, they also themselves produce high levels of 11-1 and 11-6
(Miles, 1993). The cell origin of KS spindle cells remains uncertain but it is
probably a mesenchymal progenitor of endothelial lineage (Uccini et a!.,
1994). It is still unclear whether KS can be regarded as a true malignancy or is
instead a multicentric proliferation of abnormal endothelial cells (Miles et a!.,
1993).
Before the HIV-pandemic KS was largely restricted to the members of
particular populations such as elderly southern Mediterraneah males (classical
KS) and children and adolescents from sub-Saharan Africa (endemic KS).
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Patients who received immunosuppressive therapy for organ transplant
operations also had an increased incidence of KS (iatrogenic KS) (Jacobson et
a!., 1995). Outside these groups the annual incidence of KS in the UK and
USA was extremely low, at approximately 0.02 - 0.06 per 100,000 of the
population per year (Bigger et a!., 1984). In 1981 there were a number of
reports of previously healthy young gay men in New York and San Francisco
presenting with an aggressive type of KS (Centre for Disease Control, 1981).
None of these men had any of the previously defined risk factors for the
disease, although all were found to have inverted ratios of blood CD4+ve and
CD8+ve T lymphocytes. The emergence of KS in this group (now termed
epidemic, or AIDS-KS) was amongst the first clinical evidence of the start of
the 11W epidemic. In the H1V-infected gay population the incidence of KS has
now remained fairly stable over the last fifteen years with about 30% of HIV-
infected gay men suffering from KS during the course of their HIV infection
(Jacobson et a!., 1990 and Peters et a!., 1991,). However the overall patient
mortality from KS has increased during this period, probably due to effective
treatment of other opportunistic pathogen diseases such as Pneumocystis
carnii pneumonia (PCP). Studies have shown that KS, mostly because of
pulmonary involvement, may now be responsible for over 30% of I-]IV-
infected homosexual deaths and can be found systemically in over 50% at
post-mortem (Ndimbe et at., 1994). In contrast the tumour remains extremely
rare in HIV-infected patients who do not originate from sub-Saharan Africa or
who do not have homosexual contact as their prime risk factor for BTV-
acquisition (Beral et at., 1990).
Before the discovery of the HHV8 sequences a number of viral pathogens had
been suggested as possible causative agents of KS, these included hepatitis B
virus, CMV, human papilloma virus and }{HV6, indeed viral particles of a
herpesvirus morphology had been visualised in KS lesions as early as 1972
(Giraldo et a!., 1972). However the prevalence of these viruses did not
accurately match the incidence of KS, nor the specific geogrphical, racial and
sexual-preference backgrounds of individuals at high risk of KS development.
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If a herpesvirus, in particular, was to be the cause of KS it would need to
differ in its epidemiological characteristics from all previously discovered
human herpesviruses by having a markedly restricted geographical prevalence
while being present at high frequency only in those patient groups affected.
Although the abnormal endothelial and epithelial cells may be cultured from
KS tissue HHV8 has yet to be isolated directly from such cultures, even
though these cultures have subsequently been shown to contain HHV8 DNA
(Boshoff et al., 1995 a). The failure to isolate infectious particles from KS
tissue and cultured cell lines led to the use of the RDA method by Chang and
colleagues in 1994. RDA allowed comparison between the genetic compliment
of KS cells and enabled isolation of sequence differences between that DNA
and the DNA present in unaffected cells (Lisitsyn et a!., 1993). This led to the
discovery of two small sections of DNA specific to the KS tissue.
Identification of these sequences enabled design of oligonucleotide primers for
detection of the novel sequences by the polymerase chain reaction (PCR) (see
section 1. b. 3.) and allowed comparison with previously described viral
genome sequences. When compared with known herpesviral genomes the
sequences were found to have a high degree of homology with the y-
herpesvirus group, especially HI/S and EBV. The virus from which these
sequences were thought to be derived was provisionally called Kaposi's
sarcoma-associated herpesvirus (KSHV), it is now also known as human
herpesvirus 8 (HHV8). Once PCR reagents were available for the detection of
HHV8 DNA sequences a number of studies were conducted to determine their
prevalence in a variety of tissues. It was found that almost all HIV-associated
KS tumors contained H}1V8 DNA, but in only very few non-KS control skin
samples could the virus be detected (Boshoff et a!., 1995b, Moore et a!.,
1995, Schalling et a!., 1995, and Dupin et a!., 1995). Viral particles with
typical herpesviral morphology have now been visualised by electron
microscopy from HHV8 DNA positive KS skin lesions (Orenstein et a!.,
1996). HHV8 DNA was also found at other sites in the body, in the blood of
HII\f-infected patients with KS(Whitby et a!., 1995), as well as bronchial
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washings from I-IIV-infected patients with the pulmonary form of KS (Howard
et al., 1995). In the non-HIV infected population I-[HV8 DNA was not found
in a large variety of cutaneous cancers but was consistently found in KS
tumours from the risk groups described above. These initial findings supported
the theory of a causal association between HHV8 and KS. As well as being
associated with KS, HHV8 DNA was also detected in a number of other,
predominantly FIIV-associated, malignancies including the rare body-cavity
based lymphomas (BCBL) and multicentric Castleman's disease (MCD,
Cesarman et aL, l995and Soulier et al., 1995). Recently an association with
multiple myeloma has been suggested, however to date there has been little
independent confirmation of this finding (Rettig et al., 1997asee section 3c,). 	 (
HHV8 has now been grown in a continuous culture system using HHIV8-
transformed B-lymphocytes from patients with BCBL (Arvanitakis et al., 1996
and Boshoff et aL, 1998). In these cell lines (see section 2. a.) HHV8 is
latently present in all cells, with or without the additional presence of EBV, at
a concentration of approximately 20 - 100 copies per cell. In this latent state
HHV8 produces a sufficient antigenic profile to have enabled use of the cell
lines in the development of serological assays for the detection of antibodies to
HHV8 (Miller et a!., 1996, Gao et a!., 1996 and Simpson et aL, 1996). Such
assays are analogous with those developed for the detection of EBV
antibodies using EBV latently-infected lymphoblastoid cell lines (Hotchin et
a!., 1991). Active expression of the viral lytic-cycle proteins can also be
achieved in these cell lines by stimulation with a number of compounds,
including sodium butyrate (Lennette et a!., 1996). To date no HHVS-
susceptible cell lines have been described although there have been reports of
the adenoviral-transformëd cell line 293 supporting some viral replication
(Foreman et a!., 1997).
Indirect iinmunofluorescence (IF) assays, using both the HHV8-infected
BCBL cell lines, and recombinant HHV8 proteins haVe allowed some
epidemiological surveys of the prevalence of HHV8 (see sections 2. d. and 2.
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e.). These studies indicated that, as expected, the virus is present in a very low
percentage of western populations; the seroprevalence in the UK and USA
would appear to be between approximately 1 and 5% (Simpson et cxl., 1996).
In populations from areas where KS is endemic the seroprevalence is between
3 5-70% (Gao et a!., 1996, Kedes et a!., 1996, Miller et a!., 1996 and Chang
et a!., 1996). Antibodies to the virus are also present in a high proportion of
gay men and in nearly all HIV-infected gay men with KS (Kedes et a!., 1996
and Chang et a!., 1996). Currently almost all patients with classical KS have
been found to have detectable circulating levels of antibodies to HHV8
(Simpson et a!., 1996).
It has also been found that detection of the viral genome and antibodies in the
peripheral blood of HIV-infected patients without KS is highly predictive of
subsequent KS development, further underlining the probability that HHV8
infection is required for KS development (Whitby et aL, 1995, Moore et a!.,
1996 Gao et cxl., 1996 and Martin et a!., l9q8). The very low levels of
seroprevalence in the general population, far lower than for any other human
herpesvirus, may reflect a number of important features of the virus.
Transmission appears to be predominantly by intimate sexual contact
especially of a homosexual nature. A recent study has linked type and
frequency of homosexual sex with the incidence of HHV8 infection (Martin et
a!., 1998). Also the virus may be classed as an "emerging virus", as has been
suggested for H[V, and that only recently has HHV8 spread from its
established endemic areas to infect certain individuals, such as homosexual
men, in other populations (Thong et a!., 1997).
The mechanisms by which Hhl-1'V8 may actually cause disease are stifi far from
well understood. The virus has a large linear genome of double-stranded DNA
about 170 Kb in size. The central 140 Kb of the genome are unique and have a
low G I C content of approximately 54% (the L region), flanking this unique
sequence are tandemly repeated 800 nucleotide repeats which contain a much
higher G / C content of over 80% (the H region). The frill genome sequence
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has now been determined from both a BCBL cell line virion and a clinical
isolate (Russo et a!., 1996). HHV8 contains over 70 conserved herpesviral
genes with significant homology to the gene blocks of the New World primate
tumour herpesvirus HVS, and to EBV, and its genomic organisation mirrors
that found in these two closely related viruses (Aibrect et a!., 1992 and Moore
eta!. l996.
In common with other y-herpesviruses the HE[V8 genome encodes for a
number of protein homologues to previously described human cell cycle
regulation proteins. One such homologue (HHV8 ORF 16) is analogous to
the cellular apoptosis-inhibiting protein Bcl-2 (Chang et al., 1996b). Cellular
Bcl-2 can bind to the Bax family of proteins in vivo preventing cell death, a
common host response to viral infections (Sato et aL, 1994). By encoding this
analogue the virus may be able to prolong the life-span of H}{V8-infected cells
in order to support greater genome replication and escape the effects of the
host immune response. A number of human cancers, including B-cell
malignancies (Gauwerky et al., 1988) have been found associated with a
disregulation of cellular Bcl-2 production, probably through its anti-apoptotic
effect (reviewed by Reed, 1995). HIHV8 also encodes for a homologue to the
cellular type-D cyclin (Cesarman et at., 1996 and Chang et al., 1996b). This
viral cyclin (v-cyclin) displays a 31% homology with cellular cyclin D2 (Li et
a!., 1997) and transcripts for its production have been found in the majority of
HHV8-infected spindle cells (Davis et aL, 1997). Cellular D-type cyclins are
part of the family of cellular cyclins which control cell cycle and genome
replication (reviewed in Sherr, 1996). The cyclins function by binding to
cyclin-dependent kinases (cdks) which in turn phosphorylate other proteins
involved in cell cycle regulation. Type-D cyclins act during the mid-to-late Gi
phase of the cell cycle by complexing with cdk-4 or cdk-6 to phosphorylate
the retinoblastoma tumour suppressor protein (pRb) which controls cell entry
into the S phase of division. Unphosphorylated pRb blocks cells in the Gi
phase by binding to a number of proteins including a famil,' of transcription
factors known as E2F. However the phosphorylation of pRb by D-cyclin
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causes the release of E2F which is necessary for cellular genome replication
and hence cell division. Expression of the viral D-cyclin therefore may lead to
cell cycle disregulation by causing the unregulated phosphorylation of pRb.
The importance of the pRb tumour suppresser pathway to control cell cycle
progression is underlined by the fact that both the other well studied tumour-
forming 'y-herpesviruses, EBV and HVS, cause pRb phosphorylation thereby
promoting neoplastic transformation of the infected cells. HVS, like HHV8
encodes a functional human cyclin homologue (Nicholas et a!., 1992), whereas
EBV induces over-activity of the cellular cyclins in infected cells (Sinclair et
a!., 1995).
Another mechanism by which HHV8 infection may result in uncontrolled cell
replication is by production of a viral homologue (v-Il-6) to cellular 11-6
(Neipel, 199. 11-6 was originally termed the B-cell growth factor and is an
essential cytokine required for the differentiation of B lymphocytes, the
establishment of B cell-derived lymphomas, and the proliferation of KS-
derived cell lines (Scala et a!., 1994). The unregulated production of v-11-6 in
BCBL's and KS is therefore highly likely to contribute to their malignant
growth, especially as KS spindle cells have been found in vivo to express a
high-affinity IL-6 receptor. Importantly v-11-6 has already been found to
support growth of cellular 11-6-dependant cell lines so functional activity in
vivo is probable (Moore et al., 1996).
Although EBV is the closest human relative of HHV8 as yet no HHVS
homologues to the EBV EBNA's or LMP's have been identified. In EBV-
infected cells these proteins have been shown crucial for the maintenance of
viral latency and host cell transformation (see section 1. b.). However although
lacking in these gene homologues HHV8 has a number of open reading frames
which may express proteins homologous to the cellular gene products which
are themselves induced by EBV through the activity of the EBNA and LMP
products; As well as cyclin D, 11-6 and Bcl-2, the functitrns of which are
described above, HHVS also encodes homologues to the complement
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controlling protein CR-2 and an 11-8 receptor which may have a role in
angiogenesis, a feature fundamental to the development of KS tumours
(Birkenback et a!., 1993 and Burgstahler et a!., 1995). It would appear that in
contrast to EBV, which produces viral proteins capable of interacting with
host cell proteins which then cause disruption of the normal regulation of cell
cycle control, HHV8 may itself code directly for replicas of the host anti-
apoptotic and regulation genes, and it is these viral proteins which directly
promote the inimortalisation of infected cells (reviewed in Neipel et a!., l997l
and Chang, 1997) as depicted below:
[BY gene/protein Cell protein induced Effect 	 H1HV8 gene/protein
EBNA 2
cyclin-D	 cell cycle control
	
v-cyclin
EBNA LP
LMP-1	 bcl-2	 anti-apoptosis	 v-bcl-2
gp35O/220-	 11-6—	 growth factor	 v-fl-6
With the extremely complex mechanisms of angiogenesis and cell
transformation involved in the formation of a KS lesion it does however
remain probable that HHV8 is not the sole required entity for KS lesion
development. Instead a two- or three factor model involving host cell
chemokine molecules such as MIP-la, the HHVS gene products and possibly
even interactions with HIV tat protein have also been suggested (Neipel et al.,
199'. The state of the host immune system would also appear critical in
allowing disease formation, a factor well described in association with
herpesviral pathology and intimately associated with contrbl of herpesvirus
replication and dissemination
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In summary the association between HFIV8 and KS / BCBL appears
overwhelming with virus genome present in virtually all KS and BCBL
tumours. At the cellular level the virus encodes a large array of gene products
able to initiate and support cellular proliferation and these products have been
shown to have parallels in the other known transforming herpesviruses.
This thesis describes early work relating to the role of HHV8 in KS. The work
was started a few months after the first HHV8 publication by Chang and
colleagues (Chang et aL, 1994) and includes studies describing viral
prevalence in a range of individuals. Subsequently it has been possible to
develop assays for the detection of HHV8 which have been used in the
diagnosis of different forms of KS. The effect of a number of
chemotheraputics on systemic and localised HHV8 DNA titre and KS clinical
severity has also been investigated. More recently possible mechanisms of
FIHV8 transmission have been studied, further defining the epidemiology of
the virus. These studies have made an important contribution to the
understanding of the role that HHV8 plays in KS disease and in determining
the prevalence of this new virus in a variety ofpatient populations.
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1. b. Virological Diagnostic Techniques
The following section describes the assays used in this thesis and discusses the
more recent technology in the context of the established assay types.
To make the diagnosis of a viral infection the virus itself and/or the
immunological response of the host to that virus may be detected. Each of the
assays described provides differing information and each has advantages and
limitations which must be considered. Both the type and quality of clinical
sample available, as well as knowledge of the biological properties of the viral
type to be investigated are vital in the selection of an appropriate diagnostic
technique. In general however there are four features of any diagnostic test
which must be evaluated to determine suitability in each situation:
1. The sensitivity of the assay; this is the percentage of individuals who are
truly infected which can be detected by the assay.
2. The specificity of the test; this is the percentage of individuals who are not
infected but in whom the assay still makes a detection.
3. The diagnostic window; the time between infection with an agent and the
point at which an assay can first detect that infection.
4. The operational considerations, the price of the assay, both financially and
in terms of the intensity of laboratory work required to carry out that assay.
In terms of the diagnosis of herpesvirus infections a large number of
techniques are currently available. These range from those which have been in
use for over 30 years, such as viral culture and direct electronmicroscopy, to
those developed in the last few years including the latest genome detection
methods. Very rarely is one type of test used in isolation, but usually a range
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of tests are employed to provide maximum clinical information in the context
of the first three points outlined above.
1. b. 1. Virus detection
The oldest method of identifying a viral species is by it's growth. Originally
this was performed in embryonated eggs, now it is usually in cell culture
preparations. In cell culture a specimen is added to a susceptible cell-line
capable of supporting viral replication and if infectious virus is present then the
virus will grow and produce a change in the morphology of the cell line. This
is called a cytopathic effect (CPE). The CPE can be characterised
microscopically and the virus type determined. Virus isolation has long been
the bench-mark for identification of virus infection and characterisation. A
variety of clinical samples may be investigated by inoculation into cell culture.
Samples such as vesicle fluid and skin scrapings can be recovered from the site
of disease for determination of a specific site diagnosis. Excreted fluids such as
urine and saliva may be examined for evidence of systemic infection and blood
can be investigated for the presence of viraemia. Table 1. 2. shows the various
cell lines used in culturing herpesviruses and the other methods employed for
herpesviral identification.
Although cell culture techniques are still widely used in all diagnostic
laboratories they suffer from a lack of sensitivity in comparison to some of the
more modern methodologies. For a definitive diagnosis to be made the
cultures may have to maintained for up to four weeks prior to the development
of CPE. In an effort to increase the sensitivity of virus isolation and to reduce
the amount of time required between specimen inoculation and assay result
antigen detection techniques have been combined with conventional cell-
culture (Gleaves et al., 1984). In simple virus isolation virus detection is only
possible when a CPE becomes grossly visible, however prior to this virus
replication is occurring in the cells with the expression of a variety of virus-
encoded proteins. Antibodies to these viral proteins are available and can be
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Table 1. 2. Commonly used assay systems for detecting herpesviruses
Cell culture
Herpesvirus
Culture	 Identification
Antigen detection Genome detection
(e.g. PCR)
HSV4
HSV-2
VzV
EBV
CMV
HHV-6
HHV-7
HHV-8
EEL
HEL
EEL
none
EEL
T cell lines
T cell lines
none
CPE	 EM I direct IF
CPE	 EM / direct IF
CPE	 EM I direct IF
-	 none
CPE / DEAFF pp65 antigenemia
CPEIIF	 none
CPE / IF	 none
none
rarely *
rarely *
rarely *
yes
yes
yes
rarely
yes
* - except in cases of suspected viral encephalitis
EEL -	 human embryonic lung cells
CPE -	 cytopathic effect
DEAFF - detection of early antigen fluorescent foci
IF -	 immuno-fluorescence
EM -	 electron microscopy
PCR -	 polymerase chain reaction
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used to examine the cultures for these viral antigens. Visualisation of bound
antibody is by a revealing agent, usually either a fluorescent or enzymatic
moiety attached to the antibody. Such techniques, termed immunofluorescence
assays (WA), or enzyme immuno-assays (ETA) can reduce the culture time
necessary for viral identification from a number of weeks to 24 hours. Use of
these antibody techniques also increases the specificity of the test compared
with culture alone. A comparison between viral culture and the DEAFF test,
which is based upon the antibody detection of viral antigens revealed by a
fluorescent signal, for the detection of CMV infection is described in section
3. d.. The more modern technique of genome analysis is included in this
analysis.
1. b. 2. Antibody measurement
Serological assays for the identification of a patient's antibody response to a
viral infection are the alternative diagnostic methods to actually detecting the
virus, or parts of its structure, as described above. The production of anti-
herpesvirus IgG antibody is considered diagnostic of a primary infection,
although the IgG titre may also rise during viral reactivation and re-infection.
The other class of antibody produced in primary infection is 1gM.
Immunofluorescence (IF) assays have been widely used for the detection of
IgG and 1gM response to herpesvirus infections especially in the diagnosis of
-herpesvirus infections such as EBV and HHV8 (Liaburf et al., 1975,
Hotchin and Crawford, 1990, Gao et al., 1996 and Simpson et al., 1996). In
these assays infected cells are used as a source of antigen, onto which patient
sera is incubated. If antibodies to the viral antigens are present in the infected
cells then they will bind and can be visualised as for the WA described above.
There is however a potential for serological cross-reaction with the use of IF
assays, particularly between viruses in the same sub-family (Cradock-Watson
et al., 1979). For this reason indirect solid-phase inimunoassays, such as the
enzyme-linked immunosorbant assay (ELISA) have been developed and used
for the detection of anti-VZV, HSV and CMV antibodies (described and
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discussed in Longston, 1990). In such an assay viral antigen is fixed to a solid
phase and is incubated with the patientssera. After washing away unbound
IgG's the virus-specific antibody is detected using an enzyme-labeled anti-human IgG
conjugate with a substrate specific for the enzyme.
The development of serological assays for detection of antibodies to HHV8
has been invaluable in defining the association of the virus with disease in both
the immunocompromised and immunocompetant host. In this thesis both the
IF and ELISA formats of assay have been used to detect anti-HHV8
antibodies in patient groups as described in section 2. d. and 2. e. The use of
these assays is detailed in section 3. c..
1. b. 3. Genome detection
A recent advance in the diagnosis of viral infections has been the development
of the polymerase chain reaction (PCR). This technique allows the specific
amplification of parts of the viral genome in a clinical specimen without need
for prior culture in permissive cell lines (Saiki et al., 1988). These amplified
genome sections may then be easily visualised by a variety of laboratory
techniques. Such direct amplification and detection makes viral diagnosis by
this method rapid and because of the processes involved enables single viral
genomes present in a clinical sample to be identified (Simmonds et al., 1990).
1. b. 3. i) development of a PCR reaction
To design a PCR test for the detection of a particular viral species all that is
required is knowledge of a small, unique, section of the viral genome, as little
as 200 nucleotide bases is sufficient. To the viral sequences two
complimentary oligonucleotides are designed, one for each strand of genome.
These synthetic oligonucleotides prime the subsequent exponential
amplification of the target sequence using a thermostable DNA polymerase
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enzyme. The design of the primers is crucial to the efficient amplification of
the viral genome target sequence and their design defines the annealing
temperature of the reaction. This is the temperature chosen to allow the most
efficient binding of the primer pair to the genome in preparation for the
amplification reaction. For the diagnostic detection of viral genomes, where
short DNA sections of less than 500 base pairs are amplified, primers between
18 and 24 bases are usually chosen. Amplification of short regions of DNA is
in general more efficient than amplification of longer sections of DNA. Primers
shorter than 18 base pairs have an increased risk of binding to heterologous
target sequences resulting in non-specific DNA amplification, while those
longer may require elevated temperatures to dissociate from the their
annealing sites. This elevated temperature reduces the activity of the
polymerase enzyme and thus effects overall amplification efficiency. Together
with the length of the primer the concentration of guanine and cytosine
residues (the 0 I C content) is also crucial and directly affects the annealing
temperature by introducing a greater or lesser number of hydrogen-bonding
events. Amplification of a section of genome consisting of between a 40 and
60% G / C content is optimal. As well as overall G I C content stretches of
repeated nucleotides are avoided to ensure primer annealing and dissociation
from the genome is uniform. For most diagnostic PCR assays of the type
described above primer pairs will have an annealing temperature between 50°C
- 60°C. To calculate the required annealing temperature for any primer pair
the following equation can be used to first calculate the primer melting
temperature (Tm) (Sambrook et al., 1989):
Tm= 4 x (number of G + C bases) +2 x (number of A + T bases) °C.
The annealing temperature selected in the PCR will then be approximately
5 °C below the primer Tm's, however empirical analysis may be required to
confirm the efficiency of the reaction.
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Also critical in the design of primer sequences is the avoidance of base-pairing
complementary 3' terminal ends, e.g. -GC 3' and -CG 3'. If this pairing occurs
during the amplification process reagents, such as the nucleotides and the
polymerase, will be sequestered to the production of primer dimers; short
Sections of DNA whose sequence is that of the two hybridised primers.
Production of primer dimers results in a dramatic reduction in amplification
efficiency of the intended target genome sequence and subsequent loss of PCR
assay sensitivity.
As well as the design of the oligonucleotide primers the composition of the
PCR reaction buffer is important in optimising the amplification reaction. The
PCR buffer used for all work in this thesis has, for example, a composition of
50 mM Tris and 50mM KC1 dissolved in aqueous solution, a combination well
established for use in PCR (MuIlis, 1994). The major variable component in
the buffer is the concentration of Mg2 ions. Magnesium ions are co-factors for
efficient polymerase enzyme activity and throughout the studies described a
concentration of 1.5 mM was used. If however Mg2 concentration is too low
then the efficiency of the polymerase will be reduced, if too high then the
specificity of the polymerase will be reduced (Saiki et a!., 1989).
1. b. 3. ii). PCR cycling conditions
Denaturation: Once viral DNA from a sample has been prepared for PCR
analysis (see section 1. b. 3. v.) the first step in the PCR reaction is to separate
the double-stranded DNA molecule into its two single strands, thus making
available the viral genome nucleotide sequence for annealing with the specific
oligonucleotide primers. This is achieved by heating the reaction to between
94	 and 96 °C.
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Priming: To allow the annealing of the oligonucleotide primers to the exposed
genome sequence the reaction is cooled to between 50°C - 60°C, depending
on primer Tm.
Strand extension: When primer hybridisation is complete the temperature of
reaction is increased to 72°C. At this temperature the annealed primers remain
attached to the viral genome sequences and allow the thermostable polymerase
enzyme to bind to this section of double stranded DNA (comprising single-
stranded viral genome and hybridised oligonucleotide primer). The bound
polymerase then progresses along the single-stranded viral DNA molecule
incorporating complementary free nucleotide molecules, made available in the
reaction mix. This extension process completes one round of amplification.
During the first cycle of amplification strand extension extends beyond the
point on the viral genome at which the other primer binds. However in
subsequent cycles an exponentially increasing number of DNA molecules are
produced the size of which are defined by the 5' ends of each primer. The
overall number of DNA molecules produced by the PCR amplification reaction
can be approximately calculated by the equation:
number of DNA molecules = 2 x 2
where n = the number of cycles performed.
Visualisation of PCR product molecules: Agarose gel electrophoresis is
commonly used to visualise the millions of amplified DNA molecules produced
by the PCR (Sambrook et al., 1989). This methodology involves the
separation of differently sized double-stranded DNA molecules in an agarose
matrix by the application of an electric charge through the matrix. The DNA
molecules are negatively charged and will move to the positively charged end
of the gel at a speed inversely proportional to their size. By including the DNA
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intrachelating dye ethidium bromide in the gel, bands of amplified DNA can be
viewed under ultraviolet light. As the positions of the primers in the target
genome are known the expected size of the DNA bands can be calculated.
Inclusion of a DNA size marker in the gel allows confirmation that the PCR
products seen on the gel are of the predicted size and therefore not composed
of non-specific DNA, e.g. primer dimers.
1. b. 3. iii). the nested PCR
To increase the specificity and sensitivity of the PCR technique a small aliquot
(usually 1 p.1) of the amplified DNA can be transferred to a second reaction
tube and submitted to a further number of amplification cycles (Simmonds et
al., 1990 and Mitchell et al., 1994). This second tube contains the same
reaction buffer, nucleotide solution and polymerase enzyme as the first, but
instead of providing the original oligonucleotide primers a second set which
bind to a nucleotide sequence internal to the first primer pair are provided.
Not only does this second, or nested, set of cycles increase the absolute
amount of DNA produced, making gel visualisation easier and increasing
overall assay sensitivity but, by including different primers which are specific
only for the correctly amplified sequence from the first round of PCR, it
produces a highly specific amplification product. This product is the result of
four independent primer / viral genome hybridisation reactions, therefore
further confirmation of the origin of PCR products, by methods such as
sequencing, is rarely necessary.
1. b. 3. iv). multiplex PCR
A considerable saving in the amount of time and money taken to analyse a
clinical sample for a variety of viral genome targets can be made by employing
a multiplex PCR (mPCR) methodology (Chamberlain et al., 1988 and 1992).
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In an mPCR a range of primer pairs specific for a number of nucleotide
sequences, each unique to a particular virus, are made available for
hybridisation. Careful design of the primer pairs used is critical to effective
mPCR. Ideally the sets of primers should all have similar Tm scores and
amplify sequences of a similar length. This simplifies the optimisation of the
reaction. It may also be necessary to provide an increased concentration of
both the polymerase enzyme and nucleotides to facilitate the amplification of
multiple target sequences. Multiple PCR can be more prone to the production
of non-specific amplified DNA molecules and so a nested format is used with a
high annealing temperature. Use of high annealing temperatures favours
specific primer I target binding. It may also be necessary to increase the
number of cycles used in both rounds of amplification to maintain the
et al.,
sensitivity of the assay in comparison to any single PCR (MullisM 994). The
evaluation and clinical use of a multiplex PCR assay capable of detecting six
different herpesviral genomes with a level of sensitivity and specificity similar
to those six PCR's performed separately is described in section 3. f..
1. b. 3. v). sample preparation
Before addition to the PCR reaction the clinical material being analysed will
usually have been pre-treated. Such treatment has a number of functions; most
important of these is the removal or inactivation of biological e.g.
haemoglobin, or non-biological e.g. sodium dodecyl sulphate (SDS), inhibitors
of the PCR process (Gelfand and White, 1990). These inhibitors usually affect
the thermostable polymerase enzyme, lowering or eliminating its activity and
so reducing the yield of amplified DNA produced during cycling, thus
affecting overall PCR sensitivity. Other factors, such as high salt
concentrations, may also affect the primer annealing reaction. Preparation
may also be necessary to release DNA from clinical material such as tissue to
allow presentation for amplification in the PCR prOcess.' As many of the
procedures used for the recovery of DNA from tissue samples are themselves
inhibitory of the polymerase enzyme such material may have to undergo
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further purification processes, such as phenol I chloroform treatment before
PCR analysis. The absolute sensitivity of any PCR assay can also be further
improved by using preparation methods which concentrate the DNA extracted
from a clinical sample. The physical and chemical procedures used for sample
preparation in these studies are detailed in section 2. c.
1. b. 3. vi) PCR contamination
A potentially significant problem with the PCR assay is the sensitivity with
which it can detect very small amounts of target sequence. 'Whilst this is a
useful characteristic in the detection of small amounts of viral DNA in clinical
samples it also raises the possibility of the generation of false-positive signals.
The contamination leading to false-positive amplification is usually derived
from the reaction products of previous amplifications, rather than from the
original samples. As PCR amplicons are generally small (usually between 100
and 200 base pairs) they are very stable and may persist for long periods
increasing the chance of their inadvertent addition to subsequent reactions.
Throughout this thesis stringent precautions were adhered to (Kwok and
Higuchi, 1989) and multiple negative controls included in each assay to avoid
and / or detect the generation of such inappropriate PCR signals.
In conclusion the PCR technique is an extremely sensitive, rapid and specific
method of identifying viral genomes present in clinical material. It is able to
distinguish between very closely related viral species and differentiate between
differing strains of the same virus. It is also able to accurately detect very low
numbers of viral genome in a background of differing DNA species. Since its
first practical application in 1987 (Mullis and Faloona, 1987) PCR has
revolutionised diagnostic microbiology and is now replacing a number of older
methodologies, such as culture and electron microscopy, as the assay of choice
for many viral diagnostic purposes.
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1. c. Aims of the study
This thesis concerns the development and use of a range of diagnostic
techniques for the detection of herpesvirus infections in the
immunocompromised patient.
Most of the work included involves the determination of the epidemiology and
disease associations of the recently discovered herpesvirus HHV8, also known
as KSHV. The development of genome detection methodologies for this virus
are described, as is their subsequent use to analyse virus presence in a variety
of patient and control individuals. These studies were conducted to investigate
claims made by a number of international research groups that HHV8 is the
causative infectious agent of the tumour Kaposi's sarcoma (KS). The effects
of a range of potential chemotherapy for HTV-associated KS were also
investigated as are potential routes of horizontal virus transmission.
As well as the investigation of HHV8 epidemiology the association of all the
herpesviruses with ocular and neurological disease in HII[V-infected patients
was examined in an attempt to determine the prevalence of herpesviruses at
these sites and evaluate current diagnostic PCR assays with clinical and
histological diagnosis of herpesviral involvement. Before this study the range
and extent of herpesvirus infections at these sites was not fully realised
potentially compromising the clinical response offered upon symptomatic
presentation.
Another patient group in UCL Hospitals for whom the clinical management of
herpesvirus infections was previously felt to require greater diagnostic support
were individuals undergoing allogeneic bone marrow transplantation. A six
month study was conducted after replacing the existing CMV surveillance
protocol of virus culture and DEAFF analysis in this patient group with a
nested PCR methodology. It was hoped that this system would allow a
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reduction in the toxicity of current anti-CMV prophylactic support and a more
rapid therapeutic response to emerging active CMV infection.
Finally in an attempt to simplify and reduce unnecessary cost in the overall
herpesvirus PCR diagnostic service offered in the Department of Virology,
UCL Hospitals a multiplex PCR assay was developed allowing simultaneous
detection of the six most clinically significant herpesvirus infections in the
immunocompromised patient. The evaluation of this assay, capable of
detecting HSV-1, HSV-2, VZV, EBV, CMV and HIIV8 DNA was
undertaken using control genomes and comparison made with each of the
individual virus nested PCR assays performed separately. A blinded
comparison between the two assay formats using clinical specimens previously
analysed by the individual nested PCRs was also performed. This new
multiplex assay is now replacing the use of the individual viral PCR assays,
within the Department of Virology, UCLMS, thus improving the efficiency of
the molecular diagnostic service provided.
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Section 2: Materials and Methods
2. a. Tissue culture and in vitro growth of HHV8
Two non-adherent cell lines were available for propagation of HHV8. The
first, HBL-6, was dually infected with HHV8 and EBV (Cesarman et at.,
1995 (fig. 2. 1. a). The second, BCP-1, was infected with IIHV8 alone
(Boshoff et al., 1998) (fig. 2. 1. b). Both were derived from lymphomatous
effusions taken from HTV-infected patients with body cavity-based lymphomas
(BCBL's). They were received from the The Institute of Cancer Research,
London in RPMI medium supplemented with 10% foetal bovine serum (FBS).
2. a. 1. Growth of the HBL-6 cell line
FIBL-6 was propagated in RPMI medium supplemented with 10% FBS
(complete RPMI, Appendix A) at 37°C and 5% CO2 under Category 3
conditions. Cells were counted daily in an improved Neubauer
haemacytometer (BDH) and had a viability of over 80% if maintained at
approximately 5 x 106 cells / ml in 30 ml complete RPMI in 75 cm2 culture
flasks (Nunc). This typically required a 1 in 3 dilution (splitting) of the culture
in complete RPMI twice a week and transfer of two 30 nil aliquots of diluted
culture to two new 75 cm2 culture flasks, the third aliquot of 30 ml remained
in the original flask. Once 12 culture flasks with 5 x 106 cells / ml had been
established the cells from two flasks were frozen for long-term storage. Cells
were pelleted (400g. 10 minutes) and the pellet washed twice with the original
volume RPMI. 5 ml freezing medium (Appendix A) was added to the fmal
pellet and the cells resuspended, aliquoted in 1 ml volumes, and transferred
into cryotubes (Nunc) for overnight storage at -70°C before placement in
liquid nitrogen. When required for use cells were removed from storage and
thawed rapidly in a 37°C water bath. They were washed once in 30 ml RPMI
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Figure 2. 1. a. HBL-6 cell culture viewed by phase-contrast light microscopy,
(magnification x40)
Figure 2. I. b. BCP-1 cell culture viewed by phase contrast light microscopy.
(magnification xl 00)
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and pelleted (400 g for 10 minutes). The cells were then resuspended in 10 ml
complete RPMI and placed in a 25 cm2 culture flask. After three days growth
the culture was transferred to a 75 cm2 culture flask and 20 ml more complete
RPMI added. The cultures could then be maintained by splitting as described.
2. a. 2. Growth of the BCP-1 cell line and HEL cells
The second cell line infected with HHV8, BCP-1, was received in the same
manner as the HIBL-6 line and initially grown in complete RPMI medium with
10% FBS. However it was soon noted that use of the HBL-6 protocol for
culture maintenance resulted in a 50% decrease in BCP-1 viability. To increase
the viability of this cell line a feeder-cell monolayer of human embryonic lung
(HEL) cells was used. HEL cells were revived from liquid nitiogen storage as
described for the HBL-6 cultures. After washing in RPMI the HEL cells were
resuspended in 20 ml HEL growth medium (HEL GM, Appendix A) and
placed in a 75 cm2 culture flask at 37°C in a 5% CO2 atmosphere. The flask
was incubated resting on its side to provide a maximum surface area for
establishment of the HEL monolayer. Visualization by phase contrast light
microscopy showed that these fibroblastic cells attached to the plastic of the
culture flask after approximately 3 hours and within 24 hours had begun to
form a surface-adherent cell monolayer which was confluent 3 - 4 days after
inoculation. Once the monolayer had been established the GM was removed
and 20 ml HEL maintenance medium (EEL MM, Appendix A) added. The
cell monolayers were viable for up to two weeks during which the
maintenance medium was changed every 3-4 days. To inoculate new culture
flasks with HIEL cells an existing monolayer was washed twice in 10 ml
phosphate buffered saline (PBS, Appendix A). The monolayer was stripped
from the culture flask by addition of 1 ml 1% trypsin solution, followed by
incubation at 37°C for 2 minutes. Any remaining monolayer was dislodged
from the flask surface by tapping the side of the culture flask firmly. Once the
monolayer had been separated from the plastic surface 30 ml of EEL GM was
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added, the culture flask was sealed tightly, and the medium agitated within the
flask to ensure all the EEL cells were resuspended. To the resuspended cell
solution a further 60 ml HEL GM was added and three 30 ml aliquots placed
in new 75 cm2 culture flasks.
To support BCP-1 growth HEL monolayers were prepared to a stage of near
monolayer confluence (fig. 2. 2. a.), they were then moved from the Category
2 Biohazard Laboratory in which they were prepared to the Category 3
Biohazard Laboratory. The HEL GM was removed and 30 ml BCP-1 culture
at 1-5 x 106 cells / ml was added. Growth of the BCP-1 culture in the presence
of HEL cell monolayers increased BCP-1 viability to over 90% and allowed
maintenance of that viability even when BCP-1 cell concentration approached
1 x i07 cells I ml (fig. 2. 2. b). It was also observed that after removal of the
BCP-1 culture following growth on the HEL monolayer the majority of dead
BCP-1 cells remained attached to the monolayer and so were not transferred
to subsequent cultures. Thus BCP-1 / EEL co-cultivation allowed for an
enrichment of viable BCP-1 cells after each passage to a new EEL monolayer.
After prolonged culture it was noted that growth of the BCP-1 culture on the
EEL monolayers was not continuously necessary and that co-cultivation could
be alternated with growth of the BCP-1 cells alone. A system of alternate
passage growth on monolayers and alone was instigated with no appreciable
loss of BCP-1 cell viability. By gradual reduction of FBS concentration in the
complete RPMI medium cultivation of BCP-1 's in as little as 2% FBS was
possible without affecting viability.
The BCP-1 cells were stored frozen as described previously, however use of a
freezing medium consisting 50% FBS, 30% DMSO and 20% RPMI was found
to increase cell viability upon subsequent culture in comparison with the usual
freezing medium. Growth of the BCP-1 cells continuously on EEL
monolayers for 3 - 4 passages after revival also increased cell viability and
reduced the culture time necessary to increase BCP-1 culture cell
concentration to 3 - 6 x 106 cell / ml.
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rFigure 2. 2. a. HEL's grown to near-confluence, viewed by phase-contrast light
microscopy (magnification xlOO)
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Figure 2. 2. b. BCP- 1 cells growing on HEL's, viewed by phase-contrast light
microscopy (magnification x 100)
_ . a,
.'øI. %V	
...	 S
I
•
.'
-
Y
74
2. b. Nested PCR amplifications
This section describes the general protocols for preparing nested PCR assays,
the handling of first round amplification products to allow a second round of
amplification and the analysis of the resultant DNA molecules (amplicons).
2. b. 1. Preparation of the PCR assay
The first round of the PCR was carried out in a 5Ojil reaction volume in a
300p.l thin-walled microtube (Treff Labs). The reaction mixture contained
lx reaction buffer (from lOx stock, Appendix A), 200p.M of each of the four
nucleoside triphosphates; dATP, dTTP, dCTP and dGTP (Pharmacia Ltd.,
supplied as 100mM solutions), 5Ong of each outer (first round) primer and 1
unit of recombinant Taq polymerase (Applied Biosystems). These reagents
were handled using pipettes dedicated for the purpose and 40pJ of the reaction
mix was aliquoted into each reaction tube. Sample DNA, up to a maximum of
10 pJ, was added to all assay tubes except the last 7. In 3 of these last 7 tubes
positive control DNA was added, usually at a level of 10 copies, 1 copy and
<1 copy respectively. The sample and control DNA was prepared and added
using a separate set of pipettes fitted with filter-containing tips to avoid cross-
contamination with sample DNA (Kwok and Higuchi, 1989). In the last 4
tubes lOjil of water were added, to 2 tubes with the sample pipettes and to 2
tubes with the reagent pipettes. These last four tubes control for the presence
of contaminating DNA in the reaction mix and the pipettes . Once all sample
DNA, control DNA and control water had been added, the reaction mix was
overlaid with l00fl light mineral oil (Sigma). The reaction tubes were than
closed and moved from the set-up area to a separate room, held under
negative pressure, where the thermal cycling was carried out using a Perkin
Elmer 480 thermocycler (Applied Biosystems).
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2. b. 2. PCR cycling conditions
After a single 4 minute denature step at 94°C, 35 cycles of denaturation
(usually 94°C for 20 seconds), primer annealing (between 50 - 60°C for 20
seconds, depending on the parameters of primer construction for each viral or
human DNA PCR, see table 2.1) and extension of primer sequence (usually
72°C for 20 seconds) were performed. At the completion of cycling the
reactions were maintained at 72°C for 7 minutes to ensure all primer extension
was complete. First round products were held at 1°C on the thermocycler until
required.
The second round (nested) PCR reaction mixture was identical to the first
except that the volume of reaction mixture present in each assay tube was
24 p1 Again these tubes were transported to the thermocycler after set-up in a
different room. Using filter tips 1 p.1 of the first round reaction was transferred
to act as a template for the second round reaction. In the second round
reaction only 25 cycles of amplification were required, the cycling times were
the same as for the first round (anneal temperatures for all the second round
primers are given in table 2.1).
2. b. 3. Visualisation of nested PCR products
After the two rounds of PCR the amplified DNA was analysed by ethidium
bromide gel electrophoresis (Sambrook et a!., 1989). A 100 ml 2% agarose
(Promega) gel was prepared, to which 0.5 mg / ml ethidium bromide (Sigma)
was added when the gel had cooled to below 60°C. Sample combs were
inserted and the gel allowed to set for 30 minutes at room temperature. The
sample combs were removed from the gel to provide wells for addition of the
PCR product, 10 p.1 of each PCR product was added directly for
electrophoretic separation. To at least one well in each row a molecular weight
marker was added so that the size of any PCR product could be estimated.
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The marker used for all PCR reactions was cIx 174 digested with Hae III
(Gibco-BRL), 0.3 j.tg of marker was added per well, after first mixing with
2 p.1 gel loading buffer (Appendix A) and 7 p.1 water. The agarose gel,
complete with loaded PCR products and marker, was run in an electrophoresis
tank (Flowgen) filled with lx TAE (from 50x stock, Appendix A) at between
60 and 70 mA for 1 hour. After electrophoresis the gel was removed and
placed on a UV transilluminator (Flowgen) for visualisation at 302 nm.
2. b. 4. Nested P CR for the detection of herpesvirus DNA
The principles of the nested PCR are described in section 1. b. 3. iii). Nested
primers for detection of CMV, HSV-1, HSV-2, VZV, EBV, HHV6 and
HHV7 DNA were available for use, their sequences and the cycle conditions
used for each are described in table 2.1. Details of the development of the
nested PCR's for detection of HHV8 DNA and human DNA are described in
section 3. a. 2. and 3. a. 3. The final protocols for each are described in this
section, the methods used for oligonucleotide primer design are described
below in section 2. b. 5.
University of Southampton, UK
All primers used were synthesised by OSWEL4 and supplied at a concentration
of approximately 0.3 mM in distilled water. Upon receipt primer solutions
were adjusted to 0.5 mg / ml and stored in aliquots at -20°C. With such
storage the primers have remained stable for over four years.
2. b. 5. Design of nested PCR primers for amplification of human DNA and
HHV8 DNA
A single pair of oligonucleotide primers previously used for detection of the
human gene pyruvate dehydrogenase were available (Koike, 1990). This
sequence is present as a single copy gene in the human genome allowing the
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Table 2. 1. Primer sequences, anneal temperatures and expected product sizes for
herpesvirus nested PCR and human nested PCR.
Virus	 Nucleotide	 Primer sequence (5'-3')	 PCR	 Anneal Product
(gene)	 location	 round	 temp	 size
(°C)	 (bp)
HSV-1 19-43	 ATC ACG GTA GCC CGG CCG TOT GAC A
	 1	 60	 221
(gD)	 239-2 18	 CAT ACC GGA ACG CAC CAC ACA A
51-71	 CCA TAC CGA CCA CAC CGA CGA 	 2	 50	 138
	188-166	 GGT AGTTGG TCG TFC GCG CTG AA
	
HSV-2 363-386	 TCA GCC CAT CCF CCI TCG GCA GTA	 1	 60	 183
(gO)	 546-524	 GAT C1'G GTA CFC GAA TOT CTC CG
	
422-441	 AGA CGT GCG GGT CGT ACA CO	 2	 50	 100
	522-503	 CGC GCG GTC CCA GAT COG CA
VZV	 5 1067-51087	 ACG GOT CIT 0CC GGA OCT GGT	 1	 60	 272
(gene	 51338-51315	 AAT GCC GTG ACC ACC AAG TAT AAT
29)
51091-51111	 ACC1TAAAACTCACTACCAGT	 2	 50	 208
5 1298-51279	 CFA ATC CAA GGC GGG TGC AT
CMV	 1942-1966	 GAGGACAACGAAATCCTGTFOGGCA 	 1	 58	 150
(gB)	 209 1-2067	 GTC GAC GOT GGA OAT ACT GCT GAG G
1967-1989	 ACCACCGCACrGAGGAATGTCAG	 2	 50	 100
2066-2044	 TCA ATC ATG CGT UG AAG AGO TA
EBV	 1347-1366	 GAG ACC GAA GTG AAG 0CC CT	 I	 50	 171
(large	 15 17-1498	 GOT 0CC TC UA GGA GC1 GT
internal
repeat) 1399-1421	 GCC AGA GGT AAG TOG ACT' TFA AT	 2	 54	 97
1495-1476	 GAG GGG ACC Cr0 AGA CGG GT
HHV-6 17627-17603	 AAG CIT GCA CAA TOC CAA AAA ACA 0
	 1	 60	 223
(13R)	 17405-17429	 CFC GAG TAT 0CC GAG CCC CTA ATC
17602-17580	 TOT TAG GAT ATA CCG ATG TGG COT
	 2	 60	 173
17430-17452	 TOT TAG OAT ATA CCG ATG TOG COT
HHV8 1-20
	 AGC CGA AAG OAT TCC ACC AT	 1	 58	 233
(minor 233-215 (17)	 TCC GTG TFG TCT ACO TCC A
capsid
	
protein) 22-41	 GTGCTCGAATCCAACGGATF	 2	 50	 171
193-174 (17)
	
ATO ACA CATTGG TGG TAT AT
	
}Iuman 4296 4316
	 GGG TAT OGA TGA GGA GO' GGA 	 1	 56	 186
	(P00) 4482-4462	 TO' TCC ACA 0CC CrC GAC TAA
	4339-4360	 CTTGGAGAAGAAGUGCCCAGT 	 2	 56	 122
	
4461-4438	 CCTACA ATrAAG AGTTGATCC CT
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use of the PCR for the accurate quantification of human genome load in a
clinical sample (experimentation detailed in section 3. a. 3. iii.). A pair of
nested primers was designed by analysis of the nucleotide sequence between
the two existing primers using the PCGene database, thus ensuring the
specificity of the nucleotide sequences to the human genome.
A single pair of primers for detection of HHV8 DNA were already published
(Chang et al., 1994). These two oligonucleotides were designed to amplify the
DNA sequence of a 233 bp section of the HHV8 genome termed KS330(233).
The entire sequence of KS330(233) was known allowing design of two nested
primers sited internal to the existing set. The primers were analysed using the
EMBL FASTA Server nucleotide sequence analysis program and found to be
specific to the KS330(233) sequence.
2. c. Preparation of DNA from clinical material for analysis by nested
PCR.
A large variety of clinical samples were analysed throughout this thesis, for
most types of sample existing preparation protocols were available, however
details of optimisation of the analysis of herpesvirus DNA in ocular fluid and
the analysis of HHV8 DNA in bronchoalveolar lavage (BAL) fluid are
contained in sections 3. e. 3. and 3. a. 5. respectively. The fmal protocols for
each are described in this section.
2. c. 1. Extraction of DNA from venous blood
Two methods were used to obtain DNA from peripheral venous blood. For
each method the starting material was either 5 ml venous blood collected in an
EDTA-containing vacutainer blood tube (Beckton-Dickinson) or 10 ml venous
blood mixed with preservative-free heparin (12-30 i.u. I ml). Upon receipt the
tube was centrifuged (400g for 10 minutes) to separate all cellular material
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from the plasma (upper) fraction. Plasma was removed for storage in 1 ml
aliquots at -20°C in 1.5 ml screw-topped tubes (Sarsted). The volume of
plasma removed was replaced with PBS (Appendix A) and a plastic Pasteur
pipette (BDH) was used to ensure thorough resuspension of the blood cells.
The first method for DNA extraction from peripheral blood was based upon
that adapted by Kaye et al. (1991). After resuspension in PBS the blood was
mixed in equal volume with a glycerol-based freezing medium (glycigel,
Appendix A) for storage in 1 ml aliquots at -20°C. This freezing medium
allows the blood sample to undergo a cycle of freezing and thawing without
lysis of the red and white blood cells. Upon removal from -20°C the sample
was thawed in a 37°C water bath and the cells pelleted by centrifugation
(8,000g for 5 minutes). The supernatant was removed and 1 ml lysis buffer
(LB, Appendix A) added after which the tube was vortexed to mix the LB
with the blood cells. The LB was formulated to allow lysis of the erythrocyte
and leucocyte cell membranes while the leucocyte nuclei, containing the
herpesviral DNA, remained intact. Three more cycles of pelleting, addition of
lysis buffer and vortex were then used to clear the sample of all contaminating
erythrocytes leaving the leucocyte nuclei visible as a small white pellet. The
leucocyte nuclei were then lysed by addition of 1 OOj.il extraction buffer (EB,
Appendix A) and incubation for 2 hours in a 60°C water bath. Finally the
samples were boiled for 10 minutes to inactivate the protinase K activity of the
EB and between 1 and l0j.tl added to the nested PCR.
The second method by which DNA was extracted from venous blood was by
use of a commercial DNA preparation kit (Qiagen blood kit, Qiagen). With
this system EDTAtreated whole blood may be stored, without prior
preparation, at -20°C. When required the blood was thawed, mixed to ensure
homogenicity and 50p.l mixed with 150U PBS before addition of a lysis /
extraction buffer. After incubation for 15 minutes in a 70°C water bath the
disrupted material was added to a silica column designed to capture DNA
molecules. The column was washed twice to remove contaminants and the
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DNA eluted in 50j.tl water. The DNA solution was then boiled for 10 minutes,
cooled on ice and between 1 and 10 tl added to the nested PCR.
2. c. 2. Extraction of DNA from plasma and serum
Plasma was separated from whole venous blood as described in section 2. c.
1. and stored at -20°C. Serum was prepared by centrifugation of whole clotted
blood (400 g for 10 minutes) and was also stored at -20°C. DNA was
prepared from both plasma and serum by addition of 0.5 ml water to 0.5 ml
sample, mixing by vortexing and boiling for 10 minutes. The mixture was
cooled on ice and pelleted (usually 14,000 g for 30 minutes) until a clear
supernatant was visible as a separate top phase above the coagulated protein.
Between lp.l and 10tl of the clarified supernatant were added to the nested
PCR.
2. c. 3. Extraction of DNA from cultured cells
Cells of the BCP-1 or HBL-6 lines were pelleted by centrifugation (400g for
10 minutes) and washed once in PBS before resuspension in approximately
one tenth original volume glycigel EB. The cells were incubated at 60°C for
30 minutes to allow disintegration of the cell membranes and DNA was
released from the cell nuclei by boiling for 10 minutes. After cooling on ice the
extract was clarified by centrifugation (8,000g for 10 minutes) and between 1
and 1 0!.tl of the supernatant added to the nested PCR.
2. c. 4. Extraction of DNA from solid tissue samples
Tissue samples, including skin, post-mortem biopsies of brain and solid
hypervascular sarcoma samples of varying type were snap frozen dry at either
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-70°C or in liquid nitrogen for storage. After thawing, approximately 0.5cm3
of tissue was ground under liquid nitrogen with a pestle and mortar (BDH).
lrnl of an SDS-based extraction buffer (SDS-EB, Appendix A) containing
/ proteinase K was used to resuspend the ground material which was then
transferred to a 1.5 ml screw-top tube. After incubation over-night, at 60°C,
purified DNA was prepared by addition of 0.5 ml of the extract in SDS-EB to
a mixture of buffer-saturated phenol (Appendix A) I chloroform (BDH,
99.5%), and isoamyl alcohol (BDH), in a 24 : 24 : 1 ratio. Thorough mixing
was ensured using a horisontal shaker for 10 minutes and the extracted sample
was then centrifuged (14,000 g for 10 minutes). The clear, upper, aqueous
phase resulting after centrifugation was removed to a fresh 1.5 ml tube and the
extraction process repeated with addition of a further 0.5 ml buffer saturated
phenol I chloroform / isoamyl alcohol. After this second extraction the
recovered aqueous phase was added to 0.5 ml chloroform / isoamyl alcohol in
a 24 : 1 ratio in a fresh tube and the extraction process repeated once more.
After the final extraction DNA in the aqueous phase was purified by ethanol
precipitation in the presence of excess salt (Sambrook et al., 1989). The
aqueous phase was added to 1 ml ethanol which had been cooled to -20°C
(ice-cold) and contained 120 mM NaCl. The tube was mixed by vortexing and
stored at -20°C overnight to allow DNA precipitation. Precipitated DNA was
pelleted from the solution at 4°C (14,000g for 30 minutes). The DNA pellet
was washed twice in ice-cold 100% ethanol and once in ice-cold 70% ethanol,
between each wash the DNA was repelleted (14,000g for 10 minutes). After
the final wash the majority of ethanol was removed using a fine-tipped Pasteur
pipette (BDH). The tube was left for 20 minutes in a 37°C incubator to
evaporate any remaining ethanol. The DNA pellet was resuspended 100.tl TE
buffer (Appendix A) and the concentration of DNA recovered estimated using
the equation: 1 0D260 = 50g / ml double-stranded DNA (1cm light path).
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2. c. 5. Extraction of DNA from saliva, throat 3wab transport medium, urine
and cerebro-spinal fluid.
Saliva samples were collected directly into a sterile container after first rinsing
the mouth with lOmi sterile saline solution. Cells in the saliva sample were
pelleted by centrifugation (8,000 g for 10 minutes) and the resulting cell-pellet
and supernatant stored separately. DNA from the supernatant was prepared by
boiling for 10 minutes and cooling on ice. The boiled supernatant was then
added directly to the nested PCR (Saiki et al., 1986). The same storage
preparation and DNA extraction method was used for throat swab transport
medium (Appendix A), urine and cerebro-spinal fluid (CSF) collected by
lumbar puncture. All samples were transferred to the laboratory in sterile
containers, usually on the same day they were taken. If same-day transport
was not possible they were stored at 4°C until transport could be arranged.
2. c. 6. Extraction of DNA from bronchoalveolar lavage fluid (BAL)
Bronchoalveolar lavage fluid (BAL) was taken during fibreoptic bronchoscopy
by addition of 300 ml sterile saline to the bronchial tree and recovery of
approximately lOOmi by aspiration. The BAL fluid was transported to the
laboratory within 4 hours in a sterile container. BAL fluid was stored at -20°C
both after separation into cell-pellet and supernatant fractions by
centrifugation (8000g for 10 minutes) and unfractionated. For analysis by
nested PCR 1 ml whole BAL fluid was boiled for 10 minutes, cooled on ice,
centrifuged (8,000g for 10 minutes) and l-5Ojil of the supernatant added
directly to the nested PCR. DNA was extracted from cell-free virus particles in
BAL supernatant by ultracentrifugation (1 00,000g for 30 minutes) of the
BAL supernatant and extraction of the resultant virus pellet by the phenol /
chloroform process (2. c. 4.)
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2. c. 7. Extraction of DNA from ocular fluids (vitreous and aqueous)
Ocular fluids; aqueous fluid from the anterior chamber of the eye and vitreous
fluid from the posterior chamber of the eye were usually received already
recovered from the eye. However in the study of herpesviral DNA in post-
mortem ocular fluids (section 3. e.) whole cadaver eye-balls were received
from which the two ocular fluids required recovery using a fine-bore needle
(Teruma, 19 gauge) and 5 ml syringe (Sabre). Following receipt or recovery
the ocular fluid was centrifuged (8,000 g for 10 minutes) to separate cells from
supernatant and the two fractions stored separately at -20°C. DNA was
prepared from the ocular fluid supernatant by the method of boiling described
for saliva, CSF, urine and throat swab medium supernatant and 1 to 10 .tl of
the supernatant added directly to the nested PCR.
2. c. 8. Extraction of DNA from faeces.
Faecal material was suspended in water to give a 10% slurry and mixed by
vortexing. The slurry was centrifuged (1 ,500g for 10 minutes) to pellet gross
contaminants and 0.5 ml of the supernatant re-pelleted by ultracentrifugation
(100,000g for 10 minutes). The ultracentrifuged pellet was resuspended in
2Ojil water. This was disintegrated by boiling for 10 minutes, cooled on ice,
and 1 to 10 p1 of the released DNA added directly to the nested PCR.
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2. d. Indirect immunofluorescence (hF) assay for detection of anti-
HHV8 IgG
The indirect immunofluorescence (hF) assay used for the detection of anti-
HHV8 IgG antibodies was based upon an hF assay developed by Simpson and
colleagues and used the same HHV8-infected cell line BCP-1 (Simpson et a!.,
1996). This technique is similar to a number of previously described hF assays
for detection of IgG antibody response to other human herpesviruses such as
EBV and HHV6 (Gleaves et a!., 1984 and Fox et al., 1988).
2. d. 1. Preparation of BCP-1 hF slides and sera
BCP-1 cells were grown on feeder cell layers of HEL cells as described in
section 2. a. 2. To prepare the IIF slides 2-3 ml of a BCP-1 culture at
approximately 5 x 106 cells / ml was removed from culture and pelleted by
centrifugation (400g. 10 minutes) in a 50 ml screw-top centrifuge tube
(Falcon). The cell pellet was washed in 30 ml PBS. After washing the cells
were again pelleted and then resuspended in a fixing solution of 4%
paraforrnaldehyde for 10 minutes at room temperature. After a further wash in
30 ml PBS the cells were incubated for 10 minutes at room temperature in 1%
Triton X-100 (Sigma) 1 PBS. This detergent treatment permeablises the BCP-
1 cell membranes to allow intracellular entry of anti-HHV8 serum antibodies
for interaction with virus-encoded antigens. After a final PBS wash the fixed,
permeablised cells were resuspended in imi PBS and lOjil of the resuspended
cells added to each well of a 12-well Teflon-coated slide (C.A. Henley). An
initial harvest of 1 x i07 cells enabled preparation of 10 slides with each slide
well containing approximately 5 x i0 - I x i05 cells. This concentration of
cells was found to be optimal for visualisation of fluorescent signal in the hF
assay. After the cells had been added to the slide wells they were left for 10 -
15 minutes to dry at room temperature. Slides prepared by.this method were
best used the same day, long-term storage at -20°C was found to adversely
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effect the performance of the HF assay by reducing the intensity of
fluorescence signal.
In the published description of the anti-HHV8 IgG HF assay (Simpson et al.,
1996) sera were tested at an initial dilution of 1 in 150 in PBS. However, it
was found possible to reduce this dilution to 1 in 50 by using 3% FBS / PBS
as a diluent (personal communication D. Whitby, Institute of Cancer Research,
London) without the introduction of non-specific fluorescent signal. This
initial serum dilution was therefore used throughout these studies to ensure
maximum assay sensitivity. Any samples which did produce non-specific signal
were reanalysed at dilutions of 1 in 50, 1 in 100 and 1 in 150.
2. d. 2. Detection of anti-HHV8 IgG by hF
Ten microlitres of serum diluted I in 50 in PBS / 3% FBS were added in
duplicate to the fixed BCP-1 cells on multispot slides and distributed with a
sterile pipette tip to ensure even covering of the cells. Slides were incubated in
a moist chamber for 40 minutes at room temperature before removal of the
serum by washing 6 times in PBS / 3% FBS. Fluorescin conjugated anti-
human IgG (Dako) was diluted 1 in 200 in PBS / 3% FBS and 25pi then
added to each well. After a further 40 minute incubation at room temperature
the slide was again washed 6 times in PBS / 3% FBS and excess wash solution
removed by drying in air. The slides were mounted in few drops of a mounting
solution (Appendix A), a cover slip (BDH) added and the cells examined using
a fluorescent microscope (Carl Zeiss). Known positive and negative sera were
included in each experimental set and examined first to ensure assay validity.
Positive staining for anti-HHV8 IgG was detected as a punctate,
predominantly (although not exclusively) nuclear staining of the HHV8 open
reading frame (orf) 73 latent nuclear antigen (LNA) (fig. 2. 3. b) (Rainbow et
a!., 1997). Sera not containing anti-HHVS IgG also produced an
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Figure 2. 3. a. Negative 1fF anti-HHV8 IgG signal with BCP-1 cell line
Figure 2. 3. b. Positive 1W anti-HHV8 IgG signal with BCP-1 cell line
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immunofluorescence signal, however this was recognised by a profuse,
background membrane signal which showed none of the distinct nuclear
staining pattern exhibited by positive serum (fig. 2. 3. a). When analysed sera
were scored either +, - or +I .. If equivocal the analysis of that sera was
repeated at a dilution of 1 in 100, as well as at 1 in 50 and 1 in 150.
2. e. Recombinant enzyme-linked immunoabsorbant assay (ELISA) for
the detection of anti-HHV8 IgG.
The HHV8 orf 65 gene product was chosen as a prospective antigen target for
use in the detection of anti-HHV8 antibodies because of its nucleotide
sequence homology with the EBV gene product BFRF3 (van Grunsven et at.,
1994). BFRF3 is a capsid protein which shows reactivity with over 90% of
sera from EBV-infected individuals. However as the level of homology, at the
amino acid level, of BFRF3 and HHV8 orf 65 was only 26% it was felt that
cross-reactivity between anti-EBV antibodies and anti-HHV8 antibodies
would be avoided (personal communication Thomas Schulz, University of
Liverpool).
2. e. 1. Generation of recombinant HHV8 antigen
Two segments of the orf 65 protein were expressed, ftsed to the
carboxyterminal end of the mouse dihydrofolate reductase gene product, under
the control of a T7 promoter in the expression vector pQE 42 (Qiagen). Orf
65.1 (aminoacids 2 - 170.of orf 65) and orf 65.2 (aminoacids 86 - 170) were
expressed separately. The expression construct contained a histidine tag at the
amino-terminal end of the fusion protein allowing purification by affinity
chromatography on nickel resin. The orf 65.2 recombinant protein was chosen
for assay development, this polypeptide shares only 18 aminoacids (21%
identity) with the equivalent region of BFRF3 and when 10 high-titre anti-
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EBV sera were analysed no cross-reactivity was detected (Simpson et al.,
1996).
The recombinant orf 65.2 antigen was constructed and produced by colleagues
in the Department of Microbiology, University of Liverpool. It was received in
7M urea, on dry ice, to ensure stability. Upon receipt the antigen was
aliquoted in 0.5 ml lots and placed at -70°C in 1.5 nil tubes for long-term
storage.
2. e. 2. Preparation of sera
Prior to the analysis of sera for presence of anti-Fll{V8 IgG by the orf 65.2
recombinant ELISA the serum was diluted 1 in 100 in 5% dried skimmed milk
(Marvel) / PBS-Tween-20 (Sigma) (PBS-T), (ELISA blocking buffer,
Appendix A). lOOp.1 volumes of this diluted sera were analysed in duplicate by
the ELISA.
2. e. 3. Detection of anti-HHV8 IgG using the oif 65.2 recombinant ELISA
Ninety-six well ELISA plates (Maxisorb, Nunc) were coated with lOOp.l
purified orf 65.2 recombinant protein after pre-dilution in 0. 1M / L NaHCO3,
pH 8.5 (usually 1 in 60, depending on batch concentration). The plates were
incubated overnight at room temperature in a moist chamber. After incubation
of the antigen the plate was washed 6 times in PBS-T and tapped dry on tissue
paper. The plate was then blocked with 200p.l ELISA blocking buffer (ELISA-
BB), and incubated for 2 hours at room temperature. In this state the plate
could be stored at 4°C for later use, however it was noted that assay
performance was significantly improved if plates prepared the same day were
used in each assay.
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When required the ELISA-BB was removed and the plate washed once in
PBS-T before addition of the test sera pre-diluted in ELISA-BB. The sera was
incubated on the plate for 1 hour at room temperature. Test sera was removed
by washing 6 times in PBS-T before addition of a second antibody. The
second antibody was an alkaline phosphatase-conjugated, affinity-purified,
goat anti-human IgG (Dako) diluted 1 in 1000 in ELISA-BB with 1% goat
sera (Sigma). lOOp.1 of the conjugated antibody was added to each well,
incubated for 1 hour at room temperature, and then the wells washed 6 times
in PBS-T. After tapping the plate dry the wells were washed once in
200.il 1M diethanolamine solution before addition of 200p1 of a 1 mg/mi
solution of dinitrophenyl phosphate (Sigma) in 1M diethanolamine. The plate
was incubated at 37°C for approximately 30 minutes before reading of the
colorimetric reaction spectrophotometricaly at 405 nm. If after 30 minutes
incubation the positive control sera gave an optical density (OD) of below 1.0
the plate was transferred back to the 37°C incubator and the OD checked
every 5 minutes until a sufficiently strong colorimetric reaction had been
achieved.
To determine the cut-off of positive and negative sera in each assay 3 anti-
I-IHV8 IgG negative sera were present on the ELISA plate and their mean OD
at 405 nm determined. A serum sample was deemed to contain anti-HHV8
IgG if the average OD of the two duplicates of that sample was greater than 3
times the mean of these negative control samples.
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2. f. Nested PCR herpesvirus multiplex assay
There are a variety of methods available for the detection of herpesvirus infections
in the clinical setting (see section 1. b.). Traditionally these have been based upon
the relative ease with which certain members of the herpesvirus family can be
cultured in vitro directly from patient material. However with the development of
transient culture systems such as the DEAFF test, viral antigenaemia detection
and the use of molecular diagnostic techniques such as PCR, it is now possible to
detect and measure extremely low levels of herpesvirus. These later molecular
amplification assays have been of particular advantage in identifying herpesvirus
involvement in neurological and ocular diseases of the immunocompromised host
(see sections 3. a. 6. and 3. e.).
The ultra-sensitive herpesvirus detection assay used in the Department of
Virology, UCLMS since 1992 has been the nested PCR (see section 2. b.).
Oligonucleotide primers are available for detection of all eight human
herpesviruses, although analysis for human herpesvirus 7 (HHV7) DNA is rarely
requested. In order to reduce the need for multiple individual PCR analysis on
clinical samples a multiplex nested PCR (mPCR) was developed. This assay
allows simultaneous amplification of HSV-1, HSV-2, VZV, EBV, CMV and
HHV8 DNA with the detection of amplicons by an enzyme-linked oligonucleotide
(ELONA) assay based upon an assay originally proposed for the quantification of
hepatitis C virus RNA load (Whitby and Garson, 1995).
2. f 1. Multiplex PCR assay conditions
A wide range of PCR conditions were investigated in order to maximise the
sensitivity of the mPCR-ELONA assay. Optimisation of the assay was determined
jointly by myself and by Mr. Stuart Kirk, Department of Virology, UCLMS.
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These optimisation experiments are not included in this thesis but can be found
described in Kirk et al. (submitted J Gun Micro, 1998).
In the first round amplification reaction oligonucleotide primer pairs for
amplification of HSV-1, HSV-2, EBV, VZV, CMV and HHV8 DNA were
present in the same concentration as for the individual PCR assays (see section 2.
b. 3. ). The formulation and volume of the PCR reaction buffer and concentration
of nucleotides used was also unchanged from the individual PCR assays. The
amplification enzyme Taqgold (Applied Biosystems, 1.25 units per tube) was used
instead of Taq to improve the specificity of derived amplification products. To
allow activation of the Taqgold an initial denaturation step of 95°C for 12 minutes
was employed before both rounds of the mPCR. The optimum cycle conditions
for the first round were; 95°C for 30 seconds, 50°C for 30 seconds and 72°C for
30 seconds for 40 cycles, followed by a final 7 minute, 72°C extension cycle.
The optimal cycle conditions for the second round, following the 95°C activation
step were; 95°C for 30 seconds, 46°C for 30 seconds and 72°C for 30 seconds for
32 cycles, followed by a 7 minute extension cycle at 72°C. As for the first round
reaction a 50 tl reaction volume was used and the reaction buffer and nucleotide
concentration remained the same as for the individual PCR reactions. Again 1.25
units of Taqgold were present in each reaction tube. The oligonucleotide primers
used in the mPCR second round were the same as in the second round of each of
the individual PCR assays, however the primers were present at the lower
concentration of 30 ng each and one of every pair had a biotin molecule
covalently-attached to its 5' terminus. li.l of the rnPCR first round amplification
product was used to prime the second round reaction.
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2. f 2. Multiplex PCR amplicon detection- the enzyme-linked oligonucleotide
assay (ELONA)
An enzyme-linked oligonucleotide assay (ELONA) based on that developed by
Whitby and Garson, was modified to produce a colorimetric signal (figure 2.4.)
(Whitby and Garson et al., 1995). Clear 96-well microtitre plates (Maxisorb,
Nunc) were coated with 5jig I ml streptavidin (Sigma) in a carbonate I
bicarbonate coating buffer (pH 9.6, Appendix A) at room temperature overnight.
After aspiration of the coating buffer the wells were blocked with 0.2% BSA /
PBS at 4°C overnight, or room temperature for 1 hour. Plates blocked in this
fashion were stable for up to two months if covered with a plastic plate-sealer
(ICN-Flow) and stored at 4°C.
For the detection of the rnPCR amplified products the blocking buffer was
aspirated and 5 j.tl of the mPCR second round product added to the plate, diluted
1:20 in an ELONA sample diluent (ELONA-SD, Appendix A). The product was
incubated on the plate for 30 minutes at 45°C. In the initial "screening-ELONA"
each nested ITIPCR product was added to a single microtitre well. After product
incubation the plate was washed 10 times in TrisiTweenlAzide (TTA, Appendix
A) wash buffer before final aspiration and the addition of lOOp.l 0.15M NaOH for
2 minutes at room temperature. This incubation was followed by a further 10
washes in UA wash buffer.
Anti-sense oligonucleotide probes were designed of complimentary internal
sequences to each of the 6 target virus mPCR products (table 2. 2.). These probes
were modified to have the enzyme horse radish peroxidase (HRP) covalently
attached at their 5' end. The working dilution of each probe was determined
empirically, however a dilution of 1 in 20,000 in probe diluent (ELONA-PD,
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Table 2. 2. Nucleotide sequences and location of 5'-horse radish peroxidase-
labelled oligonucleotide probes used for the ELONA detection of herpesvirus
multiplex PCR products.
Virus
(gene)
HSV-1
(gD)
HSV-2
(gO)
VzV
(gene 29)
CMV
(gB)
EBV (large
internal repeat)
Probe location on
genome
107-89
493-474
51154-51135
2013-1996
1454- 1437
Probe sequence (5'-3')
CTC CTC CTC GTA AAA TGG C
GCA lTr ACG AGA GCG TAC
CGT OTT TGC CTC CGT GAA AG
GAT GAA GAl CTT GAG GCT
GGG TGT GOT GGA GTG TTG
HHV8 (minor	 109-92	 ACACCAACAGCTGCTGC
capsid protein)
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Appendix A) was usually optimal. In the "screening- ELONA" lOOpi of a pool of
all 6 probes, diluted in ELONA-PD, was added to each well of the plate
containing mPCR products and incubated at 45°C for 30 minutes. Unbound probe
was removed by washing 10 times, with 1 minute soaks between each wash, in
0.05% Tween-20./ PBS, l00.t1 of the substrate 3,3',5,5'-tetramethylbenzidine
(TMB) in tn-sodium citrate and hydrogen peroxide diluent (Murex Biotech) was
then added and the plate incubated at 37°C for 20 minutes. The colorimetric
reaction was stopped using 2N H2SO4.
The optical densities for each well were measured spectrophotometricalty at
450nm and for each sample a test: negative ratio was calculated by dividing the
optical density of the test well by the average of the optical densities of the wells
containing the water negative controls. No substrate blank was included in this
calculation and any well having a test: negative ratio of 5 or greater was defined
as containing a detectable herpesvirus inPCR product. By using a pooi of all 6
herpesvirus-amplicon specific probes the "screening-ELONA" assay was thus able
to identify mPCR products containing any amplified herpesviral DNA. However,
the screening-ELONA was unable to determine the particular species of
herpesviral DNA present. For species typing of the screening-ELONA-positive
niPCR products 5p.l, in 95 jll ELONA-SD, of the remaining mPCR nested
product from that reaction were added to each of 6 separate streptavidin-coated
wells and incubated as before. The working concentrations of the 6 probes were
then made up individually and, after NaOH treatment of the bound amplicons, one
probe added to each of the 6 wells. ELONA detection was carried out as before,
with any well, or wells, showing a test : negative optical density ratio greater than
5 indicating the virus type, or types, present within the original sample.
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Section 3: Results
3. a. Association of HHV8 with fflV-associated KS
3. a. 1. Introduction
This first results section deals with the development of nested PCR reactions
for the detection of HHV8 and human DNA, and the use of both these assays
to investigate the prevalence of I{HV8 DNA in a variety of patient groups:
1. In the peripheral blood of HIIY-infected individuals with, and without, KS
and of healthy blood donors.
2. In the bronchoalveolar lavage (BAL) fluid of HTV-infected patients with
and without pulmonary KS.
3. In the CSF of HIV-infected patients with and without central nervous
system (CNS) lymphoma.
4. In the semen of HIV-infected gay men and a large cohort of healthy UK
semen donors.
These studies were performed to assess the distribution of HHV8 genome in a
range of individuals at varying risk of HHV8 infection, and to investigate
earlier reports of an association between HHV8 and KS.
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3. a. 2. Nested P CR for the detection of HHV8 DNA
As described in section 1. b. 3. the nested polymerase chain reaction (PCR) is
a technique for the amplification of specific sequences of DNA (Simmonds et
al., 1990). The repeated cycles of DNA amplification occurring in the nested
PCR reaction allow easy detection of as little as a single starting molecule of
target DNA making this technique ideal for analysis of herpesviral DNA in
clinical samples (Fox et a!., 1991 and Wakefield et a!., 1992). A detailed
methodology for all nested PCR reactions used in this thesis can be found in
Section 2. b. and the theory behind the design of oligonucleotide primers for
use in nested PCR is described in section 1. b. 3.
3. a. 2. i) selection of primer sequences for the second round of the HHV8
PCR
Within the KS33OBam fragment of the HHV8 genome, which contains the
KS330(233) sequence of the HHV8 PCR first round amplicon, no significant
nucleotide sequence strain variation has been noted. Studies have shown that
this KS33OBam fragment is situated in an HHV8 open reading frame (0RF26)
which has a greater than 50% homology with other known herpesvirus minor
capsid genes, especially the minor capsid genes ORF 26 of HVS and BDLF 1
of EBV respectively (Russo et al., 1996).The genetic stability of the region
enabled second round PCR primers to be designed internal to the first round
primers without risk of mismatches affecting the subsequent amplification
efficiency of the assay. The two internal primers developed; HHV8 (3) and
HHV8 (4) (see table 2.1.) were analysed using the EMBL FASTA genome
database and found to be specific for amplification of a sequence within the
first round amplicon.
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3. a. 2. ii). HHV8 nested PCR conditions, PCR specificity and confirmation of
correct sequence amplification
The projected size of the amplicons produced by the first and second round
PCR amplification for HHV8 DNA, as well as the Tm of the oligonucleotide
primers designed, was similar to the PCR reaction for amplification of CMV
DNA already in use (table 2.1.). For this reason identical reaction and cycling
conditions as for the CMV PCR were selected. When a variety of DNA
samples, prepared from glycigel-stored blood taken from patients with
cutaneous KS, were analysed by the nested HHV8 PCR all those found to
contain HHV8 DNA gave bands of equal high intensity after ethidium bromide
gel electrophoresis (fig. 3.1.1). This suggested that the 35 cycles of
amplification employed in the first round and the 25 cycles of amplification in
the second round were sufficient for use in the HHV8 PCR. The approximate
size of both first (230 bp, see figure 3.1.2.) and second (l8Obp, see figure
3.1.1.) round ampilcons was determined by comparison with the x174
markers and found to be as expected from the sequence data.
At the time of development of the HHV8 PCR no known positive control
DNA was available to include in each PCR reaction series. Therefore a sample
from the first reaction series (figure 3.1.1, number 9) which gave an amplicon
after both the first and second rounds of amplification was selected.
Visualisation of an amplification product after one round of PCR cycling
suggested that sample 9 contained a high level of HHV8 DNA. To determine
the HHV8 DNA titre of sample 9 a ten-fold dilution series of DNA from that
sample was prepared. The last dilution at which HHV8 DNA could still be
amplified, when 1 .tl of each of these dilutions was analysed, was 1 in 1 4,
therefore the titre of detectable HHV8 DNA in this sample was approximately
10,000 copies per microlitre. In each subsequent PCR reaction series tubes
containing 10, 1 and <1 detectable copies of sample 9 HHV8 DNA were
included so that inter-assay sensitivity could be monitored.
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To confirm that the amplicon produced by the first round of HHV8 PCR was
of the expected sequence a restriction enzyme (RE) digest was performed.
Sequence data from Chang and colleagues showed that within the predicted
first round amplicon sequence there existed a Pvu II RE site, cutting at base
99 of the 233 bp amplicon (Chang et al., 1994). Therefore digestion with Pvu
II should produce fragments of 99 bp and 132 bp in size when analysed by gel
electrophoresis. To determine whether Puv II could cut the first round
amplicon at this site 60 p1 of amplicon was added to 10 units of Pvu II
(Promega). After a 60 minute incubation at 37°C the digested and undigested
products were analysed. As figure 3.1.2. shows the first round amplicon was
successfully digested by Pvu II to give 2 digestion products which were both
found to migrate close to the 118 bp DNA band of the x174 markers (figure
3.1.2.). The digestion products were therefore of the predicted size and this
showed that the HHV8 first round amplicon contained the Pvu II RE site. This
proved that the HHV8 PCR amplified a sequence within the KS33OBam
sequence of the HHV8 genome.
Once correct amplification of HHV8 DNA had been confirmed, samples
known to contain human, HSV-1, HSV-2, VZV, EBV, CMV, HHV6 and
HHV7 DNA were analysed to ensure that no cross-reactivity would occur
with the HHV8 primer sets. Use of primary clinical samples was avoided in
case the patient from which they were prepared was co-incidentally HHV8
DNA positive. In all cases tissue culture supernatant was chosen and after
completing the HHV8 PCR assay no amplification products were identified
from any of these supernatants.
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3. a. 2. iii). determination of HHV8 PCR sensitivity
The absolute sensitivity of the HHV8 PCR was determined using DNA
extracted from the I-iHV8 / EBV co-infected cell-line HBL-6. A culture was
prepared and found to have a concentration of 1.35 x 106 cells I ml. 2m1 of
these cells were pelleted by centrifugation (800g, 10 minutes), washed in
RPMI and resuspended to give a stock of 1 x 106 cells / ml. A portion of this
stock solution was taken and further diluted 1: 10 in RPMI. The DNA from
0.5 ml of both the diluted and undiluted stock was prepared by phenol I
chloroform extraction. The purified DNA was resuspended in TE (Appendix
A) to give two DNA preparations, one with the concentration of 100 cells-
worth of DNA per microlitre and the other 10 cells-worth DNA per microlitre.
Ten-fold serial dilution of the prepared DNA was used to find the last dilution
which still contained detectable HHV8 DNA. For both DNA preparations it
was found that after analysing the stocks in 4 duplicate reaction series the
equivalent of 0.1 HBL-6 cells-worth HHV8 DNA could be reproducibly
detected by the FiHV8 PCR (fig 3.1.3.). The KBL-6 cell-line contains 20-50
copies of H}{V8 DNA per cell (personal communication P. Moore, Columbia
University) therefore the theoretical absolute sensitivity limit of HHV8 PCR
detection was approximately 2-5 HHV8 genomes. The number of cell
genomes present in the two DNA solutions was subsequently confirmed to be
100 and 10 respectively by analysis of the human genome load using a human
PCR (section 3. a. 3.) to the single copy gene pyruvate dehydrogenase. This
level of HHV8 PCR detection sensitivity compares well with that described by
Boshoff and colleagues (Boshoff et al., 1995) who also designed a nested
PCR for the detection of HHV8 DNA using the KS33OBam sequence. This
group found that using similar reaction conditions as described above they
were also able to detect 0.1 HBL-6 cell's worth of HHV8 DNA and defined
their absolute HHV8 PCR detection sensitivity as 10 copies of HHV8 DNA.
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3. a. 3. Nested PCRfor detection of human DNA
The reasons for developing a nested PCR for the detection of human DNA
were:
1. Herpesviral DNA is commonly found associated in vivo with cellular DNA,
a sensitive human PCR would allow the cell-load of any clinical sample to be
determined and the herpesvirus genome titre in that sample calculated as a
function of cell concentration.
2. The use of a human PCR allows confirmation of the extraction of DNA
from any clinical material and can indicate the presence of PCR inhibitors
which may be present following certain extraction techniques. Inhibitors such
as haemoglobin and heparin, remaining in blood extractions, have previously
been known to result in the generation of "false-negative" DNA detection
results (Gelfand and White, 1990).
3. a. 3. i). selection of human DNA PCR primer sequences
First round primers (PDG1 and PDG2) were already available for
amplification of a sequence within the human single-copy gene pyruvate
dehydrogenase (Koike, l99) . Use of the DNA sequence database PC Gene
provided the genome sequence between the two existing outer primers and
allowed design of two internal primers (PDG 3 and PDG 4). As well as their
use in a nested PCR for detection of human genomic DNA the second round
primers were chosen to span a site of messenger RNA (mRNA). Therefore the
size of the second round PCR product would differ depending on whether the
input analyte was DNA, or RNA which had been used to generate
complementary DNA (cDNA). The use of this PCR also provided a control
for DNA contamination in any cDNA synthesis.
105
3. a. 3. ii). optimisation of human DNA PCR reaction conditions
As for the H}1V8 PCR assay the size of first and second round amplicons of
the human PCR, and primer Tm, were similar to that of the PCR for detection
of CMV DNA (table 2.1). Therefore the reaction conditions, including primer
anneal temperatures, chosen were the same as the CMV PCR reaction.
However, when first developed the number of cycles used for amplification
was lower, at 30 cycles first round and 20 cycles second round. This number
of cycles was, however, found unable to generate PCR product bands of
equal, high intensity after the two rounds of amplification. Therefore the cycle
number was returned to the standard 35 first round and 25 second round, at
this level of amplification equal intensity bands of the predicted size (122 bp,
see fig. 3.1.4) were seen after the two rounds of amplification.
3. a. 3. iii). determination of human PCR sensitivity
Cells from the human diploid T-lymphocyte cell line J Than was available and
were used to provide human DNA for establishment of the sensitivity of the
human PCR. Cells were pelleted (800g for 10 minutes), washed in RPMI and
resuspended in PBS. The cell number was found to be 1.8 x 106 cells / ml.
DNA was extracted from 0.5 ml of these cells by phenol / chloroform
extraction. The purified DNA was resuspended in 1 00tl water and found by
spectrophotometry to have a concentration of 0.2 jtg /j.Ll . A single human cell
is known to contain approximately 10 pg of DNA, therefore this solution
corresponded to approximately 20,000 cells-worth DNA per microlitre.
Replica analysies were performed on a ten-fold serial dilution series of this
DNA solution, 2 are shown in figure 3.1.4., and from these analysies the
absolute limit of detection for the human PCR was found to be equivalent to
approximately a single cells-worth of DNA.
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3. a. 4. Study of HHV8 DNA prevalence in the venous blood and
peripheral samples from HI V-infected and uninfected individuals
3. a. 4. i). introduction
This study was undertaken to investigate the association between the presence
of HHV8 DNA in the peripheral blood of an individual and a clinical diagnosis
of KS. Previously all epidemiological data associating HHV8 with KS had
been based upon the PCR analysis of biopsy material recovered directly from
KS tissue (Chang et al., 1994, Boshoff et al., 1995, Moore et al, 1995).
Using such analysis it was difficult to determine whether HHV8 was a causal
agent of KS or merely a "passenger virus" with tropism for transformed KS
tissue. By examination of HHV8 DNA in the systemic environment it was
hoped to extend the original tissue-based findings and further investigate the
potential for a causal relationship between the virus and disease. Samples such
as throat washings and faeces were investigated so that potential routes of
virus transmission could be examined.
3. a. 4. ii) study design
Blood samples were available from 189 HIV-infected individuals; 173 male
and 16 female. Seventy of the 189 had a Center of Disease Control (CDC)
defined diagnosis of AIDS (Centers for Disease Control, 1987). Of those 70
with AIDS, 46 also had. a current diagnosis of cutaneous KS. Of the 119
individuals who were HIV-infected but without AIDS 98 did not have any
HIV-associated disease, 16 had a non-AIDS disease and 5 were unclassified.
145 individuals had homosexual contact as their primary HIV-acquisition risk
factor, 7 were bisexual, 4 possibly homosexual, for 21 a different acquisition
route was recorded, and for 12 the route of transmission was unknown. Of the
98 patients with symptom-free HIV infection 77 were enrolled in the 1990
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MRCJINSERM Concorde study and these remainder samples, together with
others, were used to examine whether presence of HHV8 DNA in the blood of
flY-infected patients without KS was predictive of subsequent KS
development. Blood samples were also available from 134 HIV antibody-
negative blood donors, these were supplied anonymously by the North London
Blood Transfusion Centre. Throat swabs in transport medium were available
from 21 AIDS-KS patients and faecal material from 18 such patients. Plasma
samples were available from 51 AIDS-KS patients. Serum samples were
available from 24 AIDS-KS patients. All patients from whom plasma and
serum were tested also had venous blood available for analysis. Samples were
prepared as described in section 2.c., DNA from all the blood was prepared
from glycigel-stored samples.
The number of circulating CD4 T-cells in venous blood was measured by flow
cytometry by members of the Department of Sexually Transmitted Diseases,
UCLMS. Statistical analysis was performed by A. Copas, Department of
Sexually Transmitted Diseases, UCLMS. Ethical approval for this study was
granted by the Clinical Investigation Panel, The Middlesex Hospital.
3. a. 4. iii) results
None of the 134 blood donors had detectable HHV8 DNA in their peripheral
blood. HHV8 DNA was detected in the blood of 24 of the 46 patients with
AIDS-KS (52%) (table 3.2.1.). In contrast HHV8 DNA was detected in only
11(8%) of the 143 HIV-infected patients without KS. In addition to analysis
for HHV8 DNA a subset of 123 blood samples were investigated for the
presence of EBV, another y-herpesvirus (table 3.2.2.). In this subset 26 (65%)
of the 40 patients with AIDS-KS, 19 (58%) of the 33 HIV-infected non-KS
patients and 6 of the 44 blood donors (12%) had detectable systemic EBV
DNA. Within this sub-set of patients the association between HHV8 and KS
remained high with 23 (58%) of the 40 AIDS-KS patients having detectable
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Table 3. 2. 2. Detection of HHV8 and EBV DNA in the blood of a sub-set of 73
HIV-infected patients and 50 UK blood donors
HHV8 DNA	 EBV DNA
Patient
group	 detected	 not detected
	
detected	 not detected
HI V-infected
patients:
with KS	 23 (58%)	 17 (42%)	 26 (65%)	 14 (35%)
without KS	 2 (6%)	 31(94%)	 19 (58%)	 14 (42%)
UK
blood donors	 0(0%)	 50(100%)	 6 (12%)	 44 (88%)
By chi squared test there is no association between having EBV DNA and KS:
p = 0.50
By chi squared test there is a highly significant association between having 1-ll-1V8
DNA and KS: p = < 0.0001
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HHV8 DNA, while only 2 (6%) of 33 HIV-infected patients without KS had
detectable HHV8 DNA. As detailed before none of the blood donors had
detectable I-IHV8 DNA.
Overall the percentage of fflV-infected patients with KS, if HHV8 DNA was
detected, was 69% while the percentage with KS if HHV8 DNA was not
detected was only 14%. For the whole group of H[V-infected patients, there
was a statistically significant association between having detectable FIHV8
DNA in peripheral venous blood and having cutaneous KS (p<O.0005 by x2
analysis).
As KS is more common in immunosuppressed HIV-negative patients
(iatrogenic KS) than the general population and herpesviruses are known to
cause a higher incidence of disease in immunosuppressed patients with low
CD4 counts (Penn, 1983 and Pertel et al., 1992) a correlation was sought
between ability to detect HHV8 DNA and absolute CD4 count. The median
CD4 count of patients with detectable HHV8 DNA was 120 (range 0 - 680),
while for those without detectable HHV8 DNA it was 300 (range 0 - 1720).
There was a strong statistical association between having detectable HHV8
DNA in blood and a reduced CD4 count (p=O.0O7 by Mann-Whitney test). It
was possible, using logistic regression analysis, to control for the effects of
CD4 count and following this there was still remained a highly significant
association between having detectable HHV8 DNA in peripheral blood and a
clinical diagnosis of KS (odds ratio 23(95% CI 8 - 66).
Of the total 189 HIV-infected patients analysed for the presence of systemic
HHV8 DNA 143 did not have KS at their first, or only, time of venepuncture.
Eleven of the 143 did however have detectable HHV8 DNA in their blood. It
was possible, by consultation of patient records, to follow the clinical status of
these patients for a median of 30 months (range 0 - 70) after blood sampling.
During this follow-up period 18 of the 143 patients developed KS. Six of these
18 patients had been among the group of 11 patients who had detectable
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HHV8 DNA in their first sample. In contrast only 12 of the 132 patients
without detectable HHV8 DNA at the time of first sampling progressed to
develop KS. Patients with more severe HIV-associated disease (CDC group
IV disease) had a shorter follow-up (median 2 months, range 0 - 48 months)
than those with symptom-free HIV-infection (median 52 months, range 0 - 70
months). From this data the KS-free survival time of all the patients who had
HHV8 DNA in their first sample, and of patients who did not, was calculated
and represented in a Kaplan-Meier plot (figure 3.2.1.). This plot shows that
those FIIV-infected patients with detectable HHV8 DNA, but no KS,
progressed much more rapidly to develop KS than those who had no
detectable HHV8 DNA (log-rank test; p<O.00005). Both these two groups
had comparable median CD4 counts; 450 for the HHV8 DNA positive patients
and 380 for the HHV8 DNA negative patients. It was estimated from the
Kaplan-Meier plot that 50% of the patients without KS in the study, who had
detectable HHV8 DNA in their blood, developed KS within 3.5 years of their
first incidence of HHV8 DNA detection.
In an attempt to identify possible transmission routes for HHV8 a number of
peripheral samples were examined, all of which came from patients with KS
(table 3.2.3.). Of the 21 throat swab medium samples available, all from
patients with detectable HHV8 DNA in their blood, only 1 contained HHV8
DNA. This patient had severe pulmonary and palatal KS at the time of
sampling and it was not possible to exclude contamination of the fluid with KS
tissue, or tissue exudate from either of these two sites. For comparison these
21 samples were also analysed for the presence of CMV, a herpesvirus known
to be commonly shed in the oral cavity of HIV-infected patients. CMV DNA
was detected in 16(76%) of the 21 samples.
HHV8 DNA was detected more commonly in serum from AIDS-KS patients
(11 / 24, 46%) than in plasma from AIDS-KS patients (5/30., 16%). In the
patients analysed all those with detectable HHV8 in plasma or serum also had
HHV8 DNA present in their unfractionated blood. Oro-anal contact has been
previously suggested as a possible route of transmission for any agent
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Figure 3. 2. 1. Kaplan-Meier plot showing that detection of HHV8 DNA in I-flY-
infected patients without KS is predictive of subsequent KS development
0	 12	 24	 36	 48	 60
Time of follow-up (months)
Proportion of individuals in whose blood HHV8 DNA was - - -
and was not (
	
) detected and who remained free of KS.
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Table 3. 2. 3: Detection of HHV8 and CMV DNA in peripheral samples from
HIV-infected patients
Sample	 Patient KS status	 HHV8 DNA detected	 CMV DNA detected
Throat swab
	 KS
	
1/21 (5%)	 16/21 (76%)
Plasma	 KS
	
5/30 (16%)	 NT
Serum	 KS
	
11/ 24 (46%)	 NT
Stools	 KS
	
0/18(0%)	 NT
NT : not tested
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associated with KS, we examined 18 stool samples from AIDS-KS patients,
none contained detectable HHV8.
3. a. 4. iv). discussion
There were a number of significant findings made in this large study of HHV8
DNA prevalence in HIV-infected patients without and without KS, and in
HIV-uninfected controls. Published in 1995 (Whitby et al., 1995) this was the
first study to demonstrate that HHV8 could be regularly detected in systemic
circulation of patients with KS and that such detection was significantly
associated with a diagnosis of KS. This was an important finding which further
strengthened speculation that HHV8 is more than a casual passenger-virus in
KS-affected tissue.
The specificity of association between HHV8 and KS was underlined by the
analysis of EBV DNA prevalence in the sub-set of patients and controls. EBV,
another y-herpesvirus with no suggested association with KS, was present
with equal frequency in both groups of HIV-infected patient regardless of KS
status. The detection of EBV, a virus with approximately 50% seroprevalence
in the UK population, in blood donors contrasted completely with our lack of
detection of HHV8 in any of these individuals. The epidemiological data
surrounding KS suggests that any virus associated with KS would be
extremely rare in the general population (Beral et al., 1990), the absence of
HHV8 DNA in this blood donor population fits well with this epidemiological
profile.
Although KS maybe one of the first AIDS-defining illnesses a patient with
HIV-infection may experience it can occur throughout the period of AIDS. It
had been suggested that the development of KS, and the ability to detect
H}{V8 DNA in KS lesions, was simply due to the severity of HIV-associated
immunosuppression KS patients were experiencing (discussed in Whitby et al.,
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1995). It was thought that not only did this chronic immunosuppression allow
for the formation of KS lesions but it also reduced the host immunological
control allowing replication of latent, ubiquitous viruses (such as the
herpesviruses, and therefore HI-1V8). However these results indicate that when
the effect of immune suppression is removed by logistic regression analysis
there was still an overwhelming association between the detection of HHV8
DNA and KS disease. This suggests that the immunosuppression associated
with HIV infection only becomes a risk factor for KS development when
HHV8 is also present.
Probably the most significant finding of the study arose from the predictive
data showing that as well as the presence of HHV8 DNA being associated
with a concurrent diagnosis of KS, that patients without KS who have
detectable HHV8 DNA in their blood are far more likely to eventually develop
KS. 50% of such patients in this study developed KS within three and a half
years of their first HHV8 DNA-positive sample. The finding that having
detectable HHV8 DNA is such a strong predictor of subsequent KS
development supports the theory of a causal relationship between HHV8 and
KS.
Any infectious agent for KS is likely to be restricted to certain groups such as
gay men, with transmission likely to be sexual rather than casual. Casual
transmission of other herpesviruses such as HHV6, CMV and EBV is usually
by contact with infected oral secretions. The finding that HHV8 DNA was
detected in only 1 of 21 oral samples, whereas CMV DNA was present in 16
of 21, suggests that HHV8 is unlikely to be transmitted by this route. Another
possible route of transmission for a KS-agent was faecal-oral. Studies have
found that gay men who experienced high levels of oro-anal contact were at
increased of developing KS during the course of their HIV disease (Beral et
at., 1993). HHV8 DNA was not detected in any of the stool samples from KS
patients, however the presence of PCR inhibitors in this DNA was not
excluded prior to analysis. Such inhibitors have been described (Shieh et at.,
1995). The presence of inhibitors, notably heparin, may also explain the
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disparity in detection of HHV8 DNA between plasma and serum (Saiki, 1989
and Gilchrist et al., 1997). The plasma used in the study was derived from
heparin-treated blood, and although the DNA extracted from that blood would
have had the heparin removed, DNA in the plasma was not fully purified but
simply boiled. In contrast the serum was prepared from unpreserved blood and
a correspondingly higher percentage of these serum samples were found to
contain HHV8 DNA.
In conclusion the data presented shows that HHV8 has many of the features
that a KS-associated agent must possess; from its highly localised prevalence
in patients with, or at greatest risk of, KS and its apparent absence in a large
blood donor population, to its limited casual shedding. The strong predictive
association between presence of the virus in disease-free REV-infected
individuals and subsequent KS disease development is powerful evidence
linking virus and disease.
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3. a. 5. Association of HHV8 DNA in bronchoalveolar lavage fluid with
pulmonary KS
3. a. 5. i) introduction
Although the skin is the most frequent site of KS presentation, mucous
membrane, lymph node and visceral organ involvement also occurs (loachim et
al., 1995). KS at these sites is usually, although not always, in association with
cutaneous lesions and systemic disease progression may be rapid. The highest
levels of patient morbidity and mortality in individuals with KS occurs when
the tumour affects the lungs; pulmonary KS (Pitchenick et a!., 1985). Studies
have found that between 18% and 32% of patients with cutaneous KS develop
pulmonary KS, with a prevalence as high as 47% described at post-mortem
(Zibrak etaL, 1986, Garay et a!., 1987 and Meduri et a!., 1986). It is thought
that up to 30% of individuals with pulmonary KS will die of respiratory failure
as a direct consequence of tumour involvement in the lungs (Mayaud et a!.,
1990). In a small study of HIV-infected patients who underwent post-mortem
at UCL Hospitals 4 of 16 had KS described as a major cause of death and each
of these 4 individuals had significant KS involvement of the lungs. This post-
mortem study also showed the extent to which KS may affect tissues in
the chest cavity with the visceral pleura, mediastinal lymph nodes, lung
parenchyma and all parts of the tracheobronchial tree involved.
Currently fibreoptic bronchoscopy is most often used to assist diagnosis of
pulmonary KS, by visualisation of "cherry red" or violaceous raised lesions
within the trachea and bronchi (Pitchennick et al., 1985). Radiological
investigation and the presence of symptoms such as dypsnea, fever and cough
are unreliable as confusion is common with other types of infection (Kaplan et
al., 1988). Bronchial and transbronchial biopsy are seldom used procedures
because of their low diagnostic yield and the associated risk of pulmonary
haemorrhage (Zibrak eta!., 1986).
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In this section a case control study is described which was set up to determine
the association between the detection of HHV8 DNA in bronchoalveolar
lavage (BAL) fluid and the bronchoscopic visualisation of pulmonary KS.
Such detection might be a useful confirmatory diagnostic test for patients with
pulmonary KS and may aid the differential diagnosis in patients with lung-
cavity KS lesions which were unusual in presentation or difficult to visualise
by bronchoscopy.
3. a. 5. ii) study design
In total 82 HIV-infected individuals admitted to the AIDS Unit, UCL
Hospitals, for investigation of lower respiratory tract disease were
prospectively examined by bronchoscopy and had BAL fluid recovered. Forty-
one study patients (40 male) had cutaneous KS, of whom 29 had concurrent
pulmonary KS diagnosed by bronchoscopy. Other respiratory tract disease in
these 41 patients is detailed in table 3.3.1.The other forty-one patients from
whom BAL fluid was available had no clinical evidence of KS, pulmonary or
cutaneous. BAL fluid had been recovered from this second group of patients
for analysis of other lower respiratory tract diseases; Pneumocystis carinii
(n=27), bacterial pneumonia (nl0), tracheitis (n=1), Mycobacterium
tuberculosis (n=2) and Mycobacterium avium-intracellulare with Aspergillus
fumigatus (n=1). Patients were selected for the study on a sequential basis.
The median CD4 counts in those patients with and without KS were similar;
30 (range = 0- 310) and 30 (range = 0 - 330) respectively.
All BAL fluid samples were screened for HHV8 DNA by analysis of lOtl and
50 j.il of whole fluid. For analysis of 50 pA the first round volume of the PCR
reaction was increased to 100 p1. If a BAL sample was found to contain
detectable HHV8 DNA the viral DNA load was determined by 10-fold end-
point titration of the BAL fluid. The cell-load of each BAL sample was also
calculated by end-point titration PCR for the single copy human gene pyruvate
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dehydrogenase. Neat BAL fluid was also examined using the
human PCR to determine whether any samples were inhibitory at that
concentration. Where sufficient fresh BAL fluid was available (from 5
patients) CD19, CD4, CD8 and CD14 cell fractions were isolated for analysis
and cell-free virus was prepared by ultracentrifugation (cell separation and
DNA preparation from these 5 samples was performed by Denise Whitby,
Institute of Cancer Research). Blood samples preserved in glycigel were
available from a portion of patients. These were extracted as described in
section 2. c. Titres of HHV8 DNA in blood were determined as for the HRV8
DNA titres in BAL fluid.
3. a. 5. iii) results
HHV8 DNA was detected in the BAL fluid from 24 (83%) of the 29
individuals with cutaneous and pulmonary KS, but was not detected in BAL
fluid from any of the 12 individuals with cutaneous KS only (table 3.3.2.).
HHV8 DNA was also undetectable in the BAL fluid from any of the 41
individuals with no KS. This association between detection of HIHV8 DNA in
BAL fluid and a bronchoscopic diagnosis of tracheobronchial KS was found to
be highly significant ( P <0.001, two-tailed Fisher's exact test). In 5 of the 24
BAL samples in which HHV8 DNA was detectable it was only detectable
when 50 p1 was analysed. The analysis of this increased volume was important
to the overall sensitivity of the test, raising it from 66% to 83%. Significantly
raising the input volume to 50 p1 did not result in detection of HHV8 DNA in
any of the BAL samples from patients without pulmonary KS.
All the BAL samples analysed contained detectable human genome, indicating
the presence of cellular material and no samples were found to be inhibitory.
Similar levels of human DNA were present in BAL
fluid from individuals with and without KS. For both groups the median
human DNA load was 100 copies per microlitre (range 10 - 10,000 copies per
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Table 3. 3. 2. Detection of HHV8 DNA in BAL fluid and peripheral blood of 82
HIIV-infected persons with, and without, KS.
BAL
	 Blood
Patient group
KS(n=41)
pulmonary &
cutaneous KS
(n=29)
cutaneous KS
only
(n= 12)
noKS (n=41)
HHV8
DNA
detected
(%)
24/29
(83)
0/12
(0)
0/41
(0)
Range (median)
HHV8 copies per
1000 cell genomes
0.02 - 1000
(1.0)
HHV8
DNA
detected
(%)
17/26
(65)
5/7
(71)
Range (median)
HHV8 copies per
ml
2-40x 106
(200)
2-40x i0
(2000)
0/6
(0)
124
microlitre). When levels of HHV8 DNA were calculated as a function of
human genome the ratio of virus I human genome was found to vary over a
5 logio range. No correlation was found between the H1HV8 DNA load per
human genome and the bronchoscopic extent of pulmonary KS, in terms of
number of lesions visible and their widespread or localised nature (table
3.3.1.).
Samples of blood were available from a proportion of individuals with
pulmonary KS (26 of 29), cutaneous KS only (7 of 12) and no KS (6 of 41).
HHV8 DNA was only detected in the blood of patients with KS and was
present at similar prevalences in those with pulmonary KS (17 / 26, 65%) and
those with cutaneous KS only (5 /7, 71%). The median HHV8 DNA titre was
similar in the two groups; 200 copies per ml (range 40 - 2 x 106 copies per ml)
in those with pulmonary KS and 2000 copies per ml (range 40 - 2 x i0 5 copies
per ml) in those with cutaneous KS only.
The cell populations were examined from the 5 BAL fluid samples in which
cell fractionation was possible. It was found that HHV8 DNA could not be
detected in any of the CD4 / CD8 (T lymphocytes) fractions nor the CD 19 (B
lymphocyte) fraction, but was detected in the CD 14 (macrophage) fraction in
one sample and in the CD4 / 8 / 14/19 depleted cell fractions of all 5 samples.
HHV8 DNA was also detected in all the cell-free fractions indicating the
presence of cell-free viral particles.
As well as the prospective analysis of BAL fluid samples there was access to a
number of samples which had been stored previously. It was therefore possible
to analyse BAL fluids taken from patients who in the prospective study had
pulmonary KS, but at the time of previous BAL had no bronchoscopic
evidence of pulmonary KS (table 3.3.3.). Archive samples from 7 patients
were available, taken between 2 and 25 months prior to the time of their first
diagnosis of pulmonary KS. At those times 4 of the 7 patients already had
cutaneous KS, while 3 had no KS at all. Five of the 7 retrospective BAL fluid
samples contained detectable HHV8 DNA, 3 from patients with cutaneous
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Table 3. 3. 3. Retrospective analysis in 7 patients of BAL fluid taken before and
after development of pulmonary KS.
Patient	 KS status	 HHV8 DNA in BAL fluid Interval between
at 1st BAL	 pre-pKS	 at pKS	 BAL's (months)
diagnosis	 diagnosis
1	 cutaneous	 + ye	 + ye
	 9
only
2. cutaneous	 +ve	 + ye
	 16
only
3. none	 +ve	 + ye
	 3
4. cutaneous	 - ye	 + ye
	 2
only
5
	
cutaneous	 + ye	 + ye
	 6
only
6. none	 ^ ye	 + ye
	 5
7. none	 - ye	 - ye
	 25
pKS: pulmonary KS
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KS, 2 from patients with no KS. In one patient HHV8 DNA was not detected
in either the retrospective sample or the sample taken at time of diagnosis of
pulmonary KS. The period prior to diagnosis of pulmonary KS in which
HHV8 DNA could be detected in BAL fluid ranged from between 2 and 16
months.
3. a. 5. iv). discussion
The previous study in section 3. a. 4. described the association between
presence of systemic HHV8 DNA and a diagnosis of cutaneous KS. In this
study the association between virus and disease is extended to the pulmonary
form of KS. There was a very clear and exclusive association between the
bronchoscopic finding of pulmonary KS and the presence of I{HV8 DNA in
BAL fluid, although virus load did not always correlate with disease extent.
The virus was not found in any patients without a diagnosis of pulmonary KS,
however in the retrospective analysis the presence of I{HV8 DNA in BAL
fluid taken from patients prior to their developing pulmonary KS was shown
to be a predictor of future pulmonary KS development. It was unfortunately
impossible to determine whether any of the patients without HHV8 DNA in
their BAL in the prospective study subsequently developed pulmonary KS in
the absence of I-1HV8 DNA.
HHV8, like the other human herpesviruses, is likely to be highly cell-
associated. It was for this reason that the level of cellular material recovered in
the BAL fluid for all patients was measured. Had the amount of human DNA
detected in BAL fluid from patients without pulmonary KS been significantly
less than in the BAL fluid of patients with pulmonary KS then the failure to
detect HHV8 DNA in patients with no pulmonary KS may have been due to
insufficient cellular recovery. However equivalent levels of human DNA were
found eliminating this possibility. Important too was the finding that in patients
with cutaneous KS only, none of whom had detectable HHV8 DNA in their
BAL fluid, the prevalence and titre of HHV8 DNA in blood was similar to that
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in the blood of those patients with pulmonary KS. This suggests that the
HHV8 DNA detected in the BAL fluid of patients with pulmonary KS is
unlikely to have originated from blood contamination of the BAL fluid nor by
the non-selective entry of HHV8 DNA-containing blood leucocytes into the
bronchial tree. If either of these factors were the processes by which the BAL
fluid of a high proportion of the pulmonary KS group came to contain
detectable HHV8 DNA then the frequency of viral DNA in BAL fluid should
have been similar in both the KS groups.
The sensitivity of detecting HHV8 DNA in BAL fluid from patients with
pulmonary KS was increased from 66% to 83% by increasing the volume of
BAL fluid analysed from 10 to 50 t1. Such an increase did not however result
in the detection of HIHV8 DNA in any of the non-pulmonary KS patients.
Raising the volume of material analysed increases the risk of introducing
greater levels of any PCR inhibitors present, however human DNA was
detectable	 in all samples. It would appear that like CSF samples
whole BAL fluid is rarely inhibitory to the PCR assay.
In contrast to previous studies (Moore et al., 1996) which indicated that
HHV8 DNA may be detected in circulating B-lymphocytes it was only
possible to detect HHV8 DNA in the macrophage fraction of a fractionated
BAL sample. Whether the macrophages were active in supporting HHV8
replication or the detection simply reflected their scavenging function could
not be determined. It has been previously reported that HHV8 DNA can be
detected in the macrophage component of KS lesions (Blasig et al., 1996). It
was also interesting to note that in all 5 fractionated BAL fluid samples the
cells remaining after depletion contained HHV8 DNA, suggesting that the
major cell, or cell-types, which do harbour and / or support HHV8 in the
respiratory tract remain to be identified.
Overall these results indicate that there is a significant role for the detection of
HHV8 DNA in BAL fluid from all HIV-infected patients suspected of having
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pulmonary KS, especially in patients with multiple lung pathology. Analysis of
BAL fluid, for the presence of HHV8 DNA, from those patients without
current pulmonary KS, but at risk of its development, may also be a useful
predictive diagnostic marker. Concurrent with the publication of this study
(Howard et a!., 1998) Tamm and colleagues (Tamm et al., 1998) published
results from a similar study of HHV8 DNA detection in BAL fluid from
patients with and without pulmonary KS. They found that HHV8 DNA could
be detected in all four prospectively analysed patients with a bronchoscopic
diagnosis of pulmonary KS and in all 10 patients with pulmonary KS from
whom stored samples were available. In 3 stored BAL samples HHV8 DNA
was detected in patients who at that time had no pulmonary KS, however all
three of these patients developed pulmonary KS thereafter. From some of the
patients multiple samples were available and overall HHV8 DNA was detected
in 15 of 19 BAL samples from patients with pulmonary KS. This detection
sensitivity, of 79%, is in close agreement with that found in our study, as is the
predictive association between having HHV8 DNA in BAL fluid and the
subsequent development of pulmonary KS.
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3. a. 6. Association of HHV8 DNA in cerebrospinal fluid (CSF) with
neurological disease in HI V-infected patients
3. a .6. i). introduction
A number of herpesvirus infections have been assooiftted with severe
neurological disease in HIV-infected patients. Cytomegalovirus has been found
at post-mortem in approximately one-third of AIDS patients and is associated
with encephalitis, polyradiculopathy and myelitis (Morgello et al., 1987).
Epstein-Barr vinis has been detected in almost all primary CNS lymphomas
/ (MacMahon et al, 1991 and Pedneault et al., 1992). The detection of both
CMV and EBV infection in the neurological setting has usually been by the
use of PCR on either tissue or CSF samples. (Arribas et a!, 1995 and Cinque
et a!., 1996).
This study was undertaken to determine the prevalence of HHV8 DNA in CSF
from a panel of HIV-infected patients who had presented with neurological
disease. Three cases of suspected HHV8-associated encephalitis have been
described in which I-IHV8 DNA was found in material obtained by stereotatic
brain biopsy for diagnosis of unexplained encephalopathy (Said et al., 1997),
and BCBL's, which are associated with HHV8, have been described in the
CNS of HIV-infected patients (Cesarman et al., 1995). However the general
incidence of KS in the CNS is low with the largest reported study showing
that less than 1% of homosexual HIV-infected patients have evidence of
neurological KS when examined at post-mortem (Levy et al., 1985).
3. a. 6. ii) study design
A panel of 36 CSF samples were available from patients who had undergone
diagnostic lumbar puncture for investigation of neurological disease. Of the 36
samples available 10 came from patients with evidence of CNS lymphoma (as
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shown by the presence of symptoms suggestive and the presence of EBV in
CSF and tissue), 4 from patients with suspected neurological CMV disease
and 4 from patients with suspected HJV encephalopathy. The 18 other patients
had an alternate neurological diagnosis. Seven of the patients also had
cutaneous KS. The median CD4 count in this patient group was 30 (range 0 -
350).
Before storage CSF samples had been separated by centrifugation into their
cell and supernatant fractions, as described in section 2. c.. The supernatants
were boiled before addition to the PCR reaction, DNA from the cell pellets
was extracted in 20 t1 EB (Appendix A), before boiling and addition to the
PCR (see section 2. c.). Ten microlitres of both supernatant and cell pellet
preparations were analysed for the presence of HHV8 DNA.
3. a. 6. iii). results
HHV8 DNA was not detected in any of the 36 CSF supernatants but was
detected in 2 of the 36 (6%) CSF pellets. One of these CSF's came from a
patient with systemic, but not CNS lymphoma and no clinically apparent KS
This patient subsequently developed CNS lymphoma over a year after the
recovery of CSF. The other CSF came from a patient with disseminated CMV
disease, no CNS lymphoma, but widespread cutaneous KS. Both these
patients also had HHV8 DNA in their blood, at 2 x i05 and 2 x 106 copies per
ml respectively. The presence of systemic HHV8 DNA was undetermined for
the other patients in the study. There was no evidence of leucocytes or
pleocytosis in either of the two CSF samples in which HHV8 was detected.
By comparison EBV DNA was detected in the CSF of all 10 patients with
brain-biopsy-confirmed CNS lymphoma and in 8 (31%) of the the 26 CSF
samples from patients without known CNS lymphoma.
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3. a. 6. iv) discussion
Overall the prevalence of HHV8 DNA (6%) in the CSF samples from this
group of extremely immunosuppressed HIV-infected patients was low, with
no specific association found between any neurological condition and the
presence of HHV8 DNA in the CNS. This compares with the much higher
prevalence of EBV DNA, which was detected in the CSF of all patients with
suspected CNS lymphoma, and in over 30% of patients without a specific
EBY-associated neurological disease. It is possible that the HIHV8 DNA
detected in the 2 CSF samples was derived from blood contaminating the
samples during lumbar puncture, or from the import of immunologicaly-
important leucocytes into the CSF, which has been reported (de Gans et al.,
1990). Both patients did have HHV8 DNA present in their blood, however in
both cases no white blood cells were noted after microscopic examination of
the CSF, nor where the samples reported to have been grossly contaminated
during recovery.
Although this study had access to a limited number of CSF samples it would
appear that unlike a number of the other herpesviruses, such as CMV and
EBV which have been found commonly associated with CNS disease in
extremely immunosuppressed HIV-infected patients (Morgello et al., 1987
and Pednanultt et al., 1992), HHV8 infection is uncommon in the neurological
environment of this patient group.
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3. a. 7. HHV8 DNA prevalence in the semen of HIV-infected homosexuals
and UK semen donors
3. a. 7. i) introduction
The incidence of KS in the HIV-infected population suggests that it may be
caused by a sexually transmitted infectious agent (Beral et al., 1990). Such an
agent, which is likely to be rare in most western populations, should also be
prevalent in individuals at increased risk of developing KS, such as gay men.
Recently it has been shown that KS is more likely to occur in men with a high
number of homosexual partners and that rates of seropositivity for HHV8 are
associated with increasing numbers of homosexual sexual contacts (Martin et
al., 1998 and Melbye et al., 1997). Such data suggests that if HHV8 is the
causative agent of KS then the virus may well be transmitted via infected
semen and that such transmission may be more common in the homosexual
population than the heterosexual population.
This study was conducted to determine the prevalence of FIHV8 DNA in the
semen of both HIIV-infected gay men and heterosexual semen donors from the
UK. It sought to examine whether the virus could be found in semen, and
therefore be sexually transmitted, and, if found in semen, there was an
association between sexual orientation, immunosuppression and viral genome
prevalence.
3. a. 7. ii) study design
Twenty-four HIV- 1 infected gay men were recruited from a London HIV
outpatient clinic, each providing at least one semen sample for analysis. As
well as providing semen samples blood was taken from each by venepuncture.
Seventeen of these men had AIDS, 15 with KS and 2 without KS. Of the
remainder 6 were symptom-free and one had non-AIDS CDC group IV
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disease. Cryopreserved semen samples were also available from 115 men who
had donated semen at a London fertility clinic over the last 15 years. HIV-
infected patients providing samples gave informed consent and the study was
approved by the Camden and Islington Community Health Services Trust
Ethics Committee.
Semen samples were processed for DNA extraction within 4 hours of
production by colleagues at the The Institute of Cancer Research, London.
The semen was separated into cell and seminal plasma (cell-free) fractions
which were then extracted separately by the phenol chloroform technique
(section 2. c. 4.). Semen from the healthy donors, which had been
cryopreserved, was thawed and extracted by myself in the same way as fresh
semen. Blood samples were stored and the DNA extracted using the QIAGEN
method detailed in section 2. c. 1. In the study PCR assays for the detection of
human, CMV and HHV8 DNA were performed as described in section 2. b.
The presence of CMV DNA in the semen samples was investigated as CMV
has previously been detected in the semen of both RIV-infected and uninfected
individuals and sexual transmission of CMV, especially between gay men is
well documented. (Drew et at, 1984 and Tijam et at., 1987). The PCR for
detection of human DNA was used to determine the levels of human DNA
recovered from the semen samples of 40 donors and all 24 HIV-infected
homosexuals.
Seminal fluid has been found to be a significant inhibitor of the PCR process
(Dyer et al., 1996). To confirm that the DNA prepared from these samples
was not inhibitory to the PCR assays a ten-fold dilution series of purified
HHV8 DNA was prepared in an HHV8 DNA-negative semen sample and the
DNA purified as previously described. The HHV8 PCR detection sensitivity in
these samples was then compared with the same HHV8 DNA dilution series
diluted in distilled water. To confirm that cryopreservation and subsequent
thawing of the donor semen did not adversely affect DNA yield or introduce
PCR inhibitors known cell numbers of the HHV8 genome-containing cell line,
HBL-6 (20 - 50 copies HHV8 DNA per cell) were introduced into an HHVS
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DNA-negative sample and the sample prepared for cryopreservation. After
overnight storage in liquid nitrogen the sample was thawed and processed as
usual. The titre of HHV8 DNA recovered was then assayed and compared to
the titre of HHV8 DNA in the same number of HBL-6 cells suspended in
RPMI (appendix A) which had been extracted immediately.
3. a .7. iii) results
The extracted DNA from seminal fluid was found to have no inhibitory effects
on the sensitivity of the HHV8 PCR and the cryopreservation procedure
resulted in no loss in DNA yield or assay sensitivity. The median level of
human DNA recovered from the semen was calculated, by serial end-point
titration, to be the same for both the HIV-infected gay men and the
heterosexual donors, at 1 x iü copies per microlitre.
Semen from 6 (25%) of the 24 HIV-infected gay men contained detectable
HHV8 DNA, 20 (83%) of 24 contained detectable CMV DNA (table 3.4.1.).
Three samples contained both genomes. HHV8 DNA was detected in 3 of the
15 patients with KS (patients 10, 11 and 15, table 3.4.2.) and in 3 of the 9
patients without KS (patients 19, 22 and 24). HIHV8 DNA was found most
often in the seminal plasma (5 of 6 patients). One patient had HHV8 DNA in
both the seminal plasma and cellular fractions (patient 10) and one patient had
HHV8 DNA in the cellular fraction alone (patient 15). The median CD4 count
in the patients with detectable HHV8 DNA in semen was 220 (range 90 - 740)
and in those without was 100 (range 10 - 490).
Four of the 6 patients with HHV8 DNA in semen also had detectable HHV8
DNA in their blood. Overall HHV8 DNA was detected in the blood of 10 / 15
(67%) of the HTV-infected patients with KS, and both the HIV-infected
patients without KS, who had HHV8 DNA in their semen, also had detectable
HHV8 DNA in their blood.
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Table 3. 4. 1. Detection rates for HHV-8 DNA and CMV DNA in semen and
blood from HIV-infected individuals, and in semen from UK semen donors.
Number HHV-8 DNA HHV-8 DNA CMV DNA
tested	 in semen (%)	 in blood (%)	 in semen (%)
Semen donors	 115	 I	 0/115(0)	 nt	 4/ 115 (3)
HIV-infected gay
men:
with KS:	 15	 3/15(20)	 10/15(67) I	 12/15(80)
without KS:	 9	
3/9r(33)	
2/9 (22)	 8/9 (89)
nt: not tested
'It
When analysed by Fishers exact test there is no statistical significance, at the 0.05 level,
between the prevalence of HHV8 DNA in the semen of HI V-infected gay men with and
without KS; (P 0.1)
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Table 3. 4. 2. Sites of HHV-8 DNA detection in HIIV-infected individuals with, and
without* KS who had detectable HHV-8 DNA in either semen or blood.
Blood
	
Semen
Patient 2	 +ve
2 rpt	 nt
Patient 5	 +ve
Patient 7	 +ve
Patient 10	 +ve
l0rpt	 nt
lOrpt	 nt
Patient 11	 +ve
Patient 12	 +ve
Patient 14	 +ve
Patient 15	 -ye
Patient 16	 -I-Ye
Patient 19*	 +ve
Patient 20	 -I-ye
Patient 21	 +ve
Patient 22*	 +ve
Patient 24*	 -ye
nt: not tested
rpt: repeat sample
'HHV-8 DNA in both cell and plasma fractions
2 HHV-8 DNA in plasma fraction alone
HHV-8 DNA in cellular fraction alone
-ye
-ye
-ye
-ye
+ve
+ve
+ve 2
+ve 2
-ye
-ye
+ve
-ye
+ve 2
-ye
-ye
-I-ye2
+ve 2
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In contrast HHV8 DNA was not detected in any of the semen from the 115
healthy donors; CMV DNA was detected in the semen of 4 of these healthy
donors. HHV8 DNA was still not detected in any of the 115 donor semen
when ten-fold more DNA was then re-analysed from each sample.
3. a. 7. iv) discussion
In this study HHV8 DNA was not found in 115 heterosexual semen samples
donated for use in assisted conception over the past 15 years. This finding is in
concordance with data from section 3. a. 4. in which FIHV8 DNA could not be
detected in the blood of a large panel of blood donors. It suggests that HHV8
can, in the UK, be rarely found in individuals outside those who are
immunosuppressed and from groups known to be at high-risk of developing
KS. Furthermore it would seem that, at present, there is a minimal risk of
acquiring HHV8 from donated semen in the UK.
Importantly the absence of detectable HHV8 DNA in the semen of healthy
HIV-negative individuals contradicts a number of earlier studies from north
America and Italy which suggested that HHV8 DNA could be detected in the
semen of a significant minority of HIIV-negative heterosexuals. (Lin et al.,
1995 and Monini et al., 1996). Lin and colleagues originally reported finding
HIHV8 DNA in the semen of 23% of HTV-negative donors, although recently
this data has been withdrawn from publication when their results could not be
repeated (Lin et a!., 1998). Instead the findings of this study would agree with
a number of more recent studies which were unable to find HHV8 DNA in the
semen and prostate from a range of different populations of HIIV-uninfected
men, including those from north America and Italy (Corbellino et al., 1996,
Tasaka et a!., 1996 and Gupta et al., 1996). As the current estimate of HHV8
seroprevalence in the UK is between 2 and 5% (Simpson . et al., 1996) the
absence of detectable HHV8 DNA in these UK semen donors would appear
unsurprising.
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The seroprevalence of CMV in the UK is approximately 50%, however only 4
semen donors had detectable CMV genome in their semen, underlining the
difficulty of detecting herpesvirai DNA in the semen of individuals with normal
immunostatus. Over 80% of the H1IV-infected patients (who are all likely to
have been previously infected with CMV) had CMV detected in their semen, a
level in accordance with a number of previous studies (Drew et a!., 1984 and
Tijam et a!., 1987). This illustrates the emergence of active CMV infection in
patients with reduced immunological control. and the relative ease of CMV
DNA detection in the semen of such individuals.
Twenty-five percent of the HIV-infected patients had detectable HHV8 DNA
in their semen and the virus was detected in a slightly higher percentage of
semen from those without KS (33%) than those with KS (20%). Overall this
difference was not statistically significant owing to the limited number of
patients from whom semen was available. It should be remembered that all the
HTV-infected patients included in the study were homosexual, and therefore at
risk of developing KS, with 12 / 24 (50%) having detectable Hl{V8 in their
blood. The finding that HHV8 DNA was more commonly detected in seminal
plasma was unusual as herpesviruses are predominantly cell-associated.
The fflV-infected patients in whom HHV8 DNA was detected in semen were
experiencing, on average, a less severe degree of immunosuppression than
those in whom HHV8 DNA was not detected, indeed one patient with
detectable HHV8 DNA in semen had a CD 4 count of over 700. Again with
limited samples this was not a statistically significant finding, but may be an
important observation if transmission of the virus is by sexual contact. For
sexual transmission to occur infected individuals would need to remain
sexually potent, and therefore relatively healthy in order to engage in activities
allowing for viral transmission to others. Such shedding of CMV in the semen
of healthy gay men is well described and is likely to contribute to the
transmission and high seroprevalence of CMV in the gay community (Lange et
al., 1984).
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Three of the HIV-infected patients without KS had detectable HHV8 DNA in
their semen, 2 of whom also had the virus detected in peripheral blood. It is
not yet known whether the finding of HHV8 DNA in semen is associated with
future development of KS, however combined with a systemic HHV8 viraemia
this would be expected from the findings of the study described in section 3. a.
4.
Even with the limited number of semen samples available from HIV-infected
homosexual men, these findings strongly support the proposed sexual
transmission of HHV8 within this social group. The presence of HHV8 DNA
in the semen of 30% of the gay men tested correlates well with the
epidemiology of KS. Studies have shown that 30% of all gay men with HIV-
associated immunosuppression will develop KS (Peters et al., 199 l. The lack
of HHV8 DNA in a large number of semen samples from heterosexual donors
would suggest that this virus is both uncommon in the general UK population
and difficult to detect in those few heterosexual immunocompetent individuals
who are infected. The incidence of HHV8 sexual transmission between
heterosexual partners in the UK is therefore likely to be low. There are
however two reports in which women have developed KS following sexual
contact, both of which occurred with a male partner from a high KS-risk social
group (Tirelli et al., 1996 and Barry et a!., 1991). These cases must then
support the possibility of heterosexual transmission of HHV8 with such
transmission potentially involved in the low-level maintenance of HHV8 in the
general population. Evidence of heterosexual transmission is also of
importance in defining the infectious risk factors associated with artificial
assisted conception procedures where semen is used without prior screening to
determine the HHV8 serological status of the donor.
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3. b. Response of HHV8 to chemotheraputic intervention in HIV-
infected patients with KS
3. b. 1. Introduction
The management of AIDS-associated KS is usually directed by the severity of
disease and the level of immune-system impairment experienced by the patient.
Current treatment protocols are particularly unsatisfactory for patients with
cutaneous lesions and no evidence of systemic or lymph-node involvement. In
this circumstance the CD4 count of the patient has been proposed as a
directing factot if the CD4 count is above 200 then local
treatment with intra-lesional chemotherapy or local radiotherapy has been
found effective, however this falls to influence the development of new lesions
(reviewed in Voim and Roenn, 1995 and in Tur and Brenner, 1996).
Alternatively for such patients systemic anti-retroviral treatment with either
zidovudine (AZT), or one of new BTV-1 protease inhibitors has been
suggested to facilitate immune system repair. In small studies such therapies
have been found to provide clinical stabilization of KS tumour load
(Shingardia et a!., 1995 and Lebbe et al., 1998). Such anti-retroviral therapy
may also be combined with a-interferon treatment, depending on the patients
ability to tolerate the associated side-effects of myelosuppression and "flu-
like" symptoms. Unfortunately a-interferon treatment is of little benefit in
those patients who have had previous systemic chemotherapy or are
experiencing viral opportunistic infections (Evens et al., 1991).
In patients with CD4 counts of less than 200 a-interferon therapy is largely
ineffective and systemic cytotoxic chemotherapy is required. Previously a
number of single-agents and combinations have been evaluated including
bleomycin, vincristine and adriamycin (Laubenstein et al., 1984 and Gill et al.,
1996). Recently liposomal daunorubicin, an anthracycline derivative delivered
in a phospholipid membrane, has been shown to provide a partial tumour
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response in between 50 - 60% of patients (Harrison et a!., 1995). However as
with all systemic cytotoxic chemotherapies side affects are common. For
daunorubicin these include including myelosuppression, hepatotoxity, cardiac
damage and liver failure. The toxicity of these chemotheraputic regimes, their
unsuitability in early disease and the restricted use of other treatments has led
to the investigation of a variety of alternative agents. These include systemic
retinoids, f3-HCG, retinoic acid and sulfated polysaccharide peptidoglycans, all
of which have shown some promise in in vitro analysis and are undergoing
clinical evaluation (Jie et a!., 1997, Lang et a!., 1997 and Bower et a!., 1997).
Since the discovery of HHV8 and its proposed involvement in the
development of KS anti-herpesviral agents have also been suggested as
possible treatments, although data as to the effectiveness of PFA and GCV is
limited (Morfeldt and Torssander, 1994 and Kedes and Ganem, 1997).
Because of the hypervascular nature of the KS tumour agents capable of
interfering with angiogenesis are also currently being evaluated as potential
therapies. One of these, thalidomide, is of particular interest because of its low
toxicity profile and the general tolerance shown by HIV-infected patients who
have been treated with the drug for pharyngeal ulceration and aphthous
stomatitis (Youle et a!., 1990). As well as having a potent anti-angiogenic
activity thalidomide is also a selective inhibitor of TNF-c synthesis (D'Amato
et al., 1994). TNF-a has been shown in vitro to stimulate KS spindle cell
proliferation and be crucial in the support of cell lines derived from KS tissue
(Samaniego et al., l99). Thalidomide also induces the anti-inflammatory T
helper cell type 2 cytokine response while inhibiting the pro-inflammatory T
helper cell type 1 response which includes interferon-y, a cytokine known to
stimulate spindle cell transformation and the mitosis of KS cells (Moreira ez'
a!., 1993, McHugh et al., 1995 and Fiorelli et a!., .1995).
This chapter describes a number of patient reports and a small phase II trial in
which a variety of alternative therapies for the treatment of KS have been
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examined. In all cases the virological response of HHV8 to these therapies is
described along with any macroscopic clinical changes in KS disease extent.
3. b. 2. Clinical and virological response in a child with HIV-associated KS
during treatment with AZT.
This case study involves a 3 year old girl of Ugandan origin who presented to
Great Ormond Street Hospital for Sick Children in July 1992. At this initial
presentation the child was experiencing recurrent respiratory infections in
association with generalised lymphadenopathy and hepatosplenomegaly.
Laboratory analysis showed her to be HIV-1 infected, the source of infection
was presumed to be maternal. At this time her CD4 T-lymphocyte count was
400. Four months after her diagnosis with HIV the girl was commenced on
septrin prophylaxis (November 1992) and enrolled in the PENTA-1 trial. The
PENTA-1 trial was a double blind placebo controlled trial comparing
immediate versus deferred therapy with azidothymidine (AZT), upon
unblinding it was discovered that the girl had received AZT while on the trial.
For the next 3 months while receiving AZT the child remained well (February,
1993), however at maternal request she was removed from the PENTA-1 trial.
The child continued to be asymptomatic for the following 12 months, although
her CD4 count declined to 33. After this 12 month period AZT therapy was
recommenced at 360 mg / m2 / day (January 1994). Seven months later
(August 1994) a firm, painless swelling appeared in the left femoral region,
this was associated with thigh oedema. The swelling was biopsied 4 months
later (December 1994) and an associated lymph node removed. Histological
examination of the biopsy tissue showed that almost the entire normal
architecture of the lymph node had been replaced by KS tissue. Staining for
acid-fast bacilli, fungi and CMV were negative, no viral inclusion bodies were
noted. After the diagnosis of lymph node KS the girl was commenced on
liposomal daunorubicin at 40 mg / m2 every 3 weeks for 18 weeks. At this
time her CD4 count had declined to 20 and she continued on AZT. Within 1
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month of initiation of daunorubicin therapy a clinical response in the femoral
swelling was noted with a decrease in oedema, however 3 months after
cessation of chemotherapy (May 1995) there was a recurrence of both
lymphadenopathy and oedema. In an attempt to relieve the recurrent
symptoms a course of localised radiotherapy was administered and the
swelling diminished. Two months after this response to radiotherapy multiple
cutaneous KS lesions appeared on the limbs (October 1995).
A number of blood samples were available for analysis for the presence of
HHV8 DNA. Table 3.5.1. gives a brief summary of the clinical course of this
child as well as the therapy received and dates of blood sampling. All blood
samples were stored in the glycigel freezing medium and DNA was extracted
as described in section 2. c. 1. The first date of venepuncture was November
1992, at the time of enrollment into the PENTA-1 trial. Although this sample
was taken over 2 years before the development of lymph node-associated KS
H1-1V8 DNA was detected at a low titre of 200 copies / ml. Such detection is
in agreement with the earlier study (section 3. a. 4.) in which HHV8 DNA in
blood was found to be predictive of subsequent KS development. Interestingly
in the next available blood sample, taken 3 months after initiation of AZT
therapy, just prior to removal from the PENTA-1 study, HHV8 DNA could
not be detected. It is possible that the 3 month treatment with AZT resulted in
an immune-system enhancement allowing clearance of the low level of
systemic HHV8 DNA detected 3 months earlier.
Although no blood sample was taken at the time of first persistent groin
swelling and histological diagnosis of lymph node KS, biopsy tissue was
available for analysis. HHV8 DNA could be detected in the tissue confirming
the visual microscopic diagnosis of KS. At this time daunorubicin therapy was
commenced. The next time of blood sampling was at the end of the 18 week
daunorubicin course and, as after the AZT therapy HITIV8 DNA was still
undetectable. This may have been the consequence of two effects; firstly the
daunorubicin may have had a direct anti-HHV8 effect thereby eliminating
detectable HHV8 DNA from the blood, or by reducing the gross tumour load
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ns
ns (HHV8 DNA
detected in biopsy)
- ye
Table 3. 5. 1. Clinical course, treatment regimen and presence of HHV8 DNA in
the blood of a child recieving AZT therapy.
Date	 Clinical course	 Treatment	 HHV8 DNA in blood
7 / 92	 }HV diagnosed	 -	 ns
9 / 92	
J	
entered Penta trial 	 AZT	 ns
11/92	 -	 AZT	 + ye (200 copies I ml)
2/93	 removed from
Penta-1 trial
1 /94	 declining CD4	 AZT
count
12 / 94	 femoral lymph node AZT and
________	 biopsy shows KS	 Daunorubicin
3 / 95	 clinical response	 AZT and
of KS	 Daunorubicin
- ye
5 / 95	 relapse of KS	 AZT	 + ye (2000 copies / ml)
and radiotherapy
10/95	 cutaneous KS	 AZT	 + ye (200 copies / ml)
ns - no sample
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in the lymph node (as was noted) there may have been less support for HHV8
replication making its detection in the blood more difficult. At the time of
lymph node KS relapse, and reappearance of oedema, HHV8 was once more
detectable in peripheral blood at 2000 copies / ml, a 10-fold higher titre than
when first detected in November 1992. As this re-emergence of HHV8
corresponded with increase in tumour mass it may be that levels of HHV8 in
the blood do respond to changes in tumour bulk. HHV8 DNA remained
detectable in the peripheral blood at a level of 200 copies / ml just prior to the
development of widespread cutaneous KS in October 1995.
In this study the detection of HHV8 DNA in a lymph node biopsy was used to
confirm the histological diagnosis of KS, and levels of I{HV8 DNA in blood
were found to mirror the use of immunosupportive AZT therapy and the
decrease in KS tumor bulk after systemic chemotherapy, as well as the re-
emergence of KS following therapy failure. These data suggest that detection,
and simple quantification, of HHV8 DNA in peripheral blood may be a useful
surrogate marker for KS tumor therapy, response and progression in the H1IV-
infected patient. As had been previously noted detection of HHV8 DNA in
peripheral blood was predictive of eventual KS development.
3. b. 3. Clinical and virological response in a child with HIV-associated KS
during treatment with thalidomide
This second case study also involves a young female with maternally acquired
HIV infection. This 13 year old girl was of Zairian origin and had emigrated to
Switzerland at the age of 9. Until this time she had been clinically well but then
had several periods of pneumonia. Over the next 3 years she developed a
number of ITIV-associated diseases, including recurrent oral candidiasis,
lymphocryptic interstitial pneumonitis and PCP. For over 1 year prior to her
development of KS, at the age of 13, her CD4 count had been 0. In early 1995
she presented with subcutaneous nodular KS lesions on both arms, the left
upper leg and the right eyelid. Diagnosis of KS was made by histological
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examination of biopsy material which showed the proliferation of spindle-
shaped cells and vascular structures with large endothelial cells, both common
characteristics of KS tumour development. After the initial diagnosis no
specific chemotherapy or radiotherapy for KS treatment was initiated and the
number and size of the lesions increased gradually over a 4 month period.
Approximately 4 months after the first development of KS (at age 14 years, 3
months), the child developed painfui oral ulcers for which no causative
pathogen could be identified. Attempts to treat this oral ulceration with topical
and systemic corticosteroids failed and therapy with thalidomide was started at
a dose of 3 mg / kg I day. The initial thalidomide treatment duration was three
weeks during which time a coincidental decrease in the size of the original KS
lesions was noted, as well as the absence of any new lesions. As both the oral
ulcers were responding to treatment and the severity of KS appeared to be
decreasing thalidomide treatment was continued. Two months later still no
new lesions had developed and the number of existing lesions had decreased
from 29 to 13 (at 14 years, 7 months). During this period the treatment with
thalidomide was augmented with local radiotherapy to improve resolution of
KS lesions at an interpharangeal joint and upper eye lid.
Unfortunately at this time (14 years, 8 months) the girl developed a Candida
albicans septicemia. This required intravenous therapy with amphotericin B,
resulting in severe neutropenia. To counter the neutropenia granulocyte
colony-stimulating factor (G-CSF) was administered. The introduction of G-
CSF was associated with an increase in the size of the existing KS lesions.
With resolution of the Candida albicans septicemia G-CSF and amphotericin
B therapy was stopped. and thalidomide treatment, which had continued
throughout, continued. After cessation of G-CSF treatment the extent of the
KS tumour bulk again decreased and then remained stable for almost 1 year
while the child continued on thalidomide. At this time she died, exact cause of
death was not established. Throughout the thalidomide treatment no adverse
effects were noted.
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Blood and skin biopsy samples were available at various times before and
during this child's thalidomide treatment. Table 3.5.2. shows the time at which
these samples were taken and the therapies being used at those times, together
with HHV8 DNA analysis of blood and biopsy tissue. As well as the
qualitative detection of HHV8 DNA in blood and the titration of viral load in
biopsy material human DNA load in the extracted biopsy was also measured
(as described in section 3. a. 5.). Such quantification enabled the HHV8 DNA
load in the biopsy tissue to be calculated as copies per human genome and
allowed more accurate comparison between different biopsy samples.
Prior to initiation of thalidomide therapy HHV8 DNA could be detected in the
peripheral blood and in biopsies of KS and, for comparison, normal tissue. At
this time a very high level of HRV8 DNA; 10 copies per human genome, was
detected in the tumor biopsy. As HHV8 DNA could be detected in the blood it
was postulated that the detection of HHV8 DNA in normal skin may have
been due to contamination of the tissue biopsy with HHV8 DNA-containing
blood. Samples taken three months later, after initiation of thalidomide
therapy, showed a dramatic decrease in the HHV8 DNA tumour load, and no
detectable HHV8 DNA in the peripheral blood or the normal skin biopsy. This
finding supports the theory that the original detection of HHV8 DNA in the
normal biopsy may have been due to blood contamination. Most significantly
the HHV8 DNA load in the tumor tissue, at a time when the KS tumor bulk of
individual lesions was noted to be clinically decreasing, had reduced from 10
copies per human genome to 0.1 copies per human genome; a 100-fold
reduction. Six days after commencement of G-CSF therapy however HHV8
DNA was once more detectable in peripheral blood, although still none could
be detected in the control tissue. At this time-point no tumour tissue was
available for analysis. The final blood sample taken was 3 months after G-CSF
therapy had been stopped and the patient was once more experiencing stable
KS, while continuing to receive thalidomide therapy. At this time HHV8 DNA
was again undetectable in the blood. Tissue samples were not available.
148
Table 3. 5. 2. HHV8 DNA in the blood and tissue of an HIV-infected child before and
during treatment with thalidomide.
Therapy
Age
l4yrs,	 none
3 mths.
HHV8 DNA copies per
HHV8 DNA
	 human genome in tissue
in blood	 Tumor	 Non-tumor
detected	 [0	 0.001
14 yrs,	 thalidomide	 not detected	 0.1	 not detected
7 mths.	 (<0.0001)
14 yrs,	 thalidomide	 detected	 ns	 not detected
8 mths.	 + G-CSF	 (<0.0001)
l4yrs,	 thalidomide	 not detected	 ns	 ns
11 mths.
ns: no sample
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This study shows both a clinical and virological response of KS and HHV8
DNA load to treatment with thalidomide in a young female with HIV-
associated KS. Interestingly upon initiation of G-CSF therapy the clinical
benefits of the thalidomide treatment appeared to be counteracted and HHV8
DNA load increased. Both these effects were reversed upon cessation of G-
CSF therapy and continuation of thalidomide treatment alone. Possible
molecular mechanisms for these effects are as follows; thalidomide is an
inhibitor of TNIF-a and angiogenesis, while inducing T helper cell type 2
cytokine production and inhibiting T helper cell type 1 cytokine production.
These effects act to reduce KS spindle cell formation and mitosis of KS cells.
This would explain the reduction of existing KS tumour bulk noted and the
absence of new KS tumour development. However G-CSF has an antagonistic
effect to thalidomide and stimulates human endothelial cell proliferation
(Bussolino et at., 1989), thus aiding the development of new KS tumour bulk
as was seen clinically. Since other therapy, in particular anti-retroviral, was
unchanged during this period it is likely that the above mechanisms exerted an
effect on KS tumor load and the changes in HHV8 DNA load in both tumour
and blood. Again it was impossible to determine whether thalidomide was
having a direct effect of HHV8 itself or whether the variation in HHV8 DNA
load was a response to change in clinical KS tumour bulk.
In summary it would appear that the use of thalidomide in this case proved of
definite clinical benefit, in terms of the control and partial resolution of severe
cutaneous KS lesions experienced by this girl. HHV8 DNA titre in blood and
tissue was again found to mirror the extent of KS tumor load. These findings
reinforce the previous suggestion of the use of HHV8 genome load,
determined by simple titration quantification, as a surrogate marker of KS
response to systemic therapy.
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3. b. 4. A phase II study of thalidomide use in HI V-infected patients with
early KS
Following the findings, described in section 3. b. 3., of the potential use of
thalidomide in the treatment of FHV-associated KS a collaborative study was
initiated with colleagues at the Kobler Clinic, Chelsea and Westminster
Hospital, London to investigate the use of thalidomide as an alternative
therapy to conventional treatments for the management of early HIV-
associated cutaneous KS.
3. b. 4. i) patient enrollment requirements and clinical definitions of therapy
response
The study was conducted at a single study centre and was designed to
establish the activity and toxicity of thalidomide in the treatment of cutaneous
AIDS-associated KS. Eligibility for enrollment was restricted to patients with
serological evidence of infection with H1IV-1, aged between 18 and 65, who
had a histopathological diagnosis of Kaposi's sarcoma. The state of their KS
had to be objectively assessable by the AIDS Clinical Trials Group (ACTG)
criteria (Krown et al., 1989). An European Clinical Oncology Group
performance status of 3 was necessary and because of the teratogenicity of
thalidomide only male patients were eligible. Informed consent was obtained
and the study was conducted by approval of the Camden and Islington
Community Health Services NHS Trust Research Ethics Committee.
The patient exclusion criteria were: active opportunistic infection, liver
function tests >3 times normal, history of neuropathy or relevant drug
hypersensitivity, systemic anti-KS therapy in the preceding month, previous
local therapy to assessable lesions, Hb<lOg / dl, platelets <100 x i0 9
 / 1 and
neutrophils <750 x 106 / 1. Anti-retroviral and protease inhibitor therapy was
noted throughout the study. Response evaluation required 8 weeks treatment
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and was performed fortnightly by a single physician using ACTG guidelines.
Toxicity to thalidomide was documented according to World Health
Organisation toxicity grading (World Health Organisation, 1979).
The treatment schedule was 100mg thalidomide given orally at night for two
months, thereafter continued therapy was offered. Blood samples were taken
for analysis of HHV8 DNA at the start of thalidomide treatment and also 4 - 6
weeks into the 8 week study. HHV8 DNA titre in blood was determined by
end-point titration of the purified blood DNA so that virological response to
treatment could be determined. A 3 log change in titre was defined as being
virologically significant. Only if both samples were taken was the patient
described as virologically evaluable. All blood samples were stored and
extracted using the Qiagen protocol described in section 2. c. 1.
Seventeen patients, median age 40 years (range 30 - 48) were enrolled. Their
median CD4 count was 36 (range 4-552) and 9 of the 17 had prior AIDS-
defining opportunistic infections. Sixteen of the 17 had received prior local
therapy for KS and one had received oral 13-cis retinoic acid. Concomitant
anti-retroviral therapy was being taken by 12 patients and was altered in 5
during the course of the trial. This was felt to be a confounding factor in only
one patient who was commenced on the protease inhibitor indinavir two
weeks after starting thalidomide.
3. b. 4. ii) clinical and virological response to therapy
Nine of the 17 patients completed 8 week's treatment and were clinically
evaluable for response. The 8 patients who were unevaluable, due to non-
completion, withdrew between 1 and 4 weeks after starting thalidomide. Six
patients had self-limiting toxicity: four developed a rash, one Raynaud's
syndrome and one nausea. No rechallenge was undertaken and the majority of
side-effect symptoms cleared quickly. One other patient was withdrawn owing
to progressive disease and one for poor compliance. Of the 9 clinically
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evaluable patients, who completed 8 weeks oral therapy with thalidomide, 6
patients achieved a partial clinical response, 1 patient had stable disease and
two progressive disease. Duration of response was from 6 to 30 weeks after
cessation of treatment.
Blood samples were available from all patients at the start of therapy at which
point HHV8 DNA was detected in 10 / 17 (59%) patients.. Five of the 6
clinical partial responders were virologically evaluable (fig 3. 5. 1.); 3 patients
(patients 3, 5 and 11) had a significant decrease in HHV8 DNA blood titre,
with all 3 having undetectable HHV8 DNA after 4-6 weeks therapy. One
partial responder (patient 15) had an unchanged titre and another (patient 7) a
decrease in HHV8 DNA titre of llog 10 which resulted in his HHV8 DNA
becoming undetectable. The sixth patient with a partial clinical response
(patient 16) was virologically unevaluable as HHV8 DNA was not detected in
his blood at either the start of treatment, or after 4 - 6 weeks of treatment.
The one patient (patient 12) with no clinical response had a 2logio decrease in
HHV8 DNA titre, although HHV8 DNA was still detectable in blood after 6
weeks of therapy. Both patients (patients 1 and 6) with progressive disease,
who completed the 8 weeks treatment regimen, could not be assessed
virologically as neither of them had detectable I-JHV8 DNA in their blood at
the start of therapy or after 4 -6 weeks of therapy. It was however interesting
to note that the one patient who was withdrawn because of progressive
disease after 4 weeks of thalidomide (see above), but who did have the second
blood sample taken at the 4 week time-point had a significant rise in viral
DNA titre of 3 log 10 (data not shown on figure). The patient who received
indinovir therapy 2 weeks after starting thalidomide had stable disease, but
was virologically unevaluable as HHVS DNA was not detected in his blood at
the start, or after 5 weeks, of thalidomide treatment.
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Log10
change -2
in HIHV8
DNA -3
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Figure 3. 5. 1. Change in HHV8 DNA titre between baseline and after 4 - 6 weeks
therapy with thalidomide in the 9 patients completing treatment course
Patient:	 5	 3	 11	 7	 15	 16	 12	 1	 6
PR* PR* PR* PR* PR PR# NC PD# PD#
PR: partial KS response
NC: no clinical change
PD: progressive KS
* patients who cleared systemic HHV8 DNA after 4 - 6 weeks treatment
# patients with undetectable HHV8 DNA before and after 4 - 6 weeks treatment
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3. b. 4. iii). study outcomes
The clinical response rate of patients receiving the full 8 weeks thalidomide
was 66%, this figure dropping to 60% if the one patient who was unevaluable,
due to disease progression, is included. Such a response rate compares
favorably to with most other systemic chemotherapy's. Conventional
chemotherapy response rates range from 25% for doxorubicin I bleomycin I
vincristine (Gill et al., 1996) to 75% for liposomal doxorubicin (Harrison et
al., 1995). HHV8 DNA was detected in approximately 60% of patients at the
start of therapy an incidence similar to that previously shown in other sections
of this thesis. Most significantly HHV8 DNA in blood was cleared in 4 of the
5 patients who completed the treatment regime, were virologically evaluable
and had a clinical partial response, this clearance was, in 3 of the 5 cases, a
drop of 3-4 logw titre of viral genome. Such a correlation in clinical response
to treatment and reduction in HHV8 DNA titre again strengthens the
hypothesis that HHV8 DNA titre could be used as a surrogate marker for
response early in the systemic treatment of KS. It should also be noted that in
the one patient with progressive disease, who had to withdraw from the study,
the HHV8 DNA titre rose by 3 log i o in 4 weeks, showing that both a decrease
and increase in clinical disease is mirrored by HHV8 genome titre change.
In comparison to other therapies used for the treatment for early KS in HIV-
infected individuals thalidomide would appear to have a number of positive
advantages. The reSponse rate in this study is higher than that found for other
non-cytotoxic therapies such as a-interferon, which are only effective in
patients with high CD4 counts. Also thalidomide is orally administered and has
no associated haematotoxicity as do the systemic chemotherapy's. A number
of patients did experience side-effects, such as rash, however these were mild
and reversible on cessation of treatment. A similar study of oral thalidomide
for cutaneous KS (Welles et al., 1997) has suggested that by careful
management of oral dose the mild side-effects experienced can be made
clinically manageable while maintaining the effectiveness of the therapy.
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3. c. Anti-HHV8 antibody prevalence in patients with haematological
malignancies
3. c. 1. Introduction
Human herpesvirus 8 has been associated with a variety of malignancies
including KS, BCBL and MCD (Chang et al. 1994.,Soulieret al., 1995 and
Cesarman et al., 1995). Outside certain patient populations, notably HIV-
infected gay men, these diseases are extremely rare. The prevalence of HHV8
infection in the UK general population has been shown to be between 1 and
5%, as defined by serological and genome analysis techniques, (Whitby et al.,
1995 and Simpson et al., 1996). However, in 1997, Rettig and colleagues
proposed an association between HHV8 and multiple myeloma (MM, Reittig
/ 
et al., 199'Z a disease with no known predilection for particular sub-groups of
the population.
Multiple myeloma is the second most frequent blood malignancy in north
America, affecting approximately 40,000 individuals at any one time, with
13,000 new diagnoses made each year. The disease is characterised by the
accumulation of immortalised plasma cells in the bone marrow, together with
the high level production of monoclonal antibody from these clonal cells. This
antibody is easily detected in both serum and urine. The systemic effects of this
cellular imbalance include skeletal degeneration, due to the formation of
osteolytic lesions, renal complications, due to the circulating levels of
monoclonal antibody and an increased likelihood of opportunistic bacterial
infections (reviewed in Vescio et at., 1995). The median survival period for a
patient diagnosed with MM is no more than 30 months, however bone marrow
transplantation has been shown to be curative in 50% of patients who survive
treatment (Gahrton et al., 1991).
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Monoclonal gammopathy of undetermined significance (MGUS) is the
precursor condition to MM and is also characterised by the presence of
monoclonal antibody in serum and urine, and an increased number of plasma
cells in the bone marrow. However patients with MGUS do not suffer from
the overt clinical symptoms associated with MM. Patients with MGUS have a
25% probability of progressing to full MM, regardless of therapeutic
intervention (Kyle et al., 1993).
Rettig and colleagues have reported that HHV8 DNA sequences could be
detected in the bone marrow stromal cells of all 15 patients they investigated
with MM, and that HHV8 proto-oncogene RNA transcripts, including the v-il
6, could also been found in these tissues. The v-il 6 homologue has previously
been shown to have a similar in vitro activity to cellular Ii 6 (c-Il 6) and is able
to support the growth of c-il 6-dependant cell lines in the absence of c-il 6
(Moore et al., 1996). Importantly c-il 6 is a well defined growth factor for
myeloma and may both stimulate myeloma cell growth and prevent the
apoptosis of malignant plasma cells (Hirano et al., 1991). It was suggested
that the production and secretion of HHV8 v-il 6 from infected stromal cells
may drive the proliferation of plasma cell clones thus promoting the
conversion of the pre-cancerous state of MGUS to full MM. Interestingly, this
group found that 25% of MGIJS patients also had detectable HHV8 DNA in
their stromal cells, a similar percentage to that defined at risk of progression
from MGUS to MM.
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3. c. 2. Study of anti-HHV8 antibodies and viral genome prevalence in
patients undergoing allogeneic bone marrow transplantation
3. c. 2. i). aims of the study
To investigate the possible association between HHV8 and haematological
malignancies, particularly MM and MGUS, a cohort of patients undergoing
allogeneic bone marrow transplantation (BMT) to correct haematological
disorders were analysed. The presence of HHV8 DNA sequences in circulating
leucocytes and serological evidence of previous infection with HHV8 was
sought and correlated with the type of haematological malignancy the patient
was being treated for.
3. c. 2. ii) patient profile and samples available for analysis
Serum and whole venous blood was available from 49 patients undergoing
sibling-related and unrelated allogeneic BMT. Reasons for transplantation
were: acute lymphocytic leukemia (n=13), non-Hodgkin's lymphoma (n=9),
acute myeloid leukemia (n=7), multiple myeloma (n=6), Hodgkin's disease
(n=5), chronic myeloid leukemia (n=4), chronic leukocytic leukemia, Burkitt's
lymphoma, chronic granulocytic leukemia, myelo-dysplastic syndrome and
unknown (all n=l). The serum came from samples received in the Department
of Virology, CCLMS for routine pre-transpiant screening for HIV- 1, hepatitis
B and C viruses and CMV. Pre-transpiant sera were used to avoid confusion
with any antibodies subsequently produced by the B-lymphocytes of the
transfused bone marrow. Ethical permission for testing was received by
Chairman's action from the Middlesex Hospital Ethics Committee.
158
The presence of antibodies for HHV8 was determined by two previously
published methods; an indirect immunofluorescence assay (IFA) using the
FIHV8-containing cell-line BCP-1, detecting antibodies directed against the
HHVS latent nuclear antigen (LAN) and by an enzyme-linked
immunoabsorbant assay (ELISA) system utilising the carboxy-terminal section
of the HHV8 orf 65 gene product as an antigen target (Simpson et al., 1996).
Sera were prepared and the assays performed as described in sections 2. d. and
2. e.
Venous blood samples were received for routine post-transplant surveillance
monitoring of systemic CMV DNA (see section 3.d.). CMV is a pathogen
associated with severe patient morbidity and mortality in these acutely
immunosuppressed patients (Meyers et al., 1984). For screening of HHV8
genome presence, the first blood sample received post-transplant was prepared
using either the glycigel extraction protocol or the QIAGEN commercial
extraction protocol, (see section 2. c. 1). Regardless of the extraction
methodology the DNA equivalent to 1 Op.l of blood was added to the first
round of the HHV8 nested PCR.
if there was serological evidence of previous HHV8 infection in the pre-
transplant serum sample, by either serological assay, or HHV8 DNA was
detected in the first post-transplant surveillance blood sample then all available
blood samples from that patient were also analysed by the HHV8 PCR.
Following the analysis for antibodies and viral DNA described above the
identity of the patients was made available. After unblinding of the patient
details those with a diagnosis of MM had DNA extracted, as before, from all
available blood samples and the presence or absence of HHV8 genome
sequences in each sample determined.
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3. c. 2. iii) study outcomes
Of the 49 patients investigated 4 had pre-transplant evidence of previous
antibody production to HHV8 infection. Of these 4, none had a diagnosis of
MM. Two patients had antibodies detected by both the WA and ELISA, one
patients had antibodies detected by the IFA only and one by the ELISA only
(Table 3. 6. 1.). One of the patients who was HHV8 antibody-positive also
had detectable HHV8 DNA in their one available post-transplant blood
sample. This sample had been taken 6 weeks after transplantation. None of
the other three patients with anti-HHV8 serum antibodies had detectable
HHV8 DNA in their blood samples at any time post-transplant. Blood
samples taken up to four months post-transplant were available from each of
these four patients.
Of the 45 patients who did not have detectable HHV8 antibodies by either
serological assay none had detectable HHV8 DNA in their first post-transplant
blood sample. The six patients with MM were all part of this group of 45
patients with no serological evidence of a previous HHV8 infection. Three of
the six with MM had a single blood sample taken post-transplant, one had
blood samples available until one month post-transplant, the other two patients
each had blood samples available up to six months post-transplant. None of
the blood samples taken from patients with MM contained detectable HHV8
DNA.
3. c. 3. Discussion
The overall prevalence of anti-HHV8 antibodies in this group of 49 patients
receiving BMT for a variety of haematological disorders was, at 8%, little
different from the declared rate of between 2 and 5% in the UK general
population (Simpson et al., 1996). There was no serological evidence to
support the recent suggestion of HHV8 involvement in MM and / or MGUS,
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+ve	 +ve
+ve	 -ye
-ye 	 I	 +ve
+ve	 +ve
-ye	 -ye
-ye	 I	 -ye
not detected
not detected
detected in single
available sample
not detected
not detected
not detected
Table 3. 6. 1. Detection of HHV8 DNA and anti-HHV8 antibodies in 49 patients
undergoing allogeneic BMT, (original haematological malignancy shown in
brackets).
HHV8 IgG detection	 HHV8 DNA in post-
pre-transpiant	 transplant blood samples
TIFA	 ELISA
Patient 1
(lymphocytic leukemia)
Patient 2
(lymphocytic leukemia)
Patient 3
(non-Hodgkin's
lymphoma)
Patient 4
(Hodgkin's disease)
Patients 5 - 10
(all with multiple
myeloma)
Patients 11 - 49
(various haematological
diseases, see text)
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indeed none of the patients with these disorders were found to have been
infected with HHV8 by serological analysis. The only patient who had
detectable HHV8 DNA in peripheral blood, who also had circulating
antibodies to the virus, was born in an area in which classical, HIV-
unassociated KS is relatively common. In such areas the prevalence of HHV8
infection in the general population may be as high as 35% (Gao et al., 1996
and Miller et al., 1996). The other 3 patients with antibodies to }-[HV8 had a
variety of unrelated haematological malignancies. These three patients with
serological, but not genome detection, evidence of previous HHV8 infection
were, as were all the patients in the study, in a period of acute
inmiunosuppression. It was interesting to note that even with such severe
damage to their immune control HHV8 DNA could not be detected in the
systemic circulation suggesting that no reactivation of the virus from latency
had occurred. It is possible that the extreme levels of leucopenia experienced
by these patients may, however, have reduced the levels of latent HHV8
present in their blood.
The low rate of HHV8 seropositivity in this study group would appear to
preclude any direct etiological association between HHV8 and the
haematological diseases found in these patients, including MM and MUGS.
While the molecular mechanisms proposed by Rettig and colleagues for the
interaction of HHV8 v-IL 6 with plasma and dendritic cells in patients with
MM would appear to have theoretical merit the absence of current or previous
HHV8 infection in any of the myeloma patients in this study seems to suggest
that such an association is extremely unlikely.
Recently, the findings of this study have been confirmed by a variety of
international investigations, which also found no association between the
presence of HHV8 DNA in peripheral blood, aspirated bone marrow or bone
marrow stromal cells and MGUS / MM (Parravicini et a!., 1997, Masood et
al., 1997 and Whitby et al., 1997). Neither was an association found between
individuals with circulating anti-HHV8 antibodies and these two conditions. At
present Rettig and colleagues remain convinced of their initial findings and
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have been supported by one other study which detected HHV8 DNA in the
bone marrow biopsies of 18 of 20 patients with MM (Rettig et al., 199kand
Brousset et al., 1997). However the inability of the other groups, as well as
ourselves, to provide supporting data especially of a serological nature, must
cast grave doubt on this proposed virus / disease association.
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3. d. Establishment of a CMV DNA survefflance service for patients
receiving allogeneic bone marrow transplantation
3. d. 1. Introduction
Bone marrow transplantation is an increasingly common method of treatment
for a variety of haematological malignancy, aplastic anaemia and genetic
diseases (reviewed in O'Reilly, 1983 and Hiemenz et al., 1993). Although the
rates of complications in bone marrow transplantation, such as graft versus
host disease (GVI{D), have decreased in recent years the immunosuppressive
regimes necessary to facilitate donor marrow engraftment still place patients at
significant risk of developing a range of opportunistic viral infections
(Brayman et al., 1992 and Winston et al., 1990). Potentially the most severe
of these are associated with CMV infection (Meyers, 1984 and Weiner et al.,
1986).
Before transplantation it is essential to determine, by serology, whether a bone
marrow recipient has previously been infected with CMV. If the patient has no
evidence of CMV then the importance of using donor marrow originating from
a similarly CMV-seronegative donor is increased. Providing such a "negative-
to-negative" donation is possible the recipient is at extremely low risk of post-
transplant CMV disease. Indeed such disease would only occur if the recipient
was exposed to CMV from an external source post-transplant, such as a
contact actively excreting CMV, or a CMV-containing blood component.
Even more importantly, if the recipient is found to be CMV-seropositive then
it is imperative that the donor marrow also originates from an individual who
is CMV-seropositive. If bone marrow from a CMV seronegative donor is
transplanted into a CMV seropositive recipient then the introduced bone
marrow, which will supply the recipient with all the immunological cells
necessary for establishment of an immune system, will have had no previous
experience of CMV. The recipient is hence at great risk of reactiviation of
their own latent CMV. This may lead to a severe CMV infection because this
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will essentially be a primary infection to the new immune system. Such
"negative-to-positive" transplants have the highest associated risk of CMV
disease, with a number of studies showing that over 70% of such patients
develop CMV infection (reviewed by Winston, et al., 1990). An intermediate
risk of CMV disease is associated with CMV seropositive donation to a CMV
seropositive recipient and CMV seropositive donation to a CMV seronegative
recipient.
CMV disease usually appears between 3 and 16 weeks after transplantation
(Meyers et al., 1980). Persistent, unexplained, fever and non-specific
symptoms in the presence of cultures negative for bacteria and fungi are
frequently the initial presenting symptoms. Such patients may also develop
other symptoms, such as hepatitis, leucopenia or thrombocytopenia, these are
often difficult to distinguish from GVHD (Winston, 1993). Unfortunately the
existing diagnostic procedures for CMV; viral culture and the DEAFF test, are
often insensitive and have been found to be influenced by the cytotoxic effects
of the blood and urine samples analysed (Fedorko et al., 1989 and Stephan et
al., 1997). Because of this a number of centers have switched to the use of
DNA assays, such as PCR, to monitor CMV genome load in patients at risk of
developing CMV-associated post-transplant disease (Sandin et al., 1991,
Vleiger et al, 1992 and Storch et al., 1994).
When CMV infection, be it primary or from reactivation, occurs in the BMT
patient, prior to functional establishment of the donor marrow, the greatest
clinical risk is the development of CMV pneumonitis. Such a pneumonitis may
have a rapid onset with fulminant respiratory failure developing over 2 - 3 days
in association with diffuse interstitial infiltrates (Winston et a!., 1990). Studies
have found that up to 15% of allogeneic BMT recipients will develop CMV
pneumonitis in the absence of effective chemoprophylaxis (Wingard et a!.,
1988). CMV infection of the lung is the most frequent cause of pneumonia in
this patient population and is associated with a high level of patient morbidity
and mortality. Untreated over 90% of all patients with a CMV pneumonitis
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will die in the first 3 weeks after presentation of clinical symptoms (Prentice et
al., 1994).
Originally it was presumed that CMV pneumonitis was due to direct viral lysis
of pulmonary cells. However it has been shown subsequently that CMV
pneumonitis is rare in autologous transplants where the patient's own bone
marrow is re-engrafted, but is far more common in allograft recipients
(Appelbaum er al., 1982). This pattern is mirrored by the incidence of GVHI)
in these patients and suggests that the immunological events associated with
GVHD may be involved in the development of CMV pneumonitis. It is now
known that both GVHD and CMV pneumonitis are associated with an
increase in level and activity of cytotoxic T-cells in the lung (Bowden et al.,
1987 and Grundy et al., 1987). When combined with data from nude mice
-	 studies, showing that CMV replication in the lung in the absence of T cells
does not lead to the development of pneumonitis, it is now thought that CMV
pneumonitis is caused by the inappropriate response of a T-cell subset to the
viral infection rather than by direct virucidal lysis of infected cells (Shanley,
1987).
Even after rapid therapeutic intervention the mortality rate in patients with
CMV pneumonitis can still be as high as 40% (Reed et al., 1988). Because of
the significance of CM V-associated pulmonary disease a number of
prophylactic treatments have been examined in those patients receiving
intermediate, or high risk BMT's. These usually involve long-term use of one
of the anti-herpesvirus chemotherapeutic agents such as acyclovir (ACV),
foscarnet (PFA) or ganciclovir (CCV), either alone, or in combination with
CMV hyper-immune IgG preparations (Prentice et al., 1994, Bowden and
Meyers, 1990 and Winston et al., 1990).
Whilst the use of prophylactic therapies has been associated with the efficient
prevention of CMV disease post-transplant the two most effective anti-CMV
chemotheraputics, PFA and CCV, are both highly toxic. Of particular concern
is treatment with GCV, a bone marrow suppressive cytotoxic drug, which may
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result in severe neutropenia and a delay in bone marrow engraftment (Schmidt
et al., 1991). Prolonged neutropenia increases the risk of developing a range
of other opportunistic infections, particularly bacterial septicaemia and fungal
pneumonia. Studies have found that even though GCV is effective in
preventing CMV disease post-transplant, because of the associated
neutropenia there is no overall improvement in rates of patient mortality when
use of GCV against placebo is compared up to 6 months after transplantation
(Goodrich et al., 1993). Foscarnet also has significant in vitro activity against
CMV, but is a potent nephrotoxic drug (Jacobson et a!., 198). As a result of
these toxicities a number of studies have considered the use of ACV (Prentice
et al., 1994 and Meyers et al., 1988). ACV is usually indicated for the
treatment of a-herpesvirus infections such as HSV-1, HSV-2 and VZV in
immunocompromised individuals. Although ACV has a lower anti-CMV
activity than GCV and PFA (because of the lack of production of a thymidine
kinase by CMV) it has now been found to be relatively effective, when
compared with placebo, in preventing emergence of CMV from latency in
post-transplant BMT patients. One study found that 22% of patients on ACV
prophylaxis developed CMV disease post-transplant whereas 38% of patients
receiving no anti-herpesvirus prophylactic treatment developed disease
(Bowden and Meyers, 1990 In this study there was no noticeable ACV -
related toxicity in the treated group.
' This was a statistically significant protective effect (Chi squared test: P = 0.0025)
Important in the management of patients post-transplant is the effective
diagnosis of active CMV infection. Ideally such a diagnosis must be made
prior to the development of clinical symptoms, a point at which the
effectiveness of treatment is reduced. Until recently the two most commonly
used methods of diagnosing CMV infection have been conventional tissue
culture and rapid-viral culture techniques such as the DEAFF test (Gleaves et
al., 1985). Conventional culture is an inappropriate method for the diagnosis
of CMV in this setting as results may take up to 3 weeks to become available
and low-level CMV viraemia may still be present even when viral culture has
proved negative (Reed et al., 1988). The introduction of the DEAFF test has
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resulted in a much more rapid diagnostic analysis, usually within 24 hours.
However this technique is relatively insensitive when compared with culture
and has associated technical problems, such as a percentage of unreadable
results due to toxicity of the sample for the cell monolayers used in the
analysis. Molecular techniques, including PCR, have been investigated as
potential alternatives for the detection of CMV. Preliminary results have
shown that PCR analysis for CMV DNA in the venous blood of post-
transplant BMT patients is a highly sensitive technique when compared to
existing culture methodologies (Stephan et al., 1997, Vlieger et al., 1992 and
Sandin et al., 1991). Detection of CMV DNA in blood may also act as an
early predictor of disease compared to culture (Storch et a!., 1994).
Comparison has been made between the detection of CMV DNA in whole
blood and detection in cell-free plasma (Woo et al., 1997 and Laue et al.,
1997). It is theoretically possible that detection of CMV DNA in whole blood
may be due to the presence of low-titre latent viral genome which is clinically
unimportant. This may lead to inappropriate treatment of patients who are at
no increased risk of disease. The detection of CMV DNA in plasma is likely to
reflect the active production of mature virions and have a higher predictive
value with regards to the development of CMV-associated disease.
3. d. 2. Development of improved clinical and virological protocols for
the management of post-transplant BMT patients at UCL Hospitals
Until 1996 patients receiving allogeneic BMT at UCL Hospitals were
monitored for CMV infection post-transplant by weekly, or twice monthly,
culture and DEAFF analysis of whole blood and urine. All patients who were
either pre-transpi ant CMV sero-positive, or whom received bone marrow from
a CMV sero-positive donor received prophylactic GCV for 6 months post-
transplant.
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Following an audit in 1996 of the CMV surveillance service provided by the
Department of Virology, UCLMS it was decided to evaluate alternative
methods of CMV detection in patients at risk of developing CMV disease. The
1996 audit raised several areas of potential concern in the service being
provided, especially in the use of DEAFF analysis as a surveillance technique
for early detection of CMV infection. As can be seen, in table 3. 7. 1., 41% of
blood samples analysed by the DEAFF test were toxic to the cell monolayer
used in the assay which rendered the result void, a slightly lower incidence of
test failures were seen in the analysis of urine and throat swab samples.
Combined with the 3 week period necessary to obtain a definitive negative
viral culture result this prompted the investigation of PCR for detection of
CMV DNA in whole blood and cell-free plasma as an alternative methodology
for identifying patients with clinically significant, active, CMV infection.
Another factor influencing a change in the surveillance service was an
alteration in the post-transplant management of the BMT patients. The levels
of neutropenia associated with the use of prophylactic GCV had raised
concern as to the overall patient morbidity and mortality associated with such
wide-spread use of this drug, even though this protocol had protected all
patients treated from overt CMV disease. It was decided to change from the
use of prophylactic GCV to prophylactic ACV. Although ACV has less
associated toxicity than GCV it has been well documented that ACV does not
provide such an effective protection against the development for CMV disease
(Bowden and Meyers, 1990). By incorporating an aggressive strategy of PCR
detection of CMV in blood, and rapid intervention with high dose intravenous
GCV in those patients with detectable CMV DNA it was hoped that CMV
disease could be prevented, while minimising the overall levels of therapy
toxicity.
169
Table 3. 7. 1. Department of Virology, UCLMS, 6 month audit of laboratory
results for CMV surveillance by the DEAFF test in allogeneic BMT recipients
CMV
Sample type	 No. of samples	 detected not detected No. toxic
(%)	 (%)	 (%)
Heparinised Blood
	
60	 l*#(1)	 35(58)	 24(41)
Urine	 62
	
4* (7)	 43 (43)	 15 (24)
Throat Swab
	
35	 0	 24 (69)	 11(31)
* CMV was grown in conventional culture from all these 5 samples
# this patient received ACV, rather than GCV, prophylaxis
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3. d. 2. i) patient samples taken for CMV surveillance analysis and frequency
of sampling
To allow comparison with the 1996 audit the existing system of CMV
surveillance, by conventional culture and DEAFF test, was continued. For this
purpose 20m1 heparinised peripheral blood samples were taken every week
post-transplant for the first 12 weeks and then twice monthly thereafter until
26 weeks post-transplant. Protocols for CMV detection using these methods
were as described by Gleaves and colleagues (Gleaves et al., 1984-). The
DEAFF and culture analysis were performed by members of the Virus
Isolation Section, The Virology Department, UCL Hospitals NHS Trust.
For analysis of CMV DNA 5 ml EDTA-preserved peripheral blood was taken
at the same time-points as the heparinised peripheral blood. The EDTA blood
was processed as described in section 2. c. 1. and the DNA prepared using the
Qiagen DNA extraction protocol described in section 2. c. 1. After extraction
CMV PCR analysis was performed on 10 tl of extracted DNA (equivalent to
the DNA present in 10 p.1 of the whole blood sample). This analysis gave a
limit of detection sensitivity for CMV DNA of 100 copies / ml of blood as the
CMV PCR has previously been shown to have a detection sensitivity of a
single copy of CMV DNA (Mitchell et al., 1994). The plasma was prepared
for PCR analysis as described in section 2. c. 2., DNA prepared from 5p.l of
plasma was analysed for the presence of cell-free CMV DNA.
3. d. 2. ii) chemotherapeutic intervention with anti-CMV therapy post-
transplant
All patients received prophylactic ACV throughout their first 26 weeks post-
transplant. However if a patient presented with clinical syrriptoms suggestive
of CMV disease a two week period of intravenous GCV was started and
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continued until symptoms resolved. If a patient with no obvious symptoms had
detectable CMV DNA in peripheral blood then a repeat sample was taken 1
week later, if CMV DNA was still present in the blood (a "consecutive +ve")
then induction GCV therapy was also initiated and continued until CMV DNA
could no longer be detected in the blood. However if the blood sample taken a
week later did not contain CMV DNA, and there were no other markers of
clinical or virological CMV, normal PCR surveillance was continued without
therapy. Following initiation of GCV therapy blood samples were then taken
weekly for investigation of CMV DNA response. Until CMV DNA became
undetectable anti-CMV therapy was continued. Throughout the study GCV
was the first treatment of choice, however because of toxicity, adverse drug
reaction and / or a failure to clear CMV a number of patients received PFA
treatment as an alternative to GCV.
3. d. 2. iii) patient profile and period of study
The above protocol for management of post-allogeneic BMT CMV infection
was initiated in October 1996 and continued until May 1997. Only patients
who provided a full set of surveillance samples, commencing immediately after
transplant and continuing until at least day 60 post-transplant, were included in
the analysis.
The total number of patients undergoing BMT during this period was 32 (14
female, 18 male). The median age of these patients was 32 years (range 16 -
46). In 14 transplants both donor and recipient were CMV-seropositive, in 13
both were CMV-seronegative and in 5 transplants the donor was CMV-
seronegative and the recipient CMV-seropositive. All patients who were
CMV-seronegative received blood and blood products post-transplant which
were known to come from CMV-seronegative donors.
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3. d. 2. iv) clinical outcome in the 32 patients receiving a BMT during the
study period
Of 32 patients who received a BMT during the study period 29 survived
beyond day 20 post-transplant to at least day 60. Of these patients the mean
follow-up time was 124 days. None of the patients in the study had any clinical
evidence of CMV during the period of the study. Two cases of fatal
pneumonitis did occur, however cause was not established due to refusal for
post-mortem examination. Neither of the 2 patients had CMV DNA detected
in any sample taken during the post-transplant period or clinical symptoms
suggestive of CMV involvement.
3. d. 2. v) detection of CMV infection by conventional culture and DEAFF
Only 2 patients had evidence of CMV infection by conventional CMV culture
(table 3. 7. 2.). Each patient had a single culture-positive result. At these times
both patients had concurrent CMV DNA in their blood when analysed by
PCR. The DEAFF test was never positive for any patient. Sample toxicity in
the DEAFF and culture tests remained a significant problem; overall 23% of
DEAFF tests were invalid because of the toxic effects of the samples on the
HEL monolayer used in the assay, 6% of culture tests were invalid for the
same reason. Half the patients in the study had at least one incidence of sample
toxicity in the DEAFF and culture analysis.
3. d. 2. vi) evaluation of CMV infection by detection of CMV DNA in blood
The average number of blood samples available for analysis from each patient
was 15. Of the 456 blood samples analysed, 93 (20%) contained detectable
CMV DNA (table 3. 7. 2.). Fourteen of the 29 patients had at least one sample
with detectable CMV DNA. Thirteen of these 14 had consecutive +ves leading
to initiation of GCV therapy. In these 13 patients there were a total of 22
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Figure 3.7.1.1. Detection of CMV DNA in blood from patients receiving a bone
marrow transplant
2.3 'r.c Ft q Ios	 I3ui1-l1tq
1$ u aa
C
.	 a$
Lanes 1, 20, 21 and 27: molecular weight marker - X 174 cut with Hae III
band sizes in nucleotides (from bottom up) 72, 118, 194, 234, 271, 310
Lanes 3 and 14: samples containing detectable CMV DNA
Lanes 2, 4 - 13, 15 and 16: samples containing no detectable CMV DNA
Lanes 17: CMV DNA +ve control containing c. 10 copies CMV DNA
Lane 18: CMV DNA +ve control containing c. 1 copy of CMV DNA
Lane 19: CMV DNA +ve control containing < I copy CMV DNA
Lanes 22 and 23: negative controls containing water added with reagent pipettes
Lanes 24 - 26: negative controls containing water added with sample pipettes
l73.
Table 3. 7. 2. Detection of post-transplant CMV infection by culture, DEAFF and
CMV PCR in 29 patients receiving a BMT and surviving to day-60 post-transplant
Samples	 Patients
CMV detection	 With one or more With one or more
protocol	 Tested Toxic Positive Tested toxic samples	 positive samples
CMV culture	 345	 19	 2	 29	 18	 2
(6%)
- DEAFF test	 346	 81	 0	 29
	
24
	
0
(23%)
Tested
CMV PCR
whole blood	 456
plasma	 263
CMV DNA
detected	 Tested
93 (20%)	 29
23* (9%)	 29
CMV DNA. detected
at least once
14#
10
* all 23 plasma samples with detectable CMV DNA came from the whole blood
samples found to contain detectable CMV DNA.
# 13 of these 14 patients had consecutive CMV DNA +ves in whole blood which
initiated the use of anti-CMV therapy
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consecutive +ve events, all of which were treated. Seven patients had one
episode, 4 had 2 episode, 1 had 3 and 1 had 4 episodes.
Plasma samples were available from all 93 whole blood samples which tested
positive for CMV DNA, 23 (25%) of these plasma samples contained CMV
DNA. A total of 170 plasma samples from blood which did not contain
detectable CMV DNA were also analysed, none of these had detectable CMV
DNA. In 6 of the 22 episodes of blood CMV DNA consecutive +ve's CMV
DNA remained completely undetectable in the corresponding plasma samples.
3. d. 2. vii) donor I recipient status of patients having at least one blood
sample with detectable CMV DNA.
Twelve of the 14 CMV-seropositive recipients of CMV-seropositive donor
marrow had at least one episode of detectable CMV DNA in blood, these 12
including both patients with positive culture results. Two of the five CMV-
seropositive recipients of CMV-seronegative donor marrow also had
detectable CMV DNA in blood at some time during the study. None of the 13
CMV-seronegative recipients of seronegative marrow (all of whom received
CMV-ve blood, blood products and marrow) had CMV DNA detected in their
blood at any time post-transplant.
3. d. 2. viii) response of systemic CMV DNA titre to GCV and PFA therapy
Figure 3. 7. 1. shows the post-transplant timing of anti-CMV therapy in the 13
patients in which it was initiated. Every patient who had an episode of
consecutive +ve CMV DNA in blood had their first CMV DNA+ve result in
the first 60 days post-transplant. All 22 incidences of consecutive +ves were
treated with anti-CMV therapy and all patients except one (who was treated
twice with PFA) were initially treated with GCV. In 6 of the 20 GCV
treatment episodes the initial 2 week GCV therapy was insufficient to clear
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Figure 3. 7. 1. Time points of anti-CMV therapy initiation in 13 patients with at
least one consecutive +ve episode of CMV DNA detected in peripheral blood
Days post-	 1st treatment	 2nd treatment	 3rd treatment
transplant	 (13 patients)	 (6 patients)	 (2 patients)
* this patient required a 4th treatment course, started on day 189.
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detectable CMV DNA from the blood, however when therapy was switched to
PFA all samples eventually became CMV DNA - ye. Clearance was in 1 week
(3 patients) to 2 weeks (3 patients) after this therapy switch. The other patient
who had two PFA treatments, cleared CMV DNA from their blood within 2
weeks of the initiation of each PFA therapy course.
3. d. 3. Discussion
The significance of CMV disease in patients receiving allogeneic bone marrow
transplantation has been well described. The prophylactic use of GCV in this
patient group has been found to have a protective effect against the
development of CMV disease but overall patient survival rates are not
increased due to the increased neutropenia experienced as a consequence of
GCV use. The alternative use of ACV has been considered (Bowden and
Meyers, 1990) and although not as active against CMV as GCV ACV has
been found to have a protective effect against the development of CMV
disease, without associated neutropenia and bone marrow toxicicty (Wolfe et
al., 1993). Recently a number of studies have shown that detection of CMV
DNA in the blood and plasma of patients post-transplant is highly predictive of
the development of active CMV disease and may be an effective marker for
the instigation of aggressive anti-CMV therapy to prevent, or modulate,
disease (Storch et al., 1994).
In this study the use of ACV prophylaxis was examined in concert with a PCR
surveillance protocol directing GCV or PFA therapy to patients with repeated
episodes of detectable CMV DNA in their blood. Of 29 patients who survived
the first 20 days post-transplant none subsequently developed CMV disease
during the study. This included 5 CMV-seropositive patients who received
CMV-seronegative donor marrow and hence were at the highest risk of CMV
disease development. CMV DNA was detected at least once in 14 of 29
patients, with anti-CMV therapy required at least once in 13 patients.
Although all treatment episodes resulted in the eradication of CMV DNA from
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peripheral blood there were 6 cases in which a therapy switch from GCV to
PFA was first required and further treatment in response to the re-emergence
of CMV DNA in blood was necessary in 6 patients. The re-emergence of
CMV DNA suggests that latent virus is an important reservoir for subsequent
infection and that the immunological environment in these patien9 remained (
favourable for reactivation up to 6 months post-transplant (the latest episode
of consecutive +ves was 180 days post-transplant, see fig. 3.7. 1.)
None of the 13 patients who were CMV sero-negative before transplantation
and who received bone marrow, blood and blood products from sero-negative
donors had detectable CMV DNA in their blood at any time. This important
observation suggests that such a rigorous surveillance protocol may be
unnecessary for this type of patient, and that the screening of bone marrow
donors and blood products for use in these patients remains an extremely
effective precaution in preventing CMV infection.
CMV DNA was detected much more frequently in whole blood than in
plasma. As CMV is a predominantly cell-associated virus this finding was
unsurprising. Previously patients with CMV DNA in their plasma have been
found to be much more likely to develop active CMV disease than patients
with virus present only in whole blood (Woo et al., 1997). The implication
being that detection of the viral genome in a cell-free environment is indicative
of an active systemic infection, whereas detection in whole blood may be due
either to sub-clinical levels of virus or to the presence of latent virus. With the
absence of CMV disease in this patient study group it is difficult to confirm or
deny the significance of these findings. However it appears unlikely that the
CMV DNA detected in whole blood originates from latent virus, as after every
treatment episode the previously detectable CMV DNA was eradicated.
Treatment with PFA or GCV would not have affected latent genome load in
such a fashion as both therapies are only active against replicating virus
through the inhibition of viral genome replication.
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Examination of the time post-transplant at which systemic CMV DNA was
first detected indicates that the first 60 days following transplant are the period
of highest risk for development of a CMV infection. Indeed no patients had
their first episode of detectable CMV DNA after this time. If this finding is
repeated in ongoing studies it may be possible to modulate the surveillance
protocol to reduce the amount of analysis required for each patient who
reaches this time point without their first episode of detectable systemic CMV
DNA.
When compared with established diagnostic assays, such as DEAFF and
culture, PCR is vastly more sensitive in its ability to detect CMV DNA in
whole blood. It is also free from the associated problem of sample toxicity, as
all the blood DNA analysed is purified before analysis in the PCR assay.
Whether such assay sensitivity is actually required cannot be answered by this
study as no comparison was made with patients relying on conventional
techniques alone, and none of the study patients developed CMV disease.
However after the conclusion of the study it was decided to cease use of
culture and DEAFF in the surveillance of these patients and to rely solely on
PCR. At the time of writing there are still no BMT patients who have
developed CMV disease while enrolled in this protocol.
The use of prophylactic ACV, coupled with PCR surveillance and GCV / PFA
intervention, has been remarkably effective in preventing the life-threatening
CMV disease common in this patient group. Data from previous studies would
suggest that (apart from the 13 CMV-seronegative recipients of sero-negative
morrow) these patients, without CMV prophylaxis, would experience a iS -
20% mortality rate due to CMV infection (data combined from Meyers et at.,
1988, Weiner et al., 1988 and Winston et at., 1990).
Although the incidence of post-transplant neutropenia has been greatly
reduced from 1996 levels, when GCV rather than ACV was the prophylactic
treatment, there has been at least one neutropenia-associated complication (of
a pneumonic PCP infection) during the study period. In future it is hoped that
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alternative therapies to intravenous GCV, such as oral GCV and cidofavir may
be used in place of intravenous GCV to combat this problem. The requirement
to treat patients after only 2 consecutive positive episodes of CMV DNA may
be further examined, so that treatment is more targeted at those patients with
the highest risk of CMV disease. The use of quantitative PCR techniques for
determining systemic CMV genome load may also allow those patients at
greatest risk of developing disease to be identified and specifically treated
(Ljungman et al., 1996).
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3. e. Herpesvirus infections of the eye and central nervous system in
patients with late-stage AIDS
3. e. 1. Introduction
As described in previous chapters herpesviruses have been associated with a
wide spectrum of diseases in immunosuppressed patient populations. In
individuals with chronic immunosuppression due to infection with HIV- 1 the
most common sites of severe herpesviral-associated disease are the eye and
central nervous system (CNS), (reviewed in Steiner, 1996 and Ugen et al.,
1992). CMV is, in particular, a significant pathogen in these patients if their
risk factor for HIV- 1 infection is homosexual contact. Such patients have been
found to have an almost 100% seroprevalence for CMV, with up to 50%
actively shedding CMV in saliva or urine (Buimovici-Klein et al., 1988). Many
HIV-infected gay men are infected with multiple strains of CMV (Leach et a!.,
1994) and it would appear that sexual transmission of CMV in this population
is a significant factor in these high exposure rates (Drew et a!., 1984). Overall
homosexuality, in contrast to other routes of HTV acquisition, has been found
to be significantly associated with the development of CMV disease after HIV
seroconversion (Gallant eta!., 1992).
Cytomegalovirus retinitis is the most common ocular disease in patients with
AIDS and is characterised as a severe necrotising infection of the retina, which
if untreated, will result in the irreversible loss of sight in the affected eye
(Bloom and Palestine, 1988). In 1992, in the United States, 20,000 cases of
CMV retinitis were diagnosed, with approximately 25% of HIV-infected gay
men likely to develop this disease at some point during their AIDS-associated
illness (Katlama, 1993).
Although CMV retinitis frequently presents unilaterally as a granular retinal
opacification, with or without associated haemorrhage, it is common for the
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other eye to also become infected with the potential for complete blindness.
Diagnosis is made clinically by fundoscopic visualisation of the damaged
retina, however several studies have shown the use of PCR analysis of ocular
fluid to be an appropriate method for discriminating between CMV retinitis
and a host of other intra-ocular infections such as ocular toxoplasma gondii
and Pneumocystis carinii choroiditis (Mitchell et a!., 1994 and Fox et al.,
1991). Following a diagnosis of CMV retinitis treatment is usually with
systemic GCV or PFA, depending on the patient's tolerance of these drugs
(reviewed in Drew, 1992). Intra-ocular treatment with GCV has been
attempted but is of limited use as it does not prevent the bilateral spread of the
virus, or CMV infection of other organs as effectively as a systemic treatment
(Heinemann, 1989). Treatment with either anti-CMV. therapy will halt the
spread of retinal destruction, but improvement of visual acuity is limited.
Patients must remain on therapy indefinitely to prevent disease progression,
however such long-term treatment is associated with the generation of drug-
resistant viral strains and may result in significant nephro- or myelotoxicity
(Henderly et al., 1987, Jabs et al., 1987, Jacobson, 1989 and Baldanti et a!.,
1995).
/ Cytomegalovirus	 is also a common pathogen in the CNS of AIDS
patients. As with CMV retinitis, CMV infection of the CNS usually occurs in
patients who are extremely immunosuppressed, predominantly those with CD4
counts below 100. Studies have shown that the risk of developing CMV
disease at an ocular, or neurological, site may be as high as 40% when a
patient's CD4 count is below 50 (Pertel et al., 1992) and up to 20% of
patients with CMV retinitis will develop neurological CMV infection at some
point during their ocular disease. Neurological infection with CMV has a
predicted mortality of 50% within 3 months of diagnosis if anti-CMV therapy
is not initiated (Peters et al., 199 l. The most common presentation of CMV
infection in the CNS is as an encephalitis, although polyradiculopathy and
myelitis have also been described (Holland et al., 1994 and Marrnaduke et al.,
1991). In the CNS, CMV has been shown to infect a wide variety of cells
including neurons, astroglial cells and endothelial cells (Myerson et al., 1984).
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Entry into the CNS is from the blood, via the blood I brain barrier with the
virus further disseminated by the CSF before infection of the brain parenchyrna
(Gray et al., 1988). As mentioned in section 1. a. 7. CMV and HTV-1 may co-
infect similar cell types, including neurological cells, and in the CNS are likely
to interact thereby upregulating the replication of both virus types (Belec et
a!., 1990). Such up-regulation may increase the severity of neurological
disease associated with joint FIIV and CMV infection (Wiley and Nelson,
1988).
Conventional diagnostic methods such as culture of the CSF or blood are of
little use in diagnosing CMV infection of the CNS, due to their low sensitivity
for infection at this site (Katlama, 1993). Symptomology may also be confused
because of the similarity with other H1V-associated neurological disease such
as HIV dementia. Molecular detection of CMV genome in CSF, or brain
biopsy, by PCR has therefore become the usual diagnostic method of choice
(Holland et al., 1994). The identification of CMV as the aetiological agent of
CNS disease is vital if appropriate therapy is to be initiated for maximum
patient benefit.
A number of other herpesvirus ocular and CNS infections have been described
in patients with AIDS. Epstein-Barr virus is highly associated with CNS
lymphoma (Pednaultt et al., 1992). Over 90% of patients with a diagnosis of
lymphoma at this site have detectable EBV DNA in their CSF or tumour
tissue. This virus has also been associated with ocular inflammation in a variety
of patients with EBV-associated systemic disease, although its significance in
the ocular disease of HIV-infected patients would appear to be limited. Both
HSV 1 and VZV have been described as causes of acute retinal necrosis
syndrome and outer retinal necrosis syndrome in patients with fflV-infection,
and HHV6 has been co-detected by PCR in the retinal lesions of a patient with
active CMV retinitis (Pepose et al., 1984, Jabs et al., 1987.band Margolis et
a!., 1991). HSV and VZV infections are associated with encephalopathy and
peripheral neuropathy in the CNS of lilY-infected patients, either of which
may cause significant patient morbidity in those affected. Treatment with ACV
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has been found to be highly effective against both HSV and VZV-associated
disease in the CNS (Dix et at., 1985, Petito et a!., 1986). Isolated cases of
HHV6 encephalitis have also been reported, however the extent to which this
virus, or its close relative HIHV7, infects the CNS and eye, thereby affecting
patient health is still largely undetermined (Saito et al., 1995). HHV8 has yet
to be described in the ocular fluid of lilY-infected patients, but recently has
been found associated with a small number of cases of encephalopathy in
severely immunocompromised AiDS patients (Said et al., 1997).
3. e. 2. Study of herpesvirus genome prevalence in post-mortem ocular
and CNS samples from HI V-infected patients
In this study material was collected to examine the prevalence of all eight
characterised human herpesviruses in the ocular fluid and CNS of a cohort of
HIV-infected patients who had died of an AIDS-associated illness. The
presence of herpesviral DNA was compared with patient pre-mortem
diagnosis and ocular examination, post-mortem anatomical description and
post-mortem histological analysis of the ocular and neurological sites. The
alms of the study were to compare the accuracy of molecular genome
detection techniques with clinical and histological observation, especially with
regard to patients with a pre- or post-mortem diagnosis of CMV retinitis and /
or encephalitis. It was also hoped that the range and prevalence of the other
herpesviruses at these two sites could be determined and an evaluation made
as to their associations with pathological disease. This is the first study of such
post-mortem material to investigate the presence of all known human
herpesviruses and provide correlation with clinical findings.
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3. e. 2. i) patient profile and samples recovered
Informed consent was obtained to recover samples from 31 H[V-infected
patients at post-mortem. Twenty-nine of the patients were male of whom 26
were homosexual, 2 were intra-venous drug users and 1 an African
heterosexual. Both female patients were heterosexual. The median age of
patients was 36 years (range 27 - 53 years). In general the level of
immunosuppression experienced by this patient group was extremely severe.
The range of CD4 counts was 0 - 380, however in all but one patient the CD4
count was below 120. The median CD4 count was just 10.
The samples recovered from each patient were dependent on the consent
provided. From patient 1 both eyes were recovered, as was a portion of frontal
lobe tissue. From patients 2 - 13 the right eye only was recovered as again was
frontal lobe tissue. From the last 18 patients both eyes were recovered,
however instead of frontal lobe tissue being sampled a portion of CSF,
collected after removal of the brain from the skull, was provided. A total of
100 vitreous and aqueous samples were removed from the cadaver eyes, all
within 24 hours of death. These were extracted and processed by the methods
described in section 2. c. 7. In the study 10 pA of aqueous and 1 tl vitreous
fluid supernatant were analysed for the presence of each herpesviral genome.
Frontal lobe tissue was prepared by SDS-protinase K digestion as described in
section 2. c. 4. The DNA from this material was not however then
subsequently purified by phenol / chloroform extraction instead it was boiled
to inactivate theproteinase K and ipi of a 1 in 10 dilution of the gross
preparation analysed. Such a dilution step has previously been shown sufficient
for avoiding inhibition of the PCR process by the SDS present in the extracted
material (personnel communication, Dr ID Fox, University College Wales
School of Medicine). Post-mortem CSF was stored and prepared for analysis
in the same manner as pre-mortem CSF, (see section 2. c. 5). Ten microlitres
of supernatant was then analysed by each of the herpesviral PCR assays.
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3. e. 2. ii) clinical and histological analysis of study patients
All the patients in the study were under the in-patient care of Dr. Rob Miller,
UCL Hospitals, a consultant HIV-physician who provided the pre-mortem
clinical evaluation. Patients with loss of visual function were referred to a
specialist HIV ophthalmic clinic and were reviewed by Dr. Peggy Frith, UCL
Hospitals, an ophthalmologist who is experienced in the diagnosis and
treatment of HIV-associated ocular disease. All post-mortems were performed
by Professor Sebastian Lucas, UCLMS, a specialist with over ten years
experience in the post-mortem analysis of HIV-infected individuals. Professor
Lucas also conducted all the post-mortem microscopic and histological
analysis of removed tissue, and provided the post-mortem clinical evaluation.
Histological diagnosis of CMV disease was by visualisation of cellular
inclusion bodies and by immuno- and histological antibody staining.
3. e. 2. iii) ophthalmic virology results
Of the 31 patients 8 (26%) had a pre-mortem diagnosis of CMV retinitis with
7 patients having bilateral retinitis and 1 patient unilateral retinitis, a total of 15
eyes with CMV disease (table 3. 8. 1.). Fourteen of these 15 CMV-affected
eyes were available for virological analysis. In all 14 eyes CMV DNA was
detected in both the aqueous and vitreous fluids. In the one patient (patient
24) with unilateral CMV retinitis both eyes were available, however CMV
DNA was detected in the vitreous and aqueous fluids of the CM V-affected left
eye only. Six of these 8 patients also had post-mortem evidence of non-ocular
CMV disease (5 in the CNS, 1 in the lungs).
Twenty-three patients did not have a pre-mortem diagnosis of CMV retinitis,
however two of these patients (patients 15 and 26) had post-mortem,
histological evidence of unilateral ocular CMV disease. In patient 15 the left
eye was affected, in patient 26 the right eye was affected. These two patients
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each had both eyes available for analysis but CMV DNA was detected in the
vitreous and aqueous fluid of the CMV-affected eyes only. One of these
patients also had CMV adrenalitis determined at post-mortem, the other had
no evidence of extra-ocular CMV disease.
A total of 21 patients were without a pre-mortem or post-mortem diagnosis of
CMV ocular disease, although a number of other ocular pathologies were
noted: 4 choroditis, 1 choroditis with cotton wool spots, 2 anterior uveitis, 2
cryptococcus, 1 toxoplasmosis, 1 hyperplastic aracnoid and 1 choroid naevus.
Nine patients had eyes considered normal by post-mortem anal ysis. Of these
(table 3.8.1., p. 188)
21 patients 7 had detectable CMV DNA in at least one eyei . Four of the 7 had
only the right eye available for virological analysis, all 4 had CMV DNA
detected in both the vitreous and aqueous of those right eyes. Three patients
had two eyes available for analysis and all 3 had CMV DNA detected in the
vitreous and aqueous fluids of both eyes. In each of these 7 patients, who had
no CMV-associated ocular disease, there was post-mortem evidence of CMV
disease at non-ocular sites of the body; 2 patients "disseminated" CMV, 2
patients CMV adrenalitis, 2 patients CMV adrenalitis and colitis. Three of the
7 had a direct histological diagnosis of CMV encephalitis.
Fourteen patients had neither CMV DNA detected in their eyes, nor evidence
of CMV-associated ocular disease. Four of these fourteen patients had non-
ocular CMV disease at post-mortem: 2 in the adrenal glands and 2 described
as disseminated.
Cytomegalovirus was by far the most commonly detected herpesvirus in the
ocular samples. In all the eyes analysed other herpesviral genomes were
detected on only 5 occasions (table 3. 8. 2.); in one patient (patient 12) EBV
DNA was detected in the right aqueous fluid, in addition this patient had CMV
DNA detected in both vitreous and aqueous fluid of the right eye but no pre-
mortem or histological diagnosis of CMV retinitis. This patient also had a post
mortem-confirmed CNS B-cell lymphoma. One patient (patient 1), with a pre-
mortem diagnosis of bilateral CMV retinitis and disseminated CMV disease,
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had detectable CMV DNA in both the aqueous and vitreous of both eyes. This
patient also had HSV-2 DNA detected in the left vitreous fluid. A patient
(patient 30) with no remarkable eye pathology had detectable VZV DNA in
the aqueous fluid of the left eye, this patient had no systemic evidence of VZV
infection, but did have VZV DNA detected in the CNS. Two patients (patients
8 and 14) had detectable FIHV8 DNA in their ocular samples. Patient 8 had
the right eye available for virological analysis and both the vitreous and
aqueous fluid contained detectable HIHV8 DNA, this patient had no other
herpesviruses detected in that eye which was found by histological analysis to
be normal. Patient 14 had both eyes available for analysis and HHV8 DNA
was detected in the vitreous fluid of the left eye, the other three ocular fluids
from this patient had no detectable herpesviral DNA. This patient had non-
specific choroiditis in both eyes. Both patient 8 and 14 had disseminated KS
reported as a major cause of death at post-mortem and both patients had
detectable HHV8 DNA detected in their peripheral blood prior to death.
Patient 8 also had HHV8 DNA detected in the CNS. No HSV-1, HHV6 or
HHV7 DNA was detected in any of the ocular samples analysed.
3. e. 2. iv) neurological study results
The detection of viral DNA in the neurological samples in this study was
correlated with post-mortem analysis of the cadaver brains, no pre-mortem
diagnoses were recorded. As with the ocular samples, CMV DNA was the
most commonly detected herpesvirus in the sample set (see table 3. 8. 3.). Of
the 31 patients 9 had CNS CMV pathology noted, 8 of these had CMV DNA
detected in their CNS. However CMV DNA was also detected in the CNS of
8 of the 22 patients without specific CMV pathology described at this site. Of
these 8 patients 6 had CMV DNA detectable in their ocular samples and all
had some evidence of systemic CMV disease. The next most frequently
detected herpesvirus at the neurological site was EBV. EBV has previously
been associated with CNS B-cell lymphoma and 4 patients in this study had a
post-mortem diagnosis of CNS B-cell lymphoma, 3 of these 4 had detectable
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Table 3. 8. 3. Detection of CMV and EBV DNA in post-mortem CNS samples from
31 patients with AIDS
CMV DNA
	
EB V DNA
Patients with
	 detected	 detected
CM V-associated CNS pathology
CM V-associated CNS pathology
with CNS lymphoma
CNS lymphoma	 2# /3	 2/3'
Other CNS disease	 4#/ 13 
4
	
3 / 13'
No CNS disease	 2# I 6 
1'	
0/6 
.1w-
# all 8 patients with CMV DNA detected in the CNS, in the absence of
CMV-associated CNS disease, had other sites of CMV disease noted
(5 ocular, 2 adrenal gland and 1 lungs).
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EBV DNA in their CNS. Of the other 27 patients with no evidence of CNS
lymphoma only 3 had detectable EBV in their CNS.
As was found in the analysis of herpesviral DNA in ocular samples, apart from
CMV and EBV which have been well defined as common pathogens in the
CNS of HIV-infected patients, other herpesviruses were rarely detected in
these patients. No HSV-1, HSV-2, H}{V6 or HHV7 was found in any CNS
samples. However 4 patients did have detectable VZV DNA in their CNS, 2 of
these patients had CMV encephalitis (both with detectable CMV DNA in the
CNS) and 2 had no post-mortem evidence of neurological disease. None of
these 4 patients had evidence of CNS, or systemic, varicella / zoster disease.
One of the 4 (patient 30) was, however, the patient in whom VZV DNA was
found in aqueous fluid. HHV8 DNA was found in the CNS of 2 patients, both
these patients had disseminated KS and one (patient 8) had also had HHV8
DNA detected in their right eye vitreous and aqueous samples.
The full PCR results from all patient samples are tabulated in the attached
Appendix C.
3. e. 3. Investigation of ocular sample inhibition of herpesviral PCRs
After completion of the herpesviral analysis on the ocular samples in this study
vitreous samples with at least 0.5 ml remaining and aqueous samples with at
least 200 p.! remaining were used to determine the possible inhibitory effects
these samples may have on the PCR process. Inhibition of PCR by factors
within ocular fluids, especially vitreous fluid, has been previously described
(Wiedbrauk et al., 1995) and could potentially result in a failure to detect
clinically important viral genomes. All selected samples had been shown in the
study to be negative for CMV DNA, as CMV was to be the control genome
used in this analysis. Before use each sample was re-tested, by the CMV PCR,
at input volumes of 0.1, 1.0 and 10 p.1 to confirm the original PCR result.
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A ten-fold serial dilution of control CMV DNA was prepared in water to
determine its CMV DNA titre in ideal amplification conditions. The lowest
dilution detected was given the arbitrary concentration of a single CMV
genome as the CMV PCR has previously been shown capable of single-copy
detection (Mitchell et al., 1994). The same dilution series was then prepared
using each of the ocular fluids as diluent and the input titre required for the
production of an amplification product determined. Three different assay
formats were investigated using these spiked samples:
A - 1 p.1 of each spiked ocular fluid analysed in a 50 p.1 volume 1st round PCR
B - 10 p.! of each spiked ocular fluid analysed in a 50p.l volume 1st round PCR
C - 10p.l of each spiked ocular fluid analysed in a l00p.1 volume 1st round
PCR
All the second round PCR's were performed, as usual, in a 25p.l volume
reaction, with a ijil transfer of the first round product to prime the second
round reaction. In total 11 vitreous and 21 aqueous samples were analysed by
this protocol, results are shown in table 3. 8. 4.
The results in table 3. 8. 4. clearly show the inhibitory effects of increasing the
volume of vitreous fluid analysed from the 1 p.1 used in the study to 10 p.1, if a
50 p.1 1st round PCR volume is employed. Of the 11 vitreous samples analysed
6 caused some form of inhibition in this format. Three of these 6 samples
resulted in a 3 log 10 drop in PCR detection sensitivity. Importantly, none of
the vitreous samples were, however, inhibitory if only 1 p.1 was analysed in a
50 p.1 reaction volume and, equally significantly, all inhibitory effects of
analysing 10 p.1 of vitreous fluid were overcome if the first round reaction
volume was increased to 100 p.1.
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Table 3. 8. 4. Inhibitory effects of ocular fluids on CMV PCR amplification
CMV DNA copies required to produce CMV amplicon
(in distilled water 1)
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As has been previously described aqueous fluid seems to contain fewer PCR
inhibitors than vitreous fluid. Only 1 of the 21 samples analysed caused any
reduction in PCR sensitivity when 10 il of aqueous was analysed in a 50 p.1
reaction volume, when this sample was tested in the other two formats no
inhibition was noted.
3. e. 4. Discussion
Most of the HIIV-infected patients analysed in this study had homosexual
contact as their primary risk factor for HIV-1 acquisition. It is this group of
patients which have been previously shown to be at greatest risk of developing
herpesvirus infections during the course of their HillY disease, especially CMV-
infection. This patient group have also been shown to be infected with the
greatest range of herpesvirus infections and the greatest number of multiple
infections with different strains of the same herpesvirus, especially CMV
(Levine, 1993 and Drew et al., 1984). They were therefore an ideal group of
patients in which to determine the significance of herpesviral ocular and CNS
infection in a severely immunocompromised population.
In the eyes and CNS of these patients there was, apart from the well described
associations between CMV and encephalopathy / retinitis, and EBV and CNS
lymphoma, a surprising lack of detectable herpesvirus genomes given the
highly sensitive detection methodology used. Of the six other herpesviruses
only HHV8 and YZV were found in eyes or CNS of more than one patient,
and both of these viruses were not associated with any particular disease
process. All but one patient with a diagnosis of CMV retinitis or
encephalopathy had detectable CMV DNA at those disease sites underlining
the clear association between the presence of CMV-related disease and CMV
genome. However a significant minority of patients also had detectable CMV
DNA in the brain or eye in the absence of overt CMV disease, although most
did have some other form of systemic CMV disease. Detection of CMV DNA
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in the absence of disease may either reflect contamination of the post-mortem
material by CMV DNA-containing blood, or the spread of virus from other
body sites. It was interesting to note that all but one patient with detectable
CMV in the brain or eye had CMV disease described somewhere in the body.
This presence of CMV DNA may have been a precursor to the development of
CMV-associated disease and previous studies have shown that detection of
CMV DNA in the eye and brain, in the absence of disease, is predictive of
subsequent disease development (Cinque et a!., l99Sand van der Meer et a!.,
1996). The finding of CMV DNA in the absence of histological evidence of
CMV pathology should, however, underline the fact that detection of
herpesviral genome in such severely immunosuppressed individuals is not
always indicative of an actual disease involvement.
As well as confirming the established association between CMV and
neurological and ocular disease in late-stage AIDS patients this study also
supported the association between EBV and CNS lymphoma. Three of the 4
patients with a clinical diagnosis of CNS lymphoma had detectable EBV DNA
in their CNS, whereas only 3 of the other 27 patients had this viral genome
detectable. The presence or absence of pre-clinical CNS lesions in these 3
patients was not described, but again studies have shown that the detection of
EBV DNA in the CSF is predictive of CNS lymphoma development in such
patients (Pednaultt eta!., 1992 and Arribas et a!., 1995).
It was possible to confirm that some ocular samples, when crudely prepared as
here, may have significant inhibitory effects on the sensitivity of the herpesviral
nested PCR assays. A significant proportion of the vitreous samples analysed
reduced assay sensitivity by up to 3 log 10 when 10 p.1 was analysed in a 50 p.1
1st round reaction volume but a 1 p.1 volume, as used in the study, was not
found to be inhibitory. The effects of these inhibitors was also negated when
the reaction volume was increased to 100 p.1. As early detection of CMV DNA
in the vitreous fluid is of pronounced clinical significance maintaining assay
sensitivity, while analysing the greatest volume of material possible, is
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paramount. The use of a 100 pi first round reaction volume, allowing a 10-
fold increase in overall assay sensitivity, by analysis of 10-fold more vitreous
fluid is, therefore, of significance in the routine diagnostic detection of
herpesviruses in the eye. Aqueous fluid was found to be rarely inhibitory to the
nested PCR even at a 10 p.1 input volume in a 50 p.1 first round reaction
volume.
In conclusion it would appear that the CNS, including the eye, is a sub-optimal
environment for the infection and replication of the majority of herpesviruses,
a finding which contrasts with the concept of the brain being an
immunologically privileged site, and the high prevalence of previous
herpesvirus infection in such a patient group. Although there have been some
reports of HSV and VZV causing CNS, and ocular, disease their "index of
suspicion" for a clinician when confronted with a patient experiencing
symptomatic disease at these sites must be low and they were not found
associated with disease in this patient group. HHV6 and 7 were not detected
in the patients tested and again would appear to be of little clinical importance
even though most, if not all, patients are likely to have been infected. There is
limited previous data regarding the association of HHV8 and ocular and
neurological disease. The HHV8 DNA detected in the brain and ocular
samples in this study was unassociated with specific disease and KS is a rare
complication of the retina or CNS, although it has been found to involve the
conjunctiva in a small number of KS patients. In a similar manner to the CMV
DNA detected in patients without CMV pathology, the detection of HHV8
may simply reflect the presence of systemic HHV8 DNA in the 3 patients
involved, or the occurrence of pre-clinical ocular or neurological lesions not
noted at post-mortem. It should, however, be remembered that the close
genetic relative of HHV8, EBV, does cause significant CNS disease so an
association of HHV8 with CNS damage cannot be completely discounted.
Overall these findings confirm a significant association between encephalitis,
retinitis and CMV, and between CNS lymphoma and EBV. These two
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herpesviruses are the most clinically important in the CNS and eyes of late-
stage AIDS patients and hence should be the principle focus of molecular
diagnostic assays such as PCR. Clinical therapeutics should be directed
accordingly. This is especially important as early treatment for both CMV and
LB V-associated CNS I ocular disease has been shown to be highly effective in
moderating disease and in delaying associated mortality (reviewed in Drew,
1992 and Donahue et al., 1995).
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3. f. Evaluation of a nested PCR multiplex assay for the detection of six
clinically important herpesvirus genomes.
3. f. 1. Introduction
Of the eight characterised human herpesviruses, six have consistently been
found associated with significant disease in immunocompromised patients:
HSV-1, HSV-2, VZV, EBV, CMV and HHV-8. Since 1992 individual nested
PCR's have been available for detection of 5 of these 6 viral genomes in the
Department of Virology, UCLMS (Mitchell et al., 1994). The sixth, HHV8,
has been available since 1995 (Howard et al., 1997). Patients for whom rapid,
molecular-based diagnosis of herpesvirus infections is most critical include
those receiving immunosuppressive therapy following allogeneic bone marrow
transplantation, patients with AIDS and neonates presenting with acute
neurological disease (Aslanzadeth and Skiest, 1994, Mitchell et al., 1994 and
Woo et al., 1997).
At the end of 1995 an internal audit was commissioned in order to evaluate the
use of molecular diagnostic techniques within the Department of Virology,
UCLMS. Over the three month period analysed it was found that
approximately 1200 herpesvirus analysies were requested on 352 clinical
samples. However only 75 herpesviral genomes were actually detected by the
individual PCR's. With such a low prevalence (21%) of herpesviral genome in
the samples received by the Department it was felt necessary to modify the
genome detection protocol so that negative samples could be rapidly excluded
while samples containing genome would continue to be reliably detected. The
most rational solution to this situation was felt to be the development of a
nested multiplex PCR (mPCR) reaction with subsequent detection of
amplicons by an enzyme-linked oligonucleotide assay (ELONA).
The method for the mPCR-ELONA is described in section 2. f.. Briefly in the
rnPCR primers for amplification of all six target herpesvirus genomes are made
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available within a single reaction mix. The reaction consists of two rounds of
amplification. The visualisation of the amplified rnPCR products is by the
capture of the second round amplicons, via covalenfly linked 5' biotin
molecules, onto a streptavidin-coated solid phase. The captured amplicons are
then single-stranded by the addition of sodium hydroxide before incubation
with a pooi of six amplicon-specific, enzyme-linked, oligonucleotide probes.
Each of the six probes used is specific for one species of amplified herpesviral
DNA. Hybridisation of a probe to the solid-phase bound mPCR product
results in presentation of a horse-radish peroxidase (HRP) molecule. When
incubated with the substrate TMB a colorimetric reaction results which, after
addition of 2N H2SO4 to stop the reaction, allows differentiation between
positive and negative rnPCR reactions by analysis at 450nm using a
spectrophotometer. Samples found to contain herpesvirus DNA by this "all-6
probe" screen are then re-analysed using each of the herpesvirus-specific
probes individually to define virus type.
The mPCR-ELONA assay was previously optimised and its absolute detection
sensitivity determined in collaboration with Mr. Stuart Kirk, Department of
Virology, UCLMSThe overall sensitivity of the assay was found to be the
same as for the individual PCR assays previously used (Mitchell et a!., 1994,
Howard et al., 1997). In general this was equivalent to a single target genome
molecule. The six HRP-oligonucleotide probes were each found specific for
their specified mPCR amplicons and no cross-reactivity was noted.
*
	
ached to inside back cover of this thesis
3. f. 2. Analysis of single copy herpesviral genome molecules using the
mPCR-ELONA assay.
Following optimisation of the mPCR-ELONA assay using control genome
samples and comparison with the individual PCR assays the positive cut-off of
the assay was set at five times the average of the negative control samples; the
test : negative ratio. In practice experience showed that the OD of a negative
control sample was usually between 0.12 and 0.17, therefore a test sample was
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only defined as containing detectable HHV8 DNA if the OD it produced was
approximately 0.9 or above. To ensure that the assay was reproducibly capable
of single copy genome detection, as had been suggested by comparison of end-
point titration sensitivity with the individual PCR's, its behaviour when
analysing mixtures containing single target molecules was investigated. Two
solutions containing low copy numbers of CMV and HSV-1 DNA were
separately prepared by ten-fold serial dilution of purified genomic DNA. To
determine the exact genome copy number of each of these solutions lj.fl from
each was diluted in 399.tl water and the total 400p.I divided equally between
40 CMV and 40 HSV-1 PCR assay tubes. Conventional individual PCR
analysis was then performed for these two targets. Fourteen of the CMV DNA
PCR tubes produced amplicons when analysed by gel electrophoresis, as did 3
of the HSV-1 DNA PCR tubes. This determined the detectable genome copy
numbers, per microlitre, of each genome in their respective solutions.
The analysis was then repeated on lp.l of these two DNA solutions by 40-tube
analysis using the mPCR-ELONA assay with HRP-probes for detection of
CMV and HSV-1 amplified products. After analysis of the ELONA results
the negative control reactions gave an average OD of 0.13. The amplicons
from 26 tubes analysed with the CMV-specific probe and 7 analysed with the
HSV-1 probe resulted in ELONA OD's greater than 5x these average
negatives (OD range 0.69 - 2.22, test : negative ratio 5 - 17, fig. 3. 9. 1.). The
remaining tubes all resulted in OD's less than 5x the average negatives (OD
range 0.12-0.18, test: negative ratio 0.92- 1.4, fig 3. 9. 1.).
These results suggest that the mPCR-ELONA can indeed reliably detect
single-copy molecules and that the 5x negative average cut-off is appropriate,
even when analysing such small amounts of target sequence. There was some
difference in the number of genomes detected in the 1 jil of control genome
solution between the two assays: 14 CMV DNA copies in the individual PCR,
in contrast to 26 copies in the mPCR-ELONA, and 3 HSV DNA copies in the
individual PCR, in contrast to 7 in the mPCR-ELONA, however with the
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Figure 3. 9. 1. Optical densities derived from 80 tube analysis, by mPCR-ELONA,
of single copy CMV and HSV genomes prepared by Poisson Distribution analysis.
Test : Negative OD ratio
OD signals from theoretical single-copy CMV genomes, 26 genomes detected
IHiWJ in 40 tubes by mPCR-ELONA, (CMV PCR detected 14 genomes in 40 tubes).
OD signals from theoretical single-copy HSV genomes, 7 genomes detected
in 40 tubes by mPCR-ELONA, (HSV PCR detected 3 genomes in 40 tubes).
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stochiometry of analysing DNA molecules in a solution at the level of Poisson
distribution this is not unusual and does not suggest a significant difference in
sensitivity between the two assay formats.
3. f. 3. Detection of herpesviral genomes in 192 clinical samples using the
mPCR-ELONA.
To determine the overall sensitivity and specificity of the mPCR-ELONA
assay in comparison to the existing individual PCR reactions a blinded panel of
192 clinical specimens was analysed. The samples used (table 3. 9. 1.) were
stored and processed as described in section 2. c. All the samples used were
received into the Department of Virology, UCLMS for routine herpesvirus
analysis and had previously had the presence or absence of herpesvirus DNA
determined by the individual PCR assays. Samples were defined as containing
detectable herpesviral genome if amplification had occurred in at least 2
separate individual PCR analyses. The majority of samples used in the
evaluation were CSF as this analyte is rarely found to contain any inhibitory
factors which might affect the efficiency of the mPCR. Analysis of the samples
by the mPCR-ELONA was done blinded to the results of the individual PCR
assays.
Seventy of the 192 samples had been found, by individual PCR, to contain
herpesvirus genomes. In total, 81 individual herpesvirus genomes were
detected in these 70 samples (11 samples contained two detectable genomes).
66 (94%) of the 70 samples were also found to have detectable herpesvirus
genome when analysed by the mPCR and the 6-probe "screening ELONA"
which detects the presence of any of the 6 herpesvirus genomes. Individual
ELONA-probe typing of the 66 mPCR-positive samples showed exact
concordance with the individual PCR analysis for every sample, including the
detection of 2 separate genomes in all samples where 2 genomes had been
detected by the individual PCR's. Overall 77 (95%) of the 81 PCR-detectable
herpesviral genomes in the clinical panel were correctly identified and typed by
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Table 3. 9. 1. Clinical samples tested by multiplex PCR-ELONA
	
Sample type	 Total number Herpesviral DNA Herpesviral DNA
tested	 not detected by	 detected by
individual PCR
	
individual PCR
CSF
	
118
	 102
	
16
Tissue culture
isolates	 32
	
12
	 20
Vesicle fluid / swab
	
10
	
2
	
8
Bronchio Alveolar
Lavage fluid	 7
	 3
	
4
Whole blood
(QIAGEN)	 6	 1	 5
Extracted white	 8
	
0
	
8
blood cells
(glycigel)
Mid stream urine	 4
	
0
	
4
Biopsy tissue	 3
	
3
	
0
Ocular:
	
Vitreous fluid
	
2
	
0
	
2
	
Aqueous fluid	 1
	
1
	
0
Plasma	 1
	
0
	
1
Totals	 192
	
122
	
70
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the mPCR-ELONA assay (table 3. 9. 2. and figure 3. 9. 2.). The test: negative
ratio OD's generated from these mPCR-ELONA positive samples ranged from
between 5 - 24 times the average of the control negatives.
There were 4 samples in which herpesvirus DNA had previously been found
by the individual PCR, but was not detected by the mPCR "screening-
ELONA." Three of these samples, all CSF's, had sufficient remainder to be
reanalysed by the individual PCR's and were confirmed as containing the
genomes originally detected (table 3. 9. 3.). The detectable genome copy
numbers of each sample were then defined by end-point titration analysis and
in all three cases found to be extremely low, at 1 copy per microlitre or less.
The fourth sample had insufficient volume remaining for retesting.
None of the 122 samples shown to have no detectable herpesviral DNA by the
individual PCR assays were found to have detectable herpesviral DNA by the
mPCR "screening-ELONA" (table 3. 9. 2.). The test : negative ratio OD's
produced from all of these samples were well below the 5x cut-off at between
0.7- 1.4 (figure 3. 9. 3.).
3. f. 4. Discussion
Over recent years a number of methods have been proposed by which PCR
may be utilised for the simultaneous detection of diverse herpesvirus genomes.
These have included the development of universal primers against highly
conserved viral gene sequences, the use of multiple primer sets in multiplex
reactions with electrophoretic separation of amplification products and the use
of restriction enzyme digestion to differentiate multiplex PCR products of
similar size by their fractionation patterns (Chenel and Griffais, 1994, One et
al., 1996 and Roberts and Storch, 1997) . Each type of methodology has
suffered from a variety of weaknesses, including a lack of detection sensitivity
and a limit to the number of species able to be analysed (Cassinotti et a!.,
1996).
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Table 3. 9. 2. Correlation of results obtained between individual nested PCR assays
and multiplex PCR-ELONA
Multiplex PCR result
HSV-1 I HSV-2 I VZV I CMV I EBV I HIHV8
Pos Neg Pos Neg Pos Neg Pos Neg Pos Neg 
F 
Pos Neg
Individual
PCR result
Positive I 10	 2* I 13	 0 I 14	 0 I 20	 0 I 12	 2* I 8	 0
Negative	 0	 126	 0	 127 0	 81	 0	 85	 0	 72	 0	 50
* discordant results between individual PCR assay and multiplex assay (see text for full
explanation)
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Figure 3. 9. 2. Test: Negative optical densities from mPCR-ELONA "all-probe"
detection of 70 samples shown to contain at least 1 herpesvirus genome by
individual PCR assay analysis
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Uppercase letters indicate herpesviral genomes detected in each
sample by individual PCR assay (Hi = HSV- 1, H2 = HSV-2,
V=VZV, C=CMV,E=EBVandK=HHV8).
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Table 3. 9. 3. Four CSF samples in which herpesvirus DNA was detected by
individual PCR assays but not by mPCR-ELONA.
Herpesvirus DNA detected 	 Herpesvirus genome load 	 Test Neg OD ratio of
by individual PCR assay	 in samples	 sample by mPCR
(+ve cut-off = 5.0)
HSV-1	 0.1 copies/p.1	 1.4
EBV	 1copy/t1	 1.2
EBV	 Is	 1.3
HSV-1	 0.1 copies/pJ	 1.0
IS = Insufficient sample for quantification analysis.
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Figure 3. 9. 3. Test: Negative optical densities obtained by mPCR-ELONA all-
probe detection of 122 samples previously found not to contain detectable
herpesvirus DNA by individual PCR analysis.
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The mPCR-ELONA assay evaluated in this chapter appears to have overcome
both these restrictions through the use of three separate hybridisation reactions
(nested PCR primers followed by an internal oligonucleotide probe) which has
allowed reaction conditions to be chosen which maintain the specificity and
sensitivity of the assay compared to the previously-used individual PCR
assays. Overall a 95% correlation was found between the two formats in the
analysis of samples containing herpesviral DNA, this correlation increases to
98% when samples found not to contain any detectable herpesvirus genome
are included in the calculation. Such a high level of agreement between the
two assays has led to discussions within the Department of Virology which
should soon result in the use of the mPCR-ELONA as our herpesvirus
molecular diagnostic assay of choice.
An analysis of the individual nested PCR assay shows an approximate cost, per
sample, of £4 (this figure includes the requirement for control reactions and all
reagents, but does not include the cost of DNA preparation). For analysis in
the mPCR-ELONA the cost is slightly higher at approximately £6 (including
both the "screening-ELONA" and subsequent type-specific analysis). However
the 1995 audit showed that, on average, each sample received has
investigation for 4 herpesvirus genomes requested. Not only does this greatly
increase the time taken to provide the service using individual PCR (the mPCR
can provide the same service with a 65% reduction in the number of assay
reactions required) but also raises the financial cost of individual PCR analysis
to £16 per sample. As a large percentage of clinical samples are found to
contain no herpesvirus genomes the most significant fiscal benefit of the
mPCR-ELONA must be the reduction in cost required to effectively screen
out negative samples.
Whilst showing a very high level of concordance with the individual PCR
assays the mPCR-ELONA did fail to detect to detect herpesvirus DNA in 4
samples. Three of the 4 samples were reanalysed and all were found to contain
very low levels of target DNA. Such a finding suggests that the mPCR-
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ELONA may be slightly less sensitive than the individual assays, although this
is unlikely as in the single target molecule analysis the sensitivity of the two
formats was found to be the same. It is possible that these 4 samples contained
a level of PCR inhibitors which adversely affected the mPCR-ELONA but not
the nested PCR's. It was unfortunately not possible to determine the presence
of inhibitors in these samples due to their limited volume. As mentioned earlier
CSF samples were chosen for the majority of the evaluation because they are
usually free from biological inhibitors, other samples analysed were all purified
prior to analysis. One simple solution to the problem of inhibitors affecting
PCR amplification would be to adapt the processing of the CSF samples so
that a purification step was included, probably similar to the Qiagen protocol
used for the preparation of whole blood (see section 2. c. 1.). However this
would increase the work load and cost of sample analysis. The alternative is to
include, within the mPCR-ELONA, a low copy-number control genome which
is added to all samples prior to the mPCR and then must be detected in the
"screening-ELONA" to confirm amplification from that sample. Such a control
genome protocol is currently being investigated within the Department of
Virology. The genome chosen is murine and would be added to each clinical
sample preparation at a level of 10 detectable copies. As soon as this addition
to the assay is available the CSF samples in the clinical panel found not to
contain any herpesvirus DNA will be spiked with the murine genome to
determine the prevalence of any inhibitors. Should such inhibitors be common
in these samples further purification will then be required, if not the murine
genome will continue to be used in the assay as an additional intra-sample
control feature.
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Section 4: General Discussion
4. a. HHV8 infection in the human host
4. a. I) Disease associations
Since its original discovery in KS tissue from an HIV-infected individual (Chang
et al., 1994), HHV8 DNA has been consistently detected in approximately 90%
of all types of KS lesions (Knowles and Cesarrnan, 1997). This includes endemic
KS (Rady et a!., 1995and Boshoff et a!., 1995, iatrogenic KS (Alkanet al.,
1997) and classical KS (Dictor et al., 1996). These early reports of viral
prevalence related to the detection of viral DNA in the KS tumour mass,
subsequent studies, including those described in section 3. a. 4., have shown that
the IIHV8-KS aetiologic link is maintained when the prevalence of HHV8
viraemia is investigated and that the presence of HIHV8 DNA in blood is
significantly associated with a clinical diagnosis of KS (Whitby et a!., 1995 and
Moore et a!., 1996). Of even greater significance is the increased probability of
HIV-infected patients, without KS, to develop KS if HHV8 is detected in their
blood, even though a delay of months, or years, may exist between detection of
the virus and development of disease. In section 3. a. 5. it was shown that this
predictive association was maintained when a specific form of KS was examined,
as 5 of 5 HP/-infected patients developed the pulmonary form of KS within 18
months of HHV8 DNA being detected in lavage fluid from their bronchial tree.
The association between HHV8 infection and KS has been underscored by the use
of serological assays for the detection of anti-HHV8 antibodies. Whereas only 1-
5% of HIV-negative UK heterosexuals have evidence of HHV8 infection
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(Simpson et al., 1996), the infection rate rises to 30-50% in areas in which }IIV-
unassociated KS is more common (Gao et al., 1996) and is over 80% in patients
with an actual diagnosis of KS (Kedes et al.,1996). With the provision of
improved serological reagents the prevalence of anti-HHV8 antibodies is expected
to rise to nearer 100% in those patients with KS. When the prevalence and
epidemiology of HHV8 is considered, together with the recent identification of
HHV8 gene products which may be involved in cell cycle dysregulation, such as
the viral homologues to cellular 11-6 (Neipel et al., 199'), type-D cyclin
(Cesarman et a!., 1996) and Bcl-2 (Chang et al., 1996) it now appears that an
overwhelming weight of evidence supports a role for HI{V8 in the development
and maintenance of KS tumours. This is not to say that HHV8 is the only
requirement for the genesis of KS lesions. As has been noted for a variety of other
virus-related cancers it is usually a range of factors which contribute to tumour
formation. One need only consider the differing forms of EBV-associated tumours
to appreciate the effect that other infectious agents, environmental factors and the
state of the host immune system may have on neoplas tic development.
In addition to KS HHV8 has been associated with a number of other diseases,
most of which mainly occur in the HIV-infected population. The most secure of
these associations is with the body-cavity-based lymphomas (Cesarman et al.,
1995 and Gessain et a!., 1997). These rare pleural malignancies have been
consistently found to contain HHV8 DNA, and whole viral particles, while no
HHV8 DNA is detected in other forms of HIV-associated and unassociated
lymphoma (Cesarman and Knowles, 1997). Indeed the HHV8-infected
imrnortalised B-lymphocytes used in section 3. c. of this thesis, for the detection
of anti-HHV8 IgG by immunofluorescence assay are derived from BCBL
effusions (Gao et al., 1996. and Boshoff et a!., 1998). The probable mechanisms
of HHV8-induced cell transformation, again through the expression of gene
products mimicking cell cycle control proteins, is well described (section 1. a. 8.
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and Boshoff et at., 1998) and supports the activity of the virus in BCBL
development.
The third disease showing a significant association with HHV8 is multicentric
Castleman's disease (Soulier et al., 1995 and Corbellino et at., 1996). Before the
discovery of HHV8 it had been reported that patients with MCD had an increased
likelihood of developing KS, approximately 13% of HIV-uninfected patients and
75% of HTV-infected patients with MCD were noted to have subsequently
developed KS (Peterson and Frizzera, 1993). The presence of HHV8 DNA in
almost all HJV-associated MCD lesions and in over half of the FIIV-uninfected
patients with MCD is therefore unsurprising, and implies a role for HHV8 in this
disease.
A variety of other cutaneous lesions, including malignant endothelial lesions,
angiosarcoma and endothelial haemangio-sarcoma, all of which have a histological
resemblance to KS, and involve similar cell types, have been investigated for the
presence of HHV8 DNA. Boshoff and colleagues examined 37 squamous
carcinoma samples (Boshoff et al., 1996) from immunocompromised patients, in
response to a study by Rady and colleagues which showed some association
between skin cancer in the immunocompromised host and HHV8 (Rady et a!.,
1995), however none of these 37 carcinoma samples were found to contain
HHV8 DNA. More recently Cathomas and colleagues found no HHV8 DNA in
30 epithelial skin tumours and non-Hodgkin's lymphoma samples (Cathomas et
al., 1997) and Chang and colleagues (Chang et al., 1996a) and Kenemy and
colleagues (Kemeny et at., 1996), were unable to detect HHV8 DNA in a large
number of benign angiogenic lesions. HHV8 DNA has been detected in 4
angiolyrnphoid hyperplasia (Gyulai et at., 1996), a venous haemangioma (Herman
et at., 1998), as well as 7 angiosarcomas (McDonagh et a!., 1996), however the
evidence currently available would suggest that such associations are still
unproven.
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Apart from KS, BCBL and MCD another disease with which HHV8 infection has
been linked is multiple myeloma. Such an association was first suggested by
Rettig and colleagues (Rettig et aL, 1997), based upon the detection of HHV8
DNA and transcription products in dendritic and transformed plasma cells from
patients with MM, and its precursor condition MGUS. A number of other studies
which investigated this proposed association were, however, unable to confirm
these findings (Parravicini et al., 1997, Masood et al., 1997 and Whitby et at.,
1997). In this thesis (section 3. c.) a serological and genomic analysis was
conducted for evidence of HHV8 infection in a cohort of patients with
haematological malignancies, including 6 with MM. The prevalence of HHV8 in
this cohort (8%) was little different to the UK average of approximately 5% and
HHV8 infection was not associated with any particular malignancy. Until further
evidence, such as that supplied for the association between HHV8 and KS is
forthcoming, argument will continue as to the validity of Rettig's claims and
therefore any association between HHV8 and myeloma must, at present, remain
suspect.
4. a. ii) Diagnostic value of HHV8 DNA and anti-HHV8 IgG detection
The clinical value of detecting HHV8 DNA in tissue from a patient with
cutaneous KS is limited as histological examination of the tumour remains a highly
accurate method for making a definitive diagnosis of KS (reviewed by Levine,
199Q. The value of detecting HHV8 DNA in the blood of HTV-infected patients
without KS may, however, be of greater importance. As such detection appears
predictive of subsequent KS development individuals with an HHV8 viraemia may
be monitored more closely for the development of early KS patches. At a very
early stage such lesions respond well to local cryotherapy, or radiotherapy
and may also be treated with non-cytotoxic systemic
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agents, including thalidomide, as described in section 3. b.. The presence of
HHV8 DNA in blood may also be useful in promoting the detection of KS
tumours presenting at non-cutaneous sites, such as the oral cavity and lymph
nodes (Yokois et a!., 1997 and Ficarra et a!., 1988), where KS may initially go
unnoticed by both the patient and clinician.
In terms of health education defining the presence of HHV8 DNA in the semen or
blood of a gay man, or the detection of antibodies to the virus, would be of
benefit in advising the patient of the transmission risk to uninfected partners. Since
the advent of the lilY-epidemic education in the prevention of viral transmission
through sexual contact, especially in the homosexual population, has been
dramatically improved. However there remain many instances in which partners
are either both HIV-infected, or uninfected, and refrain from using normal barrier
methods of protection. As I{HV8 DNA may be detected in the semen of gay men
both with, and without, KS (section 3. a. 6.) it is highly probable that sexual
transmission of this virus, like CMV, occurs in the homosexual population.
Epidemiological studies of KS incidence (Beral et al., 1990 and 1993) and
serological studies of HHV8 infection in gay men (Martin et a!., 1998) support
this theory of sexual transmission and underline the importance of avoiding
unprotected intercourse between HHV8 infected and uninfected partners.
The particular clinical situation in which detection of HHV8 DNA is of significant
benefit is in the bronchial washings from patients at risk of developing pulmonary
KS. Of all forms of KS, pulmonary KS has the highest associated rates of patient
mortality and is often only detected at post-mortem (Zibrak et al., 1986). It is also
patients with pulmonary KS which benefit most from prompt therapeutic
intervention with systemic cytotoxic treatment, especially liposomal daunorubicin
(Shurmann et al., 1994). The study in section 3. a. 5.,
as well as that by Tamm and colleagues (Tamm et al., 1998), showed that over
80% of patients with pulmonary KS have detectable HHV8 DNA in their
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pulmonary cavity. Detection of the virus at this site is, therefore, an excellent
additional diagnostic marker of pulmonary KS involvement. If found in patients
with non-specific respiratory disease such detection should focus investigation on
the heightened possibility of KS lesions being present in the bronchial tree. The
study in section 3. a. 5. also showed the predictive value of detecting HHV8 DNA
in the lungs of patients with, or without, cutaneous KS. Although no specific
therapy to prevent the development of pulmonary KS lesions in such patients is
currently offered the finding of pulmonary HHV8 DNA increases the probability
that future respiratory disease may have a KS involvement (Howard et al., 1998
andTarnmetal., 1998).
Apart from use in populations known to be at increased risk of developing
HHV8-associated disease the value of diagnostic techniques for HHV8, especially
serological analysis for anti-HHV8 antibodies, would be in the screening of blood
and tissue donors. The studies in section 3. a. 4 and 3. a. 7 suggest that the risk of
acquiring HHV8 in the UK, through the receipt of donated blood or semen is very
low, especially as homosexual men are already prevented from being donors
because of the increased risk of HIV-1 transmission. Therefore it is unlikely that
all donors would require screening for HHV8 infection, however it would appear
sensible to ensure that donations being used to treat immunocompromised
individuals, who are known to be at an increased risk of HHV8-associated
disease, are derived from HHV8-seronegative donors. Such a protocol has already
been shown to be highly effective in the prevention of CMV disease in
immunocompromised transplant patients (Martin et al., 1990 and Eastlund, 1995)
This was confirmed by the study of allogeneic bone marrow transplantation,
described in section 3. d., where none of the CMV-seronegative recipients of bone
marrow or blood products from similarly CMV-seronegative donors had evidence
of systemic CMV infection post-transplant.
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4. a iii) Possible treatments for Kaposi's sarcoma
KS remains the most common malignancy in the FffV-infected population, with
30% of all HIV-infected gay men developing KS during their HIV-associated
illness (Peters et al., 199]). Over the last 15 years a variety of therapies for KS
have been investigated, most with limited success. Recently a combination of
strategies have been proposed. For severe, systemic (especially pulmonary) KS
cytotoxic chemotherapeutics, such as the angiogenesis inhibitors (e.g. liposomal
daunorubicin) can be effective and are clearly indicated in patients with
progressive disease (Harrison et a!., 1995). Whilst being effective in the treatment
of advanced KS such therapies have significant associated toxicity's and are
impractical for use in patients with early, or limited cutaneous KS. In such
patients the traditional approach has been the use of local radiotherapy, or
cryotherapy (Volm and Roenn, 1995). This has a cosmetic value in reducing the
size and pigmentation of individual lesions but has no effect in delaying or
reducing the development of additional lesions, or moderating the systemic spread
of the disease. For this reason a variety of alternative therapies, such as the
interferon family of compounds and systemic retinoids, (Harris et a!., 1992
have been investigated. Unfortunately clinical response rates to
these treatments have been mixed, side effects are common and none have found
widespread use. Such therapies also rely on the patient having a degree of
remaining immune function. As described in section 3. 4. an alternative therapy
for the treatment of early cutaneous KS is oral thalidomide. With its low-levels of
associated side-effects and simple administration regime thalidomide was shown
to be highly active against KS in the patients who completed an eight week course
of therapy. As well as providing a partial clinical response rate of over 60% the
levels of systemic HHV8 DNA in patients undergoing treatment were greatly
reduced, indeed in most patients viral DNA became undetectable in peripheral
blood. As previously discussed it was impossible to determine whether such viral
clearance was a direct effect of the drug on HHV8, or an indirect effect due to the
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reduction in tumour load. However the clinical results of this study and one other
conducted at the National Institute of Health, USA (Welles et a!., 1997) suggest
that thalidomide may be a valuable treatment option in a patient group currently
given little therapeutic support for their KS. The response of HHV8 DNA titre in
the patients treated with thalidomide, both in those who responded to treatment
and those who had progressive disease, also highlights the possibility of using
systemic HHV8 load as a criteria for evaluating clinical response to other anti-KS
therapies.
Two other types of therapy have been suggested for the treatment of KS. The first
of these are the established anti-herpesviral agents, such as PFA and GCV. Little
information is currently available as to the effectiveness of such treatments for KS.
One study (Humphrey et a!., 1996) of five patients showed a persistence of
systemic HHV8 DNA during intravenous administration of PFA and GCV. HHV8
has, however, been found by in vitro study to be sensitive to both GCV and PFA
(Medveczky et a!., 1997 and Kedes and Ganem, 1997). The other group of
chemotheraputics which have been shown to be effective in the management of all
forms of HIV-associated KS are the anti-HJV protease inhibitors. The regression
of iatrogenic KS is well described in non-REV infected immunocompromised
patients who have their immune function restored (Sangiorgi et a!., 1993)
This suggests that debilitation of the host immune system is
crucial in the development and maintenance of KS. Therefore, probably because
of their significant immune system-enhancing effects, a number of centers have
reported a dramatic response in their patient's KS after use of the protease
inhibitors Indinovir and Ritonovir (Krischer et a!., 1998 and Lebbe et a!., 1998).
Both thalidomide and PFA also have some reported anti-retroviral activity
(Moreira et a!., 1997 and Devianne-Garrigue eta!., 1998) and it may be that their
effectiveness in the treatment of HIV-associated KS is also, in part, be due to an
associated improvement of the patient's immune function.
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Overall current therapy for REV-associated KS is still suboptimal. However with
the discovery of HHV8 and the development of potent anti-HIV therapies
progress is being made in patient management. Currently, except for the
maintenance of immune system function, there is no effective prophylactic
treatment for HIV-associated KS, therefore novel therapies such as thalidomide
warrant further investigation as they may be important in the prevention and / or
treatment of KS, especially in its early stages.
4. b. The significance of herpesvirus infections in the immunocompromised
host
In all types of immunocompromised patient herpesvirus infections and disease
cause a broad spectrum of morbidity and significant mortality. As all members of
the family can become latent following primary infection there is a constant threat
of viral reactivation in individuals with a reduced level of immune surveillance. In
HIV-infected patients most herpesviral disease occurs when the CD4 count has
dropped below 150 (Pertel et al., 1992), in patients receiving immunosuppressive
therapy following organ transplantation it is likely to occur in the first 100 days
post-transplant, before restoration of host immunity (Peters et al., 1991b and
Meyers et al., l90).
Of all the herpesvirus disease occurring in these immunocompromised patients
CMV infection is the most common and is of the greatest clinical significance. In
the study of herpesvirus genome prevalence in post-mortem samples (section 3.
e.) 19 of 31 patients (61%) had clinical evidence of CMV disease and 19 of 31
also had CMV DNA detected in either their eye or CNS. In the study of CMV in
transplant recipients (section 3. d.) 14 of the 19 patients (74%) known to have
had previous CMV infection had systemic CMV DNA detected at least once in
the post-transplant period.
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If untreated CMV causes a wide spectrum of disease in these
immunocompromised patients. HIV-infected patients are at risk of CMV-induced
cytocidal destruction of their retinal cells, which may rapidly result in patient
blindness. CMV can also infect and destroy neuronal cells causing encephalitis and
polyradiculopathy (reviewed by Bloom and Palastine, 1988). It is also likely that
CMV and HIV interact at the molecular level to up-regulate their respective rates
of replication, thereby accelerating host immune destruction (Duclos et a!., 1989
and Wiley et a!., 1988). In bone marrow transplant recipients the predominant
site of CMV disease is the lungs where tissue damage is caused not by the viral
lysis of cells, but by an immuno-pathological process involving the incorrect
activation of cytotoxic T-lymphocytes (Shanley et al., 1987).
In contrast to most other viral infections two therapeutic agents are available for
the treatment of CMV disease. Both GCV and PFA are highly active against
CMV infection (reviewed by Serody, 1993) and may arrest disease progression in
the eye, brain and lungs of immunocompromised patients. However what appears
crucial to the effective use of these treatments is their early instigation, preferably
prior to the presentation of clinical symptoms (Eddleston et al., 1997 and Reed et
a!., 1988). As shown in section 3. d. it is possible with appropriate prophylaxis
and the early detection of CMV replication, by PCR analysis, to eliminate CMV
disease from a cohort of acutely immunosuppressed transplant patients. In the
absence of prophylaxis and treatment approximately 60% of the CMV-infected
patients in this study would have been expected to develop CMV disease, with up
to 10% dying from the disease by day 100 post-transplant (Reusser et al., 1990).
Unfortunately it was not possible to conduct a parallel study of CMV surveillance
in a cohort HIV-infected patients, however other groups have reported similar
benefits to those described, in section 3. d. for the bone marrow transplant
patients, with the use of CMV-prophylaxis regimens in FIIV-infected groups
(Katlama, 1996 and Danner, 1995).
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Of the other herpesviruses investigated in this thesis only EBV was associated
with specific disease. The study of post-mortem material (section 3. e.) extended
previous reports of EBV-associated morbidity in HIV-infected patients (Pednaultt
et al., 1992 and MacMahon et al., 1991), with 3 of 4 patients with CNS
lymphoma having EBV DNA detectable in their CNS. Systemic EBV DNA was
also detected in 60% of HIV-infected patients analysed in the study of HHV8
DNA prevalence (section 3. a. 4) confirming its high prevalence in this patient
group. HSV-1 and HSV-2 were rarely detected in the study of post-mortem
material, HHV6 and HHV7 were not detected even though they have an almost
100% seroprevalence in most populations. Although VZV DNA was detected in 4
patients, in none was it associated with disease.
Without methods for eradicating herpesvirus infections after the establishment of
latency there is little chance of reducing the number of immunosuppressed patients
at risk of developing CMV, EBV and HHV8-associated disease during their
period of immune-suppression. Surveillance programs for the rapid detection of
emerging infection may be useful in allowing early treatment, however the only
truly effective mechanism of combating herpesviral infections, and preventing
associated disease, is a return of the patient to a state of restored immunological
control. In transplant patients this is possible after reconstitution of the received
bone marrow. For HIV-infected patients it would appear that the new generation
of protease inhibitor drugs (discussed in section 4. a.) are currently the most
effective means of restoring immune function. Only by allowing the patient some
form of immnune regeneration will effective long-term management of herpesvirus
infection be possible.
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4. c. Increasing the efficiency of molecular diagnostics for herpesvirus
infections
The use of molecular techniques, such as PCR, for the detection of viral genomes
has significantly increased the efficiency of herpesviral diagnosis (Storch et al.,
1994, Miller et al., 1994, and reviewed by Griffiths, 1993) and as the study of
CMV infection in transplant recipients (section 3. d.) showed, a reliance on tissue
culture and fluorescent detection assays, such as the DEAFF test, must now be
considered inappropriate for the early identification of herpesviral infection. The
speed of viral detection has also been improved, with most PCR assays providing
"same-day" results. However, although molecular techniques have provided a
significant improvement in viral diagnosis there is an increased financial and
technical cost in providing such a service. Investigation of herpesviral infections
has, until recently, been achieved by the individual analysis of each genome
species separately (Mitchell et al., 1994). As detailed in section 3. f. this method is
extremely costly and labour intensive, and has led to the investigation of
alternative methods, such as the multiplex PCR assay. The assay described in
section 3. f. allows for the detection of up to six different herpesviruses,
simultaneously, at the same level of detection sensitivity as for the individual
nested PCR's previously used. Although designed for the detection of herpesvirus
genomes the same format should be appropriate for the analysis of any variety of
infectious pathogens, depending on patient type and clinical need.
As well as its use as a diagnostic assay the multiplex system is also of value as an
epidemiological research tool, reducing the number of assays required to
determine the prevalence of target sequences in a clinical sample panel. Indeed the
analysis of herpesviral infections in the eyes and CNS of HIV-infected patients
(section 3. f.) would have been completed at a greatly reduced cost, and in far less
time, had the multiplex assay then been available.
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In addition to assay formats such as the multiplex system it will be important, for
the future management of herpesvirus infections, to develop techniques such as
quantitative PCR and reverse transcriptase PCR. Quantitative PCR has already
been shown to be a valuable aid in deciding on treatment strategy in transplant
patients with CMV infection (Peiris et al., 1995 and Ljungman et a!., 1996) and
as mentioned in section 3. d. an ability to monitor of the levels of CMV DNA in
such patients may allow a more selective approach to the use of PFA and GCV
therapy. Already in this thesis the quantification of systemic HHV8 DNA has been
found, in section 3. b., to mirror the response of clinical KS to a variety of
therapeutic agents. Reverse transcriptase PCR enables the detection of viral
messenger RNA and hence actively replicating virus. This technique has been
found valuable in predicting herpesvirus emergence from latency, especially of
CMV, and may be an early indicator of subsequent disease in immuno-
compromised patient populations (Randhawa et a!., 1994 and Gozlan et a!.,
1996).
4. d. Conclusions
Of all the viral infections affecting the immunocompromised host those caused by
the family herpesviridae are the most widespread and clinically important, making
the understanding of the epidemiology of these pathogens vital for effective
patient management. In this thesis I have described the prevalence of all eight
human herpesviruses in a variety of patient populations, and suggested improved
diagnostic assay techniques for determining the presence of individual herpesvirus
infections. Also investigated was the association between the most recently
described human herpesvirus, HHV8, and Kaposi's sarcoma. The studies
described support the argument that HHV8 is causal of KS, is sexually
transmitted, and that its detection is of significant clinical value in the HIV-
infected patient population.
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Appendix A: Culture media and buffer recipies
All media and buffers were made up in sterile double-distilled water unless
otherwise stated.
Tissue Culture Media
Complete RPM!
2.0 X iO 3 M L-glutamine
100 units / ml penicillin
100 jig / ml streptomycin
2.5 jig / ml fungazone
10% (v/v) FCS
made up in 1 X RPM!
(Dutch modification)
Freezing medium
10% (v/v) DMSO
30% (v/v) FCS
Made up in 1 X RPMI
(Dutch modication).
HEL growth medium
10% (v/v) FCS
100 units / ml penicillin
100 jig I ml streptomycin
2.5 jig / ml fungazone
made up in lx minimal Eagles medium
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Hel maintenance medium
2% FCS (v/v)
100 units / ml penicillin
100 jig I ml streptomycin
2.5 jig I ml fungazone
made up in lx minimal Eagles medium
Throat swab medium (virus transport medium)
5% FCS (v/v)
100 units I ml penicillin
100 jig / ml streptomycin
2.5 jig / ml fungazone
made up in lx Earle's salts
Buffers for serological and ELONA studies
Phosphate buffered saline (PBS)
1.5 X 101 M NaC1
1.5 X iO 3 M KH,PO4
6.3 X i0 M Na2HPO4.12H20
2.6X 1O3MKCL
pH 7.2
2OXSSC
3.0 M NaCI
3.0 X 10' M sodium citrate
p117.0
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HHV8 hF wash and diluent buffer
3% (v/v) FBS
from 20% stock
Diluted in PBS.
Carbonate I Bicarbonate diluent
0.05M carbonate / bicarbonate
pH 9.6
HHV8 ELISA Blocking buffer
5% (wlv) dried skimmed milk
0.1% (v/v) Tween 20
Diluted in PBS.
HHV8 ELISA coating buffer
HHV8 orf 65.2
Diluted in 0.1 M NaHCO3
HHV8 ELISA substrate buffer
1 mg / ml dinitrophenyl phosphate
Diluted in 1M diethanolamine
ELONA coating buffer
5 mg / ml (w/v) streptavidin
Diluted in 0.1 M 0.1 M NaHCO3
ELONA blocking buffer
0.2% FBS (v/v)
(from 20% stock)
Diluted in PBS.
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ELONA sample diluent
0.1% (v/v) FBS
from 20X stock
0.1% (v/v) Tween-20
0.01% (w/v) sodium azide
Diluted in PBS
ELONA wash buffer (TTA)
10 mM Tris-HC1 (pH 7.5)
0.05% (v/v) Tween-20
0.1% (w/v) sodium azide
Diluted in PBS
ELONA probe diluent
0.1% FCS (vlv)
from 20% stock
0.1% (v/v) Tween-20
Diluted in lox SSC
(from 20X stock)
ELONA probe wash buffer
0.05% (v/v) Tween-20
Diluted in PBS.
Mounting Solution
90% (v/v) glycerol solution
Diluted in PBS.
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Buffers for molecular studies
PCR reaction buffer (10 X RB)
5.OX 10'MKCl
2.0 X 10 M Tris
1.5 X 102 M MgC12.6H20
0.1% (w/v) gelatin
pH 8.4
Autoclave KCI / Tris and adjust pH before addition of autoclaved MgCl 2 .6H2 O /
gelatin
Gel loading buffer
30% (v/v) glycerol
0.25% (w/v) xylene cyanol
TAE (50x)
1.OMTris
6% acetic acid
5.OX 1O2MEDTA
(from pH 8 stock)
Agarose gel
1 X TAB (from 50X stock)
2% (w/v) agarose
0.05% (w/v) etidium bromide
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Glycigel freezing medium (for 1 litre)
375 ml glycerol
l.8g EDTA
15g gelatin
5.4g NaCl
I .Og sodium azide
make up to 1 litre with distilled water
heat to 70°C until all gelatin dissolved, cool and aliquot
Glycigel lysis buffer
1 X 10.2 M Tris-HCI
(pH 7.5)
1% (v/v) Triton X100
3.2 X 101 M sucrose
5.0 X 102 M MgC12
Sterilise Tris-HCI I sucrose / MgCl 2 and adjust pH before addition of Triton
Glycigel extraction buffer
1 X 10.2 M Tris-HCI
(pH 8.3)
5.OX 1O2MKC1
2.5 X iO 3
 M MgCl2
0.0001 % (w/v) gelatin
0.45% (vlv) Tween 20
0.45% (v/v) Nonidet P40
Sterilise Tris I EDTA I NaCI by autoclaving and adjust pH before addition of
gelatin I Tween-20 / Non idet P40
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SDS-extraction buffer
1.OX lO2MTris
2.5 X 102 M EDTA
1.OX 1O1MNaCI
0.5% (w/v) SDS
100 tg / ml protinase K
pH 8.0
Sterilse Tris / EDTA / NaCI by autoclaving and adjust pH before addition of
SDS
Add protinase K just prior to use.
TEN buffer
1.OX lO2MTris
1.OX 1O3MEDTA
5.OX IO2MNaC1
Buffer saturated phenol
40% (v/v) phenol
12% (v/v) TEN buffer
0.04% (w/v) hydroxyquinoline
TE buffer
1.OX 10MTris
1.OX 1O3MEDTA
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